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The mammalian liver possesses a remarkable ability to regenerate after injury to prevent immediate
organ failure. However, amid a rising global burden of liver disease, the only curative treatment for
patients with end-stage liver disease is transplantation. Elucidating the mechanisms underlying tissue
repair and regrowth will enable identification of therapeutic targets to stimulate native liver regeneration,
thereby circumventing the great paucity of available transplant organs. Here, utilizing the Fah-/- mouse
model of liver repopulation, I applied transcriptomic and epigenomic techniques to investigate the
changes occurring as hepatocytes restore organ mass following toxic injury. By labeling ribosomal or
nuclear envelope proteins, I performed the first extensive characterization of gene expression and
chromatin landscape changes specifically in repopulating hepatocytes in response to injury.
Transcriptomic analysis showed that repopulating hepatocytes highly upregulate Slc7a11, a gene that
encodes the cystine/glutamate antiporter. I demonstrated that ectopic Slc7a11 expression promotes liver
regeneration and Slc7a11 mutation inhibits hepatocyte replication. Integrative bioinformatics analyses of
chromatin accessibility revealed dynamic changes at promoters and liver-enriched enhancer regions that
correlate with the activation of proliferation-associated genes and the repression of transcripts expressed
in mature, quiescent hepatocytes. Furthermore, changes in chromatin accessibility and gene expression
are associated with increased promoter binding of CCCTC-binding factor (CTCF) and decreased enhancer
occupancy of hepatocyte nuclear factor 4α (HNF4α). In summary, my thesis work identifies Slc7a11 as a
potential driver of liver regeneration, and provides insights into the complex crosstalk between chromatin
accessibility and transcription factor occupancy to regulate gene expression in repopulating hepatocytes.
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ABSTRACT
INNVOATIVE APPROACHES TO IDENTIFY REGULATORS OF LIVER REGENERATION
Amber W. Wang
Klaus H. Kaestner

The mammalian liver possesses a remarkable ability to regenerate after injury to prevent immediate
organ failure. However, amid a rising global burden of liver disease, the only curative treatment for
patients with end-stage liver disease is transplantation. Elucidating the mechanisms underlying
tissue repair and regrowth will enable identification of therapeutic targets to stimulate native liver
regeneration, thereby circumventing the great paucity of available transplant organs. Here, utilizing
the Fah-/- mouse model of liver repopulation, I applied transcriptomic and epigenomic techniques
to investigate the changes occurring as hepatocytes restore organ mass following toxic injury. By
labeling ribosomal or nuclear envelope proteins, I performed the first extensive characterization of
gene expression and chromatin landscape changes specifically in repopulating hepatocytes in
response to injury. Transcriptomic analysis showed that repopulating hepatocytes highly
upregulate Slc7a11, a gene that encodes the cystine/glutamate antiporter. I demonstrated that
ectopic Slc7a11 expression promotes liver regeneration and Slc7a11 mutation inhibits hepatocyte
replication. Integrative bioinformatics analyses of chromatin accessibility revealed dynamic
changes at promoters and liver-enriched enhancer regions that correlate with the activation of
proliferation-associated genes and the repression of transcripts expressed in mature, quiescent
hepatocytes. Furthermore, changes in chromatin accessibility and gene expression are associated
with increased promoter binding of CCCTC-binding factor (CTCF) and decreased enhancer
occupancy of hepatocyte nuclear factor 4α (HNF4α). In summary, my thesis work identifies Slc7a11
as a potential driver of liver regeneration, and provides insights into the complex crosstalk between
chromatin accessibility and transcription factor occupancy to regulate gene expression in
repopulating hepatocytes.
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CHAPTER 1
INTRODUCTION

1

LIVER BIOLOGY
I. Function
As the hub of various biological processes, the liver performs a multitude of functions that
can be categorized as the following.
(1) Regulation of carbohydrate, protein, and lipid homeostasis. The liver undergoes
gluconeogenesis to release glycogen as glucose in response to fasting, packages excess lipids for
storage in other tissues, and processes amino acids via deamination to convert the nonnitrogenous carbon skeleton to glucose or lipids [1,2].
(2) Metabolism of nutrients, wastes, and xenobiotics. The metabolic process consists of
phases I and II. Phase I involves direct modification including oxidation, reduction, and hydrolysis
often achieved by cytochrome P450 (CYP450) proteins. Phase II is carried out by enzymes to
conjugate large molecules of phase I metabolites to decrease activity and increase solubility [3].
(3) Synthesis of bile, amino acids, coagulation factors, and serum proteins. The liver
performs the conversion of ammonia to urea through the urea cycle [4] and carries out the
conjugation of bilirubin for secretion into the bile that drains into the intestine for degradation [5].
The liver also synthesizes non-essential amino acids, bile acid from cholesterol, clotting factors for
blood coagulation, and various serum proteins such as albumin (ALB) and transferrin [2,6].

II. Cell types
The liver consists of cell types of divergent embryological origin – with two main
parenchymal cell types, hepatocytes and cholangiocytes, and nonparenchymal cells including
Kupffer cells, stellate cells, and sinusoidal epithelial cells.
Hepatocytes are the main cell type that performs the majority of liver functions mentioned
above. They occupy 60% of the liver by cell number and 80% by cell mass [7]. Cholangiocytes,
also known as biliary epithelial cells (BEC), are cuboidal cells that line the bile duct to allow passage
of bile acid from the liver to the intestine. They are less metabolic active compared to hepatocytes
but still exhibit functions such as bicarbonate synthesis and electrolyte secretion [8].
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Cholangiocytes also play an important role in regulating immune and inflammatory responses [8].
Small ducts embedded deep within the liver are called intrahepatic bile ducts whereas large ducts
that exit the liver are extrahepatic bile ducts [7].
Kupffer cells are resident hepatic macrophages that recognize stimuli introduced through
the portal circulation to perform phagocytosis and secret pro- or anti-inflammatory mediators to
defend liver against bacterial and viral infections [9]. Stellate cells exist in two states – under
quiescent conditions, they store vitamin A in lipid droplets whereas other functions remain unclear
[2]; upon liver damage, they are activated to become proliferative myofibroblasts [10]. The
myofibroblasts derived from stellate cells deposit collagen that contributes to the fibrosis or scarring
of the liver tissue, which could progress to cirrhosis with chronic liver injury [10]. Sinusoidal
endothelial cells are specific nonparenchymal cells that line the capillaries of the liver, also known
as sinusoids, to form fenestrated sieve plates that permit access of macromolecules from the space
of Disse, an interstitial area that surrounds hepatocytes. This structure allows hepatocytes to
extract a variety of protein-bound substrates and xenobiotics from the circulation [11].

III. Structure
The liver is composed of building blocks termed ‘lobules’, which contains parenchymal and
nonparenchymal cells, the bile duct, and vessels of the circulatory system including the hepatic
artery, portal vein, and central vein (Figure 1.1). The portal vein, hepatic artery, and the bile duct
are often referred to as the portal triad due to their spatial proximity. A typical lobule is considered
to be a hexagonal unit with the central vein in the middle and the portal triad at the six corners [12].
The portal vein and the hepatic artery are the two main sources of blood supply for the liver, with
the portal vein providing two-thirds of the blood from the small intestine and the hepatic artery
contributing to the remaining one-third of the blood from the celiac artery. The blood from these two
sources mixes as it passes through sinusoids, and enters the central vein to exit the liver [7]. Owing
to the direction of the blood supply, which moves from the portal triad to the central vein, the portal
area is considered ‘zone one’ and the central area as ‘zone three’.
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Hepatocytes synthesize and transport bile acids via a specialized channel formed by two
adjacent cells, also referred to as the canaliculus. Bile is produced in the canaliculi as a mixture of
bile acids, metabolites, and bilirubin secreted from hepatocytes; it enters the bile ducts that
ultimately drain into the duodenum. Bile acids assist in lipid and cholesterol emulsification in the
intestines, and are reabsorbed from the terminal ileum and transported back to the liver through
the portal vein, recycling in a route known as the enterohepatic circulation. Contrary to the blood
flow, bile flows from zone three to zone one [6]. Hepatocytes in proximity to the portal triad are
referred to as periportal or zone one hepatocytes, those adjacent to the central vein are pericentral
or zone three hepatocytes, and cells between zone one and three are referred to as zone two
hepatocytes.
Apart from the spatial distribution, hepatocytes from different zones express divergent sets
of genes to carry out various metabolic functions, a property known as metabolic zonation, which
is tightly controlled by the Wnt/β-catenin signaling pathway [13]. Periportal hepatocytes perform
gluconeogenesis, fatty acid oxidation, urea production, and glutathione (GSH) detoxification,
whereas pericentral hepatocytes conduct glycolysis, lipogenesis, ketogenesis, and xenobiotic
metabolism [14]. Multiple cell types coupled with metabolic zonation allow the liver to carry out
diverse metabolic and biosynthetic functions central to homeostasis.

IV. Development
In mice, the parenchymal cells of the liver develop from the definitive endoderm from the
anterior primitive streak of the gastrulating embryo on embryonic day (E) 7.5 [15]. By E8.5,
endoderm patterning is complete and can be categorized from the anterior to posterior as the
foregut, midgut, and hindgut regions [16]. Hepatic specification subsequently begins on E9.0 when
hepatic endoderm cells extend off the posterior foregut [17] and continue to thicken to establish the
liver diverticulum [18]. Early signals important for the initiation of liver specification include fibroblast
growth factor (FGF) family members emanating from the developing heart [19] and bone
morphogenic proteins (BMP) from the septum transversum mesenchyme [20] of the mesoderm.
4

Simultaneously, transcription factors of the GATA binding proteins [21] and forkhead box A (FOXA)
subfamily [22] activate transforming growth factor β (TGFβ), WNT, and NOTCH signaling within the
endoderm. Additionally, FOXA1 and GATA4 function as ‘pioneer factors’ that bind to
heterochromatic DNA to establish transcriptional competence of downstream gene programs
required for further differentiation [2,23]. The liver bud gives rise to hepatoblasts, bipotential
progenitor cells that express α-fetoprotein (AFP) and ALB [24,25]. Prior to differentiation,
hepatoblasts continue to migrate and proliferate into the septum transversum assisted by a gradient
TGFβ signal from the portal vein mesenchyme starting on E13.5 [26]. Cells in proximity to the portal
vein receive a higher TGFβ concentration that promotes expression of hepatocyte nuclear factors
1β (HNF1β) and HNF6, leading to the expression of cholangiocyte marker genes such as
cytokeratin 19 (CK19) [26]. Hepatoblasts located away from the portal vein receive lower levels of
TGFβ, resulting in elevated expression of HNF1α and HNF4α, which induce hepatocyte-specific
gene expression such as ALB and CYP450 [27]. Beginning on E18, the differentiated hepatocytes
continue to mature and undergo a metabolic switch from a glucose-consuming tissue to a glucoseproducing organ. Developing hepatocytes at distinct locations in the liver also experience metabolic
zonation to establish differential gene expression and protein production [2]. This process is
regulated by complex crosstalk of signaling networks including the hepatocyte growth factor (HGF),
glucocorticoids, HNF, and the Wnt/β-catenin pathway [27].

V. Homeostasis
Tissue turnover typically occurs through two models: replication of existing cells and
differentiation of progenitor cells. While the presence of stem cells in the adult liver has long been
contested, it is currently accepted that mature resident hepatocytes proliferate for homeostatic
maintenance. Since differentiated hepatocytes are long-lived cells with a turnover rate of up to
several months in vivo, under normal physiological conditions, fewer than 0.1% of the hepatocytes
undergo replication at any time in the uninjured adult liver [28]. It is, therefore, questionable whether
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stem cells are required at all for normal liver maintenance considering the long life span and low
replication rate of mature hepatocytes.
Lineage-tracing in rodents is widely used to identify the source of hepatocyte homeostasis.
The most debated model, the ‘streaming liver hypothesis’, implemented DNA radiolabeling assays
in the rat liver and observed that newly-formed hepatocytes occur near the portal vein and flow
towards the central vein to replenish the liver parenchyma [29]. The streaming liver hypothesis
implies the existence of a stem cell compartment proximal to zone one and posits that periportal
hepatocytes display a higher replication capacity, hence the ability to derive new cells from the
portal vein to the central vein. Over time, it is found that the entire liver lobule contains hepatocytes
derived from zone one [29]. However, evidence both for and against the streaming liver hypothesis
has been provided. Genetic tracking that utilizes the cholangiocyte marker ‘sex-determining region
Y (SRY)-box 9’ (SOX9) to label all BECs via a tamoxifen-inducible system in the adult liver of
Sox9CreERT2;RosaLSL-LacZ mice observed LacZ spreading in a portal-to-central direction that
eventually occupied the entire liver parenchyma within a year [30]. These studies suggest SOX9positive cholangiocytes as a source of mature hepatocytes to maintain the homeostatic liver.
Nonetheless, studies using different lineage-tracing systems have not observed the same
evidence [31,32]. Other radiolabeling assays failed to detect movement of marked periportal
hepatocytes towards the pericentral area in the adult liver [32]. Another transgenic
Sox9CreERT2;RosaLSL-YFP line generated with a bacterial artificial chromosome (BAC) found that YFPpositive cholangiocytes are restricted within the bile ducts and do not migrate to the central vein
[33]. Labeling of adult hepatocytes of the RosaLSL-YFP mouse through injection of AAV8-TTR-Cre, a
hepatotropic adeno-associated virus (AAV) serotype 8 that expresses the Cre recombinase under
the hepatocyte-specific transthyretin (TTR) promoter, did not demonstrate any YFP-negative
hepatocytes in the liver parenchyma or near the periportal region [34]. These results indicate that
all newly-derived hepatocytes are from preexisting mature cells and exclude the possibility of
progenitors contributing to adult liver homeostasis. More recently, a ‘reverse-streaming hypothesis’
in which WNT-enriched pericentral hepatocytes expand to the periportal region have been
6

proposed [35], albeit with much controversy. In summary, the current evidence does not support
the notion of liver stem cells as a source of mature hepatocytes during normal homeostasis;
instead, hepatocytes are likely maintained by replication of preexisting cells.

VI. Diseases
Liver disease accounts for roughly 2 million annual deaths worldwide, of which 15% of the
mortality results from acute hepatitis, 35% from hepatocellular carcinoma (HCC), and 50% from
complications related to cirrhosis [36]. Strikingly, the combination of cirrhosis and HCC constitutes
3.5% of global deaths [37]. Although accurate statistics are not available due to the scarcity of
mortality data from developing countries [36] and the underestimation of liver diseases as a cause
of death [38], there is a discernible increase in the global burden of both acute and chronic liver
disease [36,37,39].

A. Types of liver disease
Alcoholic liver disease
Alcohol contributes to over 50% of cirrhosis-related mortality and heavy alcohol
consumption is associated with the development of cirrhosis [40]. For heavy drinkers — daily
ethanol consumption of over 30g — the incidence of cirrhosis ranges from 1-6%, depending on the
dose [41]. Furthermore, alcohol use exacerbates preexisting liver injuries [37]. Approximately 20%
of patients with alcoholism develop alcoholic hepatitis, a clinical representation of jaundice and liver
failure after chronic alcohol abuse, with a daily mean ethanol consumption of 100g [42]. Coupled
with the rising rate of obesity globally, the severity of alcoholic liver disease, especially alcoholic
fatty liver disease, is expected to worsen [37].
The molecular mechanism of alcohol-induced liver injury involves the oxidative metabolism
of ethanol that shifts the oxidative-reduction potential in the liver, preventing fatty acid oxidation
and inhibiting the tricarboxylic acid cycle that normally promotes lipolysis [43]. Additionally, ethanol
activates sterol regulatory element-binding protein 1 (SREBP-1) [44], prevents peroxisome
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proliferator-activated receptor α (PPARα) binding to the DNA [45], and inhibits AMP-activated
protein kinase (AMPK) activity [46], leading to activation of fatty acid synthesis and metabolic
remodeling that contributes to the development of fatty liver [47].

Non-alcoholic fatty liver disease (NAFLD)
Fatty liver, also called steatosis, is defined as excess accumulation of triglycerides in over
5% of fat in hepatocytes [48]. NAFLD encompasses two distinct conditions, steatosis without liver
injury and steatosis with hepatocyte necrosis, referred to as non-alcoholic steatohepatitis (NASH)
[48]. The global prevalence of NAFLD is estimated to be 25.2% [49] and of NASH is between 27% [49–52]. Current epidemiological studies potentially underestimate due to the difficulty of
detecting fatty liver unless through imaging or liver biopsies [49]. Moreover, the increasing rates of
comorbid conditions associated with NASH such as obesity, type 2 diabetes mellitus, and
hyperlipidemia contribute to the rapidly growing burden of NAFLD [49]. Particularly in the case of
NASH, chronic liver injury followed by lobular and portal inflammation in the form of collagen
deposition and scar tissue production often lead to progression to fibrosis, cirrhosis, and HCC [48].
The exact mechanisms of NAFLD and NASH development are not completely understood
and likely involve extensive interactions between various pathways. Three leading sources have
been identified to contribute to NAFLD. (1) Increased uptake of fatty acids via diet, activation of de
novo lipogenesis, and increased adipose tissue lipolysis, resulting in the accumulation of hepatic
fatty acids. (2) A combination of fatty acid-induced extrinsic cell death through upregulation of cell
death receptors and their ligands [53], as well as intrinsic cell death via increased endoplasmic
reticulum (ER) stress [54], leading to Jun N-terminal kinase (JNK) activation, reactive oxygen
species (ROS) production, and mitochondrial uncoupling [55]. Fatty acid-induced cell death is
followed by the release of damage-associated molecular patterns (DAMPs) into the extracellular
space [56–58]. (3) Triggering of hepatic inflammation due to fatty acids, DAMPs released by dying
hepatocytes, and endotoxin from the intestine [59], inducing the production of cytokines and
chemokines with subsequent recruitment of immune cells [60] and activation of nonparenchymal
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cells [61,62]. In particular, the transformation of stellate cells into collagen-producing myofibroblasts
further exacerbates NASH and promotes progression to fibrosis [63,64].

Drug- or toxin-induced liver injury
The liver is the first organ to be perfused by blood through the portal vein from the intestine
for first-pass metabolism and is thus the initial filter for molecules before they enter into the general
circulation. Therefore, exposure to environmental toxins can be severely damaging to hepatocytes.
Substances

such

as

alcohol,

acetaminophen,

Amanita

phalloides

mushrooms,

and

idiosyncratically, common drugs including anabolic steroids and antibiotics can cause acute liver
failure [65]. At a rate of 18%, drug-induced liver injury is the leading cause of post-market
withdrawal during drug development [66]. Acetaminophen is the primary etiology for drug-induced
liver injury in the US and the UK, whereas herbal and alternative medicine are the leading causes
in the East [37]. The exact mechanisms of liver injury vary by the drug consumed or the toxin
ingested, but generally involves oxidative stress accumulation, mitochondrial dysfunction,
hepatocyte necrosis and apoptosis, immune response stimulation, and nonparenchymal cell
activation [67].

Viral hepatitis
Viral hepatitis refers to liver inflammation induced by viral infections, routinely caused by
five hepatotropic viruses, hepatitis viruses A, B, C, D, and E. While viral hepatitis affects individuals
from all geographic locations, middle and low-income areas are disproportionately affected [37].
An estimated 1.34 million annual deaths are associated with hepatitis-related mortality [68].
Hepatitis A and E typically result in acute, self-contained illnesses, whereas hepatitis B and C lead
to immune-mediated chronic liver disease. There is an increased risk of developing HCC and
cholangiocarcinoma (CAA) among patients with hepatitis B and C, although the rate of cirrhosis
progression and tumorigenesis display individual heterogeneity [69]. The pathogenesis of hepatitis

9

B and C virus includes complex crosstalk between the host and virus that involves immune
activation of CD4+ helper T cells, CD8+ effector T cells, and natural killer cells [69,70].

B. Consequences of liver disease
Acute liver failure
Acute liver failure, also known as fulminant hepatic failure, is defined as the clinical
presentation of severe liver injury and hepatic encephalopathy within 8 weeks of the first symptoms
without preexisting liver disease [71]. Other than the liver and the brain, acute liver failure also
affects organs including the heart, lungs, pancreas, and kidney [72]. Hepatitis A, B, and E infections
are the predominant causes of acute liver failure worldwide [72]. In the US, drug-induced injury
contributes to approximately 50% of acute liver failure cases [73].

Cirrhosis
Cirrhosis is the end-stage of all chronic liver disease that develops from an asymptomatic
phase termed ‘compensated’ cirrhosis to a progressive ‘decompensated’ phase marked by
complications of ascites, jaundice, encephalopathy, and variceal bleeding [74]. Features of
cirrhosis include regenerative and nodular parenchyma, widespread deposition of fibrotic tissues,
and hepatocyte necrosis [75]. Patients with cirrhosis have a 5-10-fold increased risk of mortality
[76]; death occurs due to a variety of complications including infections, kidney failure, and
gastrointestinal bleeding [77]. Common causes of cirrhosis include alcohol abuse (60-70%),
chronic hepatitis B or C (10%), and NAFLD (10%) [78].

Liver cancer
Considering the late-stage at diagnosis in most cases, HCC exhibits a 5-year survival rate
of 18.4% with an annual rise of mortality by 2.4% [79]. Currently, 40% of HCC results from hepatitis
B, 40% from hepatitis C, 11% from alcohol use, and 9% from other causes [37]; however, the
etiology varies significantly for different countries. Non-viral factors contribute to a larger pool of
10

HCC in regions with a low incidence of viral hepatitis. In the US, 25% of HCC patients present with
alcoholic-liver disease and 20-30% could display metabolic syndrome or NAFLD [80]. In contrast,
viral hepatitis contributes to approximately 90% of HCC cases in Vietnam [81]. The etiology is
expected to change drastically due to the increasing prevalence of NAFLD and NASH [82].
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LIVER REGENERATION
I. Historical overview
Regeneration, defined as cell regrowth or repair, is widely represented in metazoa [83]. In
lower organisms, whole body or tissue regeneration is easily achieved. Invertebrates such as
planarians are capable of whole-body regeneration from as little as 1/279th of the original body [84]
and lower vertebrates including amphibians are capable of regenerating complete appendages. In
mammals, the regenerative ability is restricted to select tissues including the skin, cartilage, digits,
muscle, intestinal epithelium, and liver [85]. The evolutionary importance of the liver in maintaining
a regenerative ability likely stems from it being the largest metabolic organ in the mammalian
system, as nutrient and xenobiotic metabolism subject the liver to frequent, unpredictable
environmental insults. It is presumed that the regenerative ability has been retained in animals in
order to recover from massive liver injuries following exposure to food toxins [86]. Human’s ability
to regenerate the liver has long been known, even codified in Greek mythology by the story of
Prometheus. After stealing fire and giving it to humanity, Prometheus is chained on Mount Atlas
and punished to eternal torment by Zeus. An eagle would feed on his liver daily, only for it to grow
back overnight just to be eaten again the next day [87].
Fewer than 0.1% of hepatocytes are in mitosis under physiological conditions [88] with the
typical life span of 200-400 days [32]. The liver can regenerate upon loss of the parenchyma via
toxin-induced liver injury or surgical tissue removal. Generally, mature hepatocytes replicate to
repopulate the liver under normal conditions but hepatocyte progenitor cells (HPCs) can arise when
hepatocyte DNA synthesis is severely impaired [89]. In fact, hepatocytes have an almost unlimited
replicative capacity as serial partial hepatectomy (PHx) has demonstrated the rat liver to be able to
regenerate after 18 surgeries [90], and serial transplantation of mouse hepatocytes showed their
ability to replicate at least 69 times without loss of function [91]. Given a stimulus, hepatocytes can
rapidly re-enter the cell cycle to restore liver mass and function. Furthermore, the process of cell
proliferation is terminated as soon as the liver mass is restored to its original liver-to-body weightratio [88,92]. In the event when over 90% loss of the parenchyma occurs, the liver can fail to
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regenerate [93]. With the increasing global burden of liver disease, understanding the regulation of
liver regeneration promises to identify potential therapeutic targets to promote tissue repair and
regrowth after liver injury.

II. Rodent models of liver regeneration
Various rodent models have been developed to study the regenerative response and can
be categorized by the stimulus to induce hepatocyte proliferation into surgical-, chemical-, or
genetically-induced liver injury paradigms.

A. Surgical-induced liver regeneration
Partial hepatectomy
PHx is the most widely-used technique to study liver regeneration in rodents, in which twothirds of the liver is surgically removed to induce cell growth and proliferation of the remnant lobes
to restore liver mass and function within 10-14 days [94]. Due to the clean removal of the liver
lobes, the majority (~95%) of the remaining mature hepatocytes enter the cell cycle in a
synchronous fashion that is also species-specific [95]. In both rats and mice, hepatocytes enter G1
4 h post-PHx [96]; DNA synthesis initiates at 12-18 h [97] and proliferation peaks at 24 h in rats
[98], while a 20 h lag is observed in mice due to a longer G1 [96]. At 36 h after PHx, approximately
40% of hepatocytes are in S phase [99]. The well-defined time periods for various cell cycle entry
points provide the opportunity to study the regulatory mechanisms of adult hepatocyte transitioning
from G0 to G1, and from G1 to S in vivo [100]. While PHx reflects what is seen in living-donor liver
transplantation, which occurs in less than 5% of transplant cases in the US annually [101], this
model does not recapitulate what is seen in human liver diseases that involve inflammatory
responses and necrotic cell death [102]. Nonetheless, the high accuracy and reproducibility of the
PHx model have allowed understanding of the signaling pathways and transcriptional control that
take place during hepatocyte replication. It is worth noting that even though injury responses are
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not seen in PHx, the majority of signaling networks underlying the regenerative process are similar
within most liver repopulation models [95].

Ischemia/reperfusion (I/R) injury
I/R injury occurs due to prolonged low oxygen tension in tissues followed by normalized
oxygen perfusion, leading to significant inflammatory responses that cause organ damage and
dysfunction, as often seen during liver transplantation or organ hemorrhage [103]. In rodents, I/R
injury is modeled via an artery clamp in rats [104] and a lobular clamp in mice [105] to temporarily
block the blood supply to the liver. Recovery from I/R injury varies depending on the duration of
ischemia, which generally lasts for 30-90 min. A significant injury is frequently observed 12 h later,
followed by a peak proliferative response at 48 h, with complete recovery by 96 h [106].
The process of I/R injury can be separated into two phases. In the initial phase,
complement triggers Kupffer cell activation followed by the release of ROS that induces oxidative
damage to hepatocytes [104]. The hepatic architecture is unchanged in the initial phase, but injured
and dying hepatocytes release signals to exacerbate inflammation that feedforward to complement
and Kupffer cell activation, leading to the production of tumor necrosis factor α (TNFα) [107] and
cytokines such as interleukin 12 (IL12) [108]. In the late phase, the combination of adhesion
molecule expression on sinusoidal endothelial cells and secretion of CXC chemokines from
nonparenchymal cells result in the recruitment of neutrophils to the liver followed by the release of
oxidants and proteases to induce widespread destruction of the parenchyma [109,110]. The late
phase of I/R injury thus induces significant changes in the hepatic architecture mainly through
necrotic cell death [103].

Bile duct ligation
In bile duct ligation, the common bile duct, which drains bile produced in the liver to the
small intestine, is irreversibly ligated, resulting in inflammatory responses, obstructive cholestasis,
and fibrosis within the first 2 weeks followed by cirrhosis at 4 weeks [111]. Contrary to PHx,
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cholangiocytes are the main cell type to regenerate after bile duct ligation as an extensive
proliferation of bile duct cells are observed; DNA synthesis begins at 24 h and peaks at 48 h after
the surgery [112]. However, when the proliferative capacity of cholangiocytes is impaired, as in the
case of treatment with the biliary toxin methylene diamiline, mature hepatocytes are able to
transdifferentiate into cholangiocytes to rescue the biliary epithelium [113].

B. Chemical-induced liver regeneration
D-galactosamine (GalN)
Intraperitoneal injection of GalN contributes to hepatocyte death through three sources, (1)
uridine 5'-diphospho (UDP)-galactosamine derivatives that inhibit RNA and protein synthesis [114],
(2) endotoxin accumulation that leads to complement activation and necrotic cell death [115], and
(3) mast cell degranulation that causes extensive inflammation [115]. Necrosis is scattered but
more prevalent around the pericentral region [116]. Peak plasma alanine transferase (ALT) and
aspartate aminotransferase (AST), as well as maximal necrosis, occur at 24 h followed by DNA
synthesis that peaks at 48 h after GalN administration [117]. Hepatocyte proliferation, ensuing as
early as 24 h post-GalN, is the main source of regeneration, but a contribution of oval cells 48-96
h after drug treatment is observed at higher GalN doses [116].

Carbon tetrachloride (CCl4)
The main contributors of hepatotoxicity after CCl4 administration are the zone 3 CYP450
enzymes [118]. CYP2B1, 2B2, and 2E1 [119,120] form reactive metabolites of CCl4 including
trichloromethyl (CCl3*) and trichloromethyl peroxyl (CCl3OO*) radicals that modify proteins, lipids,
and DNA in hepatocytes, leading to necrotic cell death [121]. Parenchymal necrosis is most
prominent in pericentral hepatocytes due to the high expression of CYP450 proteins [118]. The
peak of cell death occurs at 24 h, followed by DNA synthesis highest at 36 h [122], and repopulation
to replace lost liver mass that is completed within 7-10 days [106]. In addition, long-term CCl4
exposure promotes fibrosis and even cirrhosis due to stellate cell activation that deposits collagen
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and matrix proteins [123,124]. Thus, repeated CCl4 treatment is often used as a model for chronic
liver injury.

Thioacetamide (TA)
TA was initially introduced as a fungicide but quickly realized to be hepatotoxic and
carcinogenic [125]. A single-dose administration leads to acute injury [126], subchronic exposure
induces fibrosis [127], and chronic use results in liver cancer [125]. Similar to CCl4, TA toxicity
stems from bioactivation through CYP450 enzymes, especially CYP2E1 [128,129] that metabolizes
TA to TA-sulfoxide and TA-sulfone, active intermediates that cause necrotic cell death [130]. In
addition, toxic TA metabolites induce oxidative stress and lipoperoxidation, leading to the
destruction of cell membranes [131,132]. However, the exact mechanisms of TA-sulfone-induced
cell death and replication response are not clear, since TA has not been widely used as a
hepatotoxin for liver regeneration studies. Hepatic necrosis peaks at 24 h [133] with maximal DNA
synthesis at 36-48 h after TA administration [134].

Acetaminophen (APAP)
APAP is a common analgesic and antipyretic drug due to its safety and efficacy. In the US,
APAP overdose is the most common cause of acute liver failure, accounting for 46% of cases [135].
APAP is normally eliminated by phase II conjugation reactions including glucuronidation and
sulfation followed by excretion through the kidneys [136]. However, at toxic doses, the phase II
enzymes are saturated and excess APAP is metabolized instead by CYP2E1 to the reactive
metabolite N-acetyl-p-benzoquinone imine (NAPQI) [137] followed by depletion of GSH, the cell’s
primary defense against oxidative damage. Subsequently, excess NAPQI forms covalent bonds
with proteins to induce reactive oxygen and nitrogen species such as peroxynitrite [138].
Translocation of JNK [139] and the cell death protein BCL2-associated X protein (BAX) [140] to the
mitochondrial outer membrane further induces membrane permeabilization and the release of
mitochondrial proteins, eventually leading to severe centrilobular hepatic necrosis [141,142].
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Necrosis begins 12 h after APAP overdose, peaks at 36 h [143], and subsides gradually over 60 h
[144], whereas hepatocyte proliferation begins at 12 h and peaks at 24-36 h post-APAP
administration [144].

C. Genetically-induced liver regeneration
Fumarylacetoacetate hydrolase (FAH) deficiency
The Fah-/- mouse is a model of hereditary tyrosinemia type I (HTI), an autosomal recessive
disease [145,146]. HTI patients are deficient in the enzyme FAH, the last enzyme in the tyrosine
catabolic pathway [147], resulting in accumulation of the toxic metabolites succinylacetone (SA),
succinylacetoacetate (SAA), fumarylacetoacetate (FAA), and maleylacetoacetate (MAA) that form
DNA adducts [147]. In addition, FAA depletes intracellular GSH stores [148] and triggers cell cycle
arrest in G2/M followed by induction of apoptosis [149]. FAA also activates cyclin-dependent kinase
1 (CDK1) and caspase-1 (CASP-1) to induce cell cycle arrest and subsequent expression of CASP3, resulting in mitochondrial dysfunction as demonstrated by cytochrome c release [149]. FAH is
primarily expressed in the liver and kidney [150], and at a lower level in endocrine glands and the
gastrointestinal tract [151].
The incidence of tyrosinemia is around 1 in 100,000 to 1 in 120,000 worldwide and is
considered a rare disease [152] except for Scandinavia and the province of Quebec, where the
overall incidence is 1 in 16,000 [152]. In particular, the Saguenay-Lac-St-Jean area in Quebec has
a prevalence of 1/1,846 [153,154] due to a founder effect [155]. To date, more than 35 mutations
in FAH have been described [152], including missense mutations leading to 16 amino acid
replacements, splice site mutations, and nonsense mutations [156]. Interestingly the
pathophysiological phenotype differs between humans and mice, and disease severity also varies
greatly between individuals [152].
While an oversimplification, liver phenotypes in HTI patients can be categorized into acute
or chronic phases [157]. In the acute phase, morphological alterations can vary greatly and include
an enlarged or shrunken liver, fibrosis with ductular proliferation in the surrounding region, and
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different degrees of hepatocyte steatosis [158]. The most detrimental phenotype in the acute phase
is liver crises, repeated episodes of liver insufficiencies due to liver decompensation, and generally
manifests as hepatomegaly and coagulopathy [159]. Liver crises are typically present in early
infancy before 2 years of age and historically speaking, around 80% of patients died before the age
of 2 due to acute liver failure [159,160]. In the chronic phase, cirrhosis is often observed in HTI
patients due to the prolonged hepatic injury [161]. There is also an increased risk of developing
HCC in patients beyond 2 years of age, ranging from 15% [162] to 37% [163]. In addition, increased
frequency of dysplasia, aneuploidy, and variable gene expression are observed in tyrosinemic
livers [164]. The exact mechanism of elevated cancer risk is not completely understood but likely
stems from the mutagenic environment in the liver due to the accumulation of reactive metabolites
FAA, MAA, SA, and SAA, cultivating a milieu in which aberrant growth factors lead to altered gene
and protein expression [164]. HTI patients also exhibit other organ dysfunctions including
nephromegaly and renal failure [165], painful paresthesias and motor paralysis [166], and
occasionally islet hypertrophy and hypoglycemia [167]. Orthotopic liver transplantation was
considered the only curative treatment of HTI in the 1980s with an over 90% survival rate [168,169].
The development of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) [170]
gained widespread popularity as early treatment for HTI prevents HCC and circumvents the need
for transplantation [171,172]. NTBC is a potent inhibitor of 4-hydroxyphenylpyruvate dioxygenase
(HPPD) [173], the second enzyme in the tyrosine catabolic pathway, and thus prevents the
production of the toxic intermediates SAA, SA, MAA, and FAA.
The mouse model of HTI was developed via targeted deletion of the FAH gene [145,146].
Fah-/- mice recapitulate the major biochemical and phenotypic alterations observed in HTI patients
such as hypertyrosinemia, accumulation of SA, liver failure, renal tubular damage, and occasional
tumorigenesis [174]. Interestingly, the Fah-/- mouse exhibits a much more severe liver phenotype
than HTI patients as mice die within 12 h after birth from fulminant liver failure and hypoglycemia
[145], likely attributed to higher levels of toxic metabolites, lower GSH concentrations, and
increased sensitivity to FAA, MAA, and SAA in neonatal mice compared to humans [145,175]. Fah18
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mice require early treatment with NTBC to survive beyond birth and a portion of FAH-deficient

livers still develop tumors despite long-term NTBC administration, possibly resulting from
suboptimal NTBC doses or other metabolic pathways that produce FAA and MAA found only in
mice [145].
Fah-/- mice undergo liver repopulation by viral- or nonviral-mediated gene therapy to restore
FAH function, transplantation with FAH-positive hepatocytes, or genome editing to correct Fah
mutations. Liver injury is induced upon NTBC withdrawal, and FAH-negative hepatocytes
experience inflammation, necrosis, or apoptosis [145,174]. Only hepatocytes with FAH expression
are selected in vivo to proliferate and repopulate the injured liver parenchyma [176].
Transplantation with wild type hepatocytes revealed the competitive growth advantage of FAHpositive cells to repopulate the mutant liver, as injection of as few as 1,000 hepatocytes successfully
rescued the phenotype of FAH deletion, requiring on average an estimated 16 cell doublings to
restore liver mass [176]. Liver repopulation can also be carried out through retroviral induction of
FAH expression ex vivo in Fah-/- hepatocytes followed by transplantation of the transduced cells
[177]. Gene transfer via retrovirus [176], adenovirus [178], and AAV2 or 8 [179] also results in
significant colonization of FAH-expressing hepatocytes. However, 9 out of 13 mice treated with
adenovirus developed HCC after 9 months of liver repopulation from untransduced cells that
constitute less than 10% of the liver [178]. Additionally, DNA-mediated transposition with the
Sleeping Beauty (SB) transposable element is able to achieve permanent transgene expression
through genomic integration from the plasmid containing FAH complementary DNA (cDNA)
following hydrodynamic tail-vein injection [180]. Less than 0.1% of hepatocytes display integration
and repopulate the liver to reverse the lethal phenotype after NTBC removal [180]. More recently,
the clustered regularly interspaced short palindromic repeats (CRISPR) system has been utilized
in Fah-/- mice that harbor a point mutation [181]. Expression of single guide RNAs (sgRNA) and a
repair template was successful in directing the CRISPR-associated protein 9 (CAS9) nuclease to
produce a targeted, double-stranded DNA break followed by homologous recombination to repair
the Fah gene defect [181].
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Since only FAH-positive hepatocytes undergo clonal expansion to repopulate the injured
liver, the Fah-/- mouse also provides a remarkable tool to lineage-trace regenerating hepatocytes
by tracking FAH-expressing cells. Coexpression of markers such as luciferase [182] and GFP [183]
can be utilized to specifically trace and isolate repopulating hepatocytes for phenotypic studies.
Furthermore, gene-activating or -silencing molecules can be tethered to FAH expression to
functionally identify the significance of multiple genes during liver regeneration, including the use
of small hairpin RNA (shRNA) [184], cDNA [185], gRNA [186], and tough decoy (TuD) microRNA
(miRNA) inhibitors [187]. Fah-/- immunodeficient mice are also used to grow billions of human
hepatocytes (Azuma et al. 2007).

Urokinase plasminogen activator (uPA) overexpression
uPA is a fibrinolytic enzyme that transforms plasminogen into plasmin to remove fibrin clots
[188]. Hepatocyte-specific uPA overexpression regulated under the albumin enhancer and
promoter leads to increased plasma uPA levels, fibrinogen depletion, followed by neonatal death
within 3 days postpartum due to bleeding of the abdominal cavity and intestinal tract [189].
Hepatocytes that silenced uPA expression, mediated mainly by intrachromosomal recombination,
are able to achieve complete regeneration of uPA transgenic mice [190]. Similar to the case in the
Fah-/- model, loss of transgene expression in individual hepatocytes confers a selective advantage
so that clonal expansion of the uPA-normal cells reconstitute the liver parenchyma [190]. The uPA
transgenic mice can also be corrected with transplantation of wild-type hepatocytes that undergo
an estimation of 12-18 rounds of replication [191]. Furthermore, xenogenic cell transplantation from
rat [192] or human [193] hepatocytes can be performed in immunodeficient mice carrying the uPA
transgene to generate chimeric livers. The uPA transgenic model, therefore, serves as an excellent
paradigm to study liver regeneration after cell transplantation [190,191], drug metabolism in the
chimeric human livers [194], and liver diseases including HBV [195] and HCV [193].

20

D. Models to study HPCs
As introduced above, liver regeneration is carried out by the proliferation of preexisting
mature hepatocytes under normal physiological conditions [97]. Only when the replicative ability of
resident liver cells is severely hindered, in the case of drug treatment or chronic liver injury, will
HPCs be called into action to regenerate the injured parenchyma [89]. One source of HPC is the
‘oval cells’, small cells with oval nuclei that emerge during chemical hepatocarcinogenesis [89] or
hepatotoxin-induced injury in rodents [196]. Since oval cells display intermediary phenotypes and
histology between hepatocytes and cholangiocytes, their activation is also referred to as ‘ductular
reaction’ [197]. The origin and contribution of oval cells have long been contested due to the lack
of genetic lineage-tracing evidence; thus, the progenitor/descendant relationship was mostly
inferred from their spatial proximity to hepatocytes or cholangiocytes [198,199]. Mature hepatic
cells are other sources of HPC as hepatocytes and cholangiocytes are able to assume the role of
facultative stem cells for one another and transdifferentiate into the other parenchymal cell type.

2-acetylaminofluorene (2-AAF) + PHx
2-AAF is a carcinogen that causes DNA damage and prevents DNA synthesis in
hepatocytes, leading to the development of liver cancer [200]. Treatment of dietary 2-AAF for 2
weeks followed by PHx has been used as a model to induce ductular reactions in rats, as
hepatocytes are unable to undergo cell replication [201]. Activation of 2-AAF is mediated by Nsulfotransferase to generate the active N-OH 2-AAF radical that translocates into the nucleus to
induce DNA damage [202]. However, N-sulfotransferase is not expressed in mice, thus limiting the
use of 2-AAF as an inhibitor of DNA synthesis in this species [202]. Interestingly, isotope labeling
to track DNA synthesis observed labeled ovals cells but few hepatocytes, indicating that oval cells
do not become hepatocytes after AAF-induced liver injury [201]. Another later experiment, however,
identified labeled ovals cells and subsequently hepatocytes, establishing a precursor-product
relationship between the two cell types during liver regeneration [203]. 2-AAF is also used in
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combination with CCl4 or allyl alcohol in rats to cause centrilobular or periportal damages that
induce oval cell activation [204].

3,5-dietoxycarbonyl-1,4-dihydro-collidine (DDC) diet
DDC prevents heme biosynthesis and causes the accumulation of protoporphyrin, leading
to severe porphyria and liver injury [205]. Treatment with 0.01% DDC for 2-4 weeks activates a
ductular reaction and prolonged treatment results in liver cancer in mice [206]. Currently, there is
no consensus on HPC markers in the DDC model but induction of HPC markers including A6 [207],
CK19 [208], epithelial cell adhesion molecule (EpCAM) [209], and FOXL1 [210,211] have been
reported.

The choline-deficient, ethionine-supplemented (CDE) diet
Another model to induce a ductular reaction is the CDE diet, in which a choline-deficient
diet supplemented with 0.05-0.15% (w/v) ethionine mixture in the drinking water is provided to rats
[212] or mice [213] for up to 4 weeks. Choline is a lipotropic factor important for the secretion of
very-low-density lipoprotein (VLDL) [214]; a deficiency in choline causes intracellular lipid
accumulation and hepatocyte membrane rupture, ultimately leading to steatosis followed by
cirrhosis [215,216]. When combined with the potent hepatocarcinogen ethionine, activation of oval
cells can occur followed by induction of liver cancer [212].

III. Mechanisms of liver regeneration
The majority of mature hepatocytes reside in the reversible, nonreplicative G0 phase under
homeostasis [28]. Upon injury, liver cells re-enter the cell cycle and progress through G1, S (DNA
synthesis), G2, and M (mitosis) phases. The cell cycle is tightly-controlled by cyclin proteins, in
which the levels rise and fall to activate downstream target CDKs that control progression through
various cell cycle checkpoints (Figure 1.2) [217,218]. The cyclin D-CDK4/CDK6 complex is the first
to be detected followed by cyclin E-CDK2 formation to promote G1/S transition [219–221]. Next,
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cyclin A-CDK1/CDK2 is activated to regulate S phase along with cyclin B-CDK1 assembly to
modulate G2/M entry [222,223]. Regenerating hepatocytes are highly synchronous in the PHx
model [224], whereas in other paradigms, hepatocytes traverse the cell cycle in a non-synchronous
order [95]. While most studies regarding the mechanisms underlying liver regeneration are
conducted in the PHx model due to its popularity, numerous signaling pathways have been shown
to be important for other models as well. Regardless of the source of injury, liver regeneration is
composed of three distinct phases, the initial ‘priming’ phase where hepatocytes acquire an
enhanced ability to replicate [225], the second ‘progression’ phase that allows hepatocytes to
proceed through the cell cycle to recreate an adequate cell number and mass [226–228], and the
final ‘termination’ phase where liver cell proliferation is stopped once liver mass has returned to
normal [86,228,229].

A. Priming
The priming phase is the initiating event in which terminally-differentiated hepatocytes
acquire enhanced replicative ability that allows for the transition from a quiescent state (G0) to a
competent state (G1) [225,226]. Cytokines released from non-parenchymal cells in the liver act as
paracrine factors to promote signaling pathways in hepatocytes [228]; TNFα [230,231] and IL6
[232] are essential cytokines secreted by Kupffer cells in the early signaling phase. Pretreatment
with TNFα increases the proliferative response to growth factors in rats [233], while administration
of TNFα antibodies [231] as well as deletion of type I TNFα receptor (TNFR1) [234] inhibits DNA
replication and impairs liver regeneration. TNFα activates nuclear factor kappa B (NF-κB) both in
Kupffer cells to increase IL6 transcription [234] and in hepatocytes to activate cell proliferation [235].
IL6 is a proinflammatory cytokine that mediates the acute-phase response [236]. During
the initial phase of liver injury and repopulation, IL6 is secreted from Kupffer cells due to stimulation
by TNFα [231,234]. IL6 binds to its receptor glycoprotein 130 (gp130) [237] to activate transcription
factors, usually within the first hour of PHx, including NF-κB, activator protein 1 (AP-1), signal
transducers and activators of transcription 3 (STAT3), and CCAAT enhancer-binding protein β
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(C/EBPβ), ultimately leading to the expression of immediate-early genes such as Jun, Fos, and
Myc [238,239]. Later studies identified induction of as many as 73 immediate-early genes during
the priming phase [240] and another study reported that almost 40% of immediate-early genes are
induced via IL6 [241]. Deletion of IL6 leads to a decrease of immediate-early gene expression
followed by a 70% reduction of DNA synthesis [232].
The importance of TNFα and IL6 as priming factors can be replicated in other regeneration
paradigms including I/R injury [242], CCl4 [243,244], and APAP hepatotoxicity [245,246], in which
downstream activation of pathways including NF-κB and STAT3 induces expression of immediateearly genes to promote cell cycle entry. Nonetheless, controversies regarding the role of cytokines
during the priming phase arise when conflicting results were found. TNFα-deficient mice do not
exhibit reduced DNA synthesis or delayed regeneration after PHx [247,248]. Similarly, studies
utilizing IL6- or gp130-deleted mice have demonstrated that IL6 does not mediate cell cycle entry
but activates adaptive responses and apoptosis to fine-tune the regenerative process
[237,249,250].

B. Progression
Hepatocytes acquire proliferative competence after priming and transition from G1 to S
phase [226–228]. Commitment to progress through the cell cycle is mediated through early G1
exposure to growth factors including epidermal growth factor (EGF) [251], TGFα [252,253], and
HGF [254]. These factors are also known as ‘direct mitogens’ due to their ability to independently
induce cell growth in cultured hepatocytes. Furthermore, infusion or overexpression of EGF [255],
HGF [256], or TGFα [257] triggers hepatocyte proliferation and liver enlargement in normal rats.
Both HGF and EGF stimulate liver regeneration as paracrine factors [258,259], while TGFα
promotes hepatocyte replication in an autocrine fashion [253].
HGF is produced primarily by stellate cells [260], activated by urokinase [261], and
released from the extracellular matrix during liver regeneration [259]. Plasma levels of HGF are
increased by 20-fold as early as 1 h after PHx in rats [262]. HGF binds to the receptor tyrosine
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kinase HGF receptor (MET) [263] to induce TGFα synthesis in hepatocytes [264], as well as to
stimulate proliferation and survival pathways such as mitogen-activated protein kinase (MAPK) and
phosphoinositide 3-kinase (PI3K) signaling directly, leading to the activation of transcription factors
ETS domain-containing protein (ELK1), MYC, and C/EBPβ [265,266]. Inhibition of HGF activation,
including deletion of urokinase [267], administration of an anti-HGF antibody [268], and conditional
disruption of Met [269,270] causes an impaired regenerative response after PHx and hepatotoxininduced liver injury.
EGF is produced by the Brunner's gland in the duodenum [271] and continuously supplied
to the liver through the portal circulation [258]. Interestingly, no significant change in plasma EGF
concentration was detected after PHx [258], with another study suggesting activation of the
sympathetic system could increase EGF production via norepinephrine [272]. Alternatively, the
removal of two-thirds of the liver mass has been suggested to increase the load of EGF per
hepatocyte by 3-fold [86,229].
TGFα is released from the hepatocyte plasma membrane by the TNFα-converting enzyme
(TACE) that is activated through secreted TNFα during the priming phase [273]. The transcript level
of TGFα increases after 2-3 h, peaks at 12-24 h, and persists for 48 h post-PHx [253]. Both EGF
and TGFα activate the receptor tyrosine kinase EGF receptor (EGFR) [274] to induce proliferation
and prevent apoptosis via activation of MAPK, PI3K, and STAT pathways [265,266,275]. Treatment
with antisense oligonucleotides and antibodies against TGFα reduces the number of replicating
hepatocytes [264,276]. However, the redundancy of EGFR ligands has made it difficult to
definitively demonstrate the requirement of EGF and TGFα for regeneration. Tgfa-/- mice do not
show a significant decrease in DNA synthesis or a delay in regeneration after PHx [277], possibly
due to EGF compensation. However, mice with targeted EGFR deletion display a delayed G1 to S
phase transition and a decreased expression of cyclin D1 after PHx [278], documenting the
importance of EGFR signaling during the progression phase.
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C. Termination
After cell growth and proliferation to restore the loss parenchyma are complete, liver
regeneration stops through the activation of termination signals. Most research has focused on the
mechanisms that induce hepatocyte replication and less is understood about the termination
process. Additionally, the connections between the termination of liver regeneration and the
pathogenesis of liver cancer have equally attracted attention.
TGFβ is the most well-known factor to repress hepatocyte proliferation. Produced by
stellate cells [279], TGFβ is normally sequestered in the extracellular matrix [280]. Many
mechanisms are implicated to release TGFβ during liver regeneration, but no direct evidence has
been provided [281], suggesting multiple factors could be at play to exert the tight regulation of
TGFβ localization. TGFβ mRNA is increased within 3-4 h and peaks at 48-72 h after PHx in rats
[282]. Contrarily, all three TGFβ receptor subtypes are downregulated at the transcript and protein
levels following PHx and only recover at 120 h [283], causing a decreased TGFβ sensitivity in
regenerating hepatocytes isolated after 24-72 h post-PHx [284]. Resistance towards TGFβ via
norepinephrine modulation could explain the observation that hepatocytes are able to continue
DNA synthesis until 72 h post-PHx despite increased TGFβ levels [285]. Cascades of the ‘small
mothers against decapentaplegic’ (SMAD) proteins are activated upon TGFβ receptor
phosphorylation [286,287] to increase expression of CDK inhibitor p15 [288] and prevent assembly
of cyclins and CDK complexes, including cyclin E-CDK2 [289,290] and cyclin D-CDK4 [290],
leading to reversible cell cycle arrest at G1 [289]. TGFβ is a potent inhibitor of EGF-induced DNA
synthesis in cultured rat hepatocytes [291], and infusion of TGFβ reversibly prevents hepatocyte
replication by over 60% at 24 h that returns to normal by 72 h after PHx in rats [292]. Conflicting
studies, however, have questioned the significance of TGFβ as a termination factor.
Overexpression of TGFβ1 under control by the albumin promoter causes hepatic fibrosis due to
collagen deposition but does not affect liver regeneration [293]. Similarly, conditional removal of
the TGFβ type II receptor increases cyclin D and E expression, allowing accelerated S phase entry
to enhance hepatocyte proliferation, but no effect on the termination of regeneration was observed
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[294]. Activin, another member of the TGFβ family, is also implicated in the termination phase as
an autocrine agent that inhibits DNA replication, as its pharmacological inhibition with follistatin
promotes DNA synthesis and leads to hepatomegaly following PHx in rats [295,296].
C/EBPα is a hepatocyte-enriched transcription factor that regulates the expression of
multiple liver-specific genes [297,298]. C/EBPα is transcriptionally regulated during liver
regeneration with a decrease in gene expression by 60-80% 1-3 h [299] and remains repressed
until 24 h after PHx [300]. The drop of Cebpa transcripts during hepatocyte replication echoes
previous observations of its antiproliferative quality in terminally-differentiated adipocytes [301].
C/EBPα induces cell-cycle arrest through various pathways including stabilization of the CDK
inhibitor p21 to disrupt formation of cyclin-CDK complexes [302,303], modulation of growthinhibiting E2F-RB complexes [304,305], direct inhibition of CDK2 and CDK4 [306], induction of
proteasome-dependent degradation of CDK4 [307], and others [308]. Cebpa-/- hepatocytes exhibit
increased DNA synthesis in culture and rapidly form proliferative nodules when inoculated into mice
[309]. Similarly, Cebpa-/- mice display elevated transcript levels of Jun and Myc, as well as an
increased hepatocyte proliferation [310].
Another important regulator of liver mass is the Hippo pathway, named after the Drosophila
hippo gene, which encodes a kinase that regulates organ growth, cell proliferation, and
developmental apoptosis [311,312]. The mammalian orthologs ‘mammalian sterile 20-like 1’
(MST1) and 2 kinases [311] activate the large tumor suppressor 1 (LATS1) and 2 proteins to
phosphorylate and inhibit the activity of the transcriptional coactivator yes-associated protein
(YAP), leading to its nuclear export and protein degradation [313,314]. The Hippo signaling
pathway is altered after PHx, with increased nuclear localization of YAP by 4 h [315] and decreased
kinase activity of MST1 and MST2 1-3 days post-PHx [316]. Upon activation, YAP increases the
expression of genes involved in hepatocyte proliferation such as Ki67, Myc, and H19 [313].
Conditional YAP activation induces liver overgrowth by over 50% after 1 week, and persistent YAP
elevation causes tumorigenesis [313,317]. Similarly, deletion of MST1 and MST2 in mouse livers
leads to loss of YAP phosphorylation and nuclear retention, followed by hepatomegaly and HCC
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[318]. The mechanism of YAP inactivation at the end of liver regeneration is not fully understood
but is hypothesized to include regulation by components of the extracellular matrix such as integrinlinked kinase (ILK) [319,320] and glypican-3 [321,322] to prevent nuclear localization of YAP in
both PHx and toxin-induced liver injury.

D. Other factors to consider
Liver regeneration depends on a complex regulatory network that includes multiple
additional soluble mediators, signaling pathways, and transcription factors not discussed above.
(1) Growth factors including vascular endothelial growth factor (VEGF) [323,324], platelet-derived
growth factor (PDGF) [325,326], FGF [327,328], and heparin-binding EGF-like growth factor (HBEGF) [329]. (2) Extracellular signals such as bile acids [330], serotonin [331], insulin [332,333],
norepinephrine [334,335], complement [336], and CXC chemokines [337,338]. (3) Pathways such
as Wnt/β-catenin [339,340] and Notch/Jagged [341] signaling. (4) Growth-promoting nuclear
receptors including [342] retinoid X receptor (RXR) [343], PPARα [344,345], farnesoid X receptor
(FXR) [330], and pregnane X receptor (PXR) [346]. (5) Growth-inhibiting nuclear receptors [342]
such as PPARγ [347,348] and HNF4α [349]. (6) Other factors such as microRNAs [350].
These signaling pathways have been implicated in multiple liver regeneration models and
manipulation of the pathways generally shows consistent outcomes across various paradigms with
some exceptions. For instance, CXC chemokines promote regeneration after PHx [337] but inhibit
hepatocyte proliferation during I/R [351]. This could be due to the difference in CXC concentration
— 10 times higher following I/R — suggesting that a moderate increase of CXC chemokines
promotes but higher expression inhibits hepatocyte proliferation [352]. Another example is TNFα
signaling, in which TNFR1 deletion prevents DNA synthesis and delays liver regeneration after PHx
[353], but an overexpression cDNA screen identified TNFR1 to be a potent repressor of liver
repopulation in the Fah-/- mouse [185]. The difference in TNFR1 expression levels, TNFα signaling
activation, injury duration, or the inflammatory context could explain the divergent findings [185].
Finally, it is also worth noting that no single gene deletion results in complete abrogation of the
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regenerative process, but at most causes a reduction of replicating hepatocytes and a delay of cell
cycle progression, suggesting substantial redundancy of the diverse signaling pathways
modulating liver regrowth [354].

IV. Source of regenerating hepatocytes
Regenerating hepatocytes can arise from three main sources in a context-dependent
manner: expansion of preexisting hepatocytes, differentiation of oval cells, or transdifferentiation
from cholangiocytes. As discussed above, resident hepatocytes are the first responders to
replenish the hepatocyte pool but oval cells and cholangiocytes have been suggested more than
sixty years ago as contributors of liver regeneration when DNA synthesis is severely impaired in
hepatocytes. During the past decade, several lineage-tracing studies in mice have attempted to
qualify the contribution of various proposed progenitor cells to hepatocyte regeneration. Using the
Sox9CreERT2 system to trace all cholangiocytes, 1-2% of regenerating hepatocytes were lineagelabeled after CCl4, APAP, and DDC administration, indicating that only a small percentage of BECs
contribute to liver regeneration under these settings [30,34]. A similar conclusion was drawn when
oval cells are labeled with osteopontin (OPN) after CDE diet but not with CCl4 or DDC treatment
[355]. Other studies have suggested that FOXL1-expressing HPCs give rise to hepatocytes after a
DDC-supplemented diet [211], or that LGR5-positive organoids can repopulate Fah-/- mouse livers
after transplantation [356]. Interestingly, using a Krt19CreERT2 system in conjunction with DDC or
CDE treatment, no label-bearing hepatocytes arise after regeneration, suggesting that all new
hepatocytes come from preexisting liver cells [357]. This was likely due to limited injury which did
not completely block hepatocyte proliferation, thus deviating the need for replacement from
cholangiocytes acting as facultative progenitors. However, when hepatocyte regeneration is
completely abrogated by severe liver injury, inhibition of hepatocyte replication, or induction of
hepatocyte senescence, a large contribution of cholangiocyte-derived hepatocytes to the
regenerating liver has been documented [358–360]. As it turns out, mouse hepatocytes are more
resilient than those from rats in terms of retaining proliferative potential in the face of liver injury,
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possibly explaining some of the discrepancies in the literature regarding the importance of
cholangiocytes and oval cells as facultative hepatocyte.

V. Clinical implications
To date, the only curative treatment for end-stage liver disease is liver transplant. While it
is the second most common solid organ transplantation after kidney transplant, less than 10% of
global liver transplantation needs are met at current rates [37]. Multiple strategies under active
research for the treatment of liver disease [361,362] include (1) transplantation of primary
hepatocytes or induced pluripotent stem cells (iPSCs), (2) induction of endogenous hepatocyte
replication via pharmacological agents, cytokines, or growth factors, (3) bioartificial livers that
incorporate hepatocytes into a dialysis-based artificial system to carry out the main metabolic
functions of the liver, and (4) organ bioengineering that utilizes a xenogenic scaffold infused with
mature hepatocytes to produce a functional liver graft. With the rising healthcare burden of chronic
liver disease, a deeper understanding of the mechanisms underlying liver repair and regrowth will
enable a broader utilization of regenerative medicine.
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LIVER TRANSCRIPTIONAL CONTROL
I. Overview
Gene regulation is fundamental for all organisms; in particular, the complexity of eukaryotic
transcriptional control allows intricate regulation of expression patterns to adapt to environmental
queues. Transcriptional regulation occurs on several levels. (1) Cis-regulatory modules provide
essential information for transcription factor binding and serve as a platform for the assembly of
regulatory complexes. (2) Chromatin architecture including nucleosome patterning, histone
modification, and DNA methylation impacts the accessibility of the transcriptional machinery. (3)
Intra- and interchromosomal interactions establish topological hotspots for long-range regulation of
gene expression [363].

A. Transcription factors
Transcription factors are trans-acting proteins that bind to cis-regulatory modules at the
promoter or enhancer to activate or repress transcription [364]. Regulation of gene expression is
achieved through various mechanisms including stabilization or blockade of RNA polymerase II
[365], direct or indirect modification of chromatin structure [366], and recruitment of coactivator or
corepressor proteins to the protein-DNA complex [367]. Recruitment of transcription factors to
target sites is established mainly through the structure and sequence of the DNA-binding domains
[363]. Evolutionarily-related transcription factors often share similar DNA recognition motifs and
demonstrate binding redundancy. The specificity of transcription factors is determined by (1)
cooperative or competitive binding with other regulatory proteins [368,369], (2) flexibility of the
DNA-binding domain to recognize noncanonical motifs with mechanisms not yet clear [370], and
(3) posttranslational modifications to affect subcellular localization, protein-protein interactions, and
DNA binding activity of the transcription factors [371]. These mechanisms allow spatiotemporal
binding of transcription factors to fine-tune eukaryotic gene transcription and establish distinct gene
expression patterns.
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B. Chromatin architecture
DNA is compacted into chromatin in the eukaryotic genome. The basic unit of chromatin is
the nucleosome, which consists of 147 base pairs (bp) of DNA tightly wrapped around a histone
octamer with two copies of core histones H2A, H2B, H3, and H4 each [372]. Chromatin is
historically categorized into one of two states based on its accessibility to the transcriptional
machinery. Heterochromatin is highly condensed, transcriptionally inactive, and associates with
repressive histone modifications, whereas euchromatin is relatively accessible to transcriptional
complexes, marked with active histone modifications, and contains actively-transcribed genes
[373,374]. Diverse mechanisms contribute to the modification of chromatin structure and
subsequent changes to DNA accessibility, including nucleosome positioning and occupancy via
ATP-dependent

chromatin

remodelers

[375,376],

DNA

methylation

through

DNA

methyltransferases (DNMT) and demethylation via ten-eleven translocation (TET) proteins [377],
and epigenetic modifications of the core histones such as methylation, acetylation,
phosphorylation, and ubiquitination [378].

C. Three-dimensional structure
The three-dimensional structure of chromatin provides an additional layer of transcriptional
control through the regulation of nuclear organization and chromosomal interactions.
(1) Nuclear organization. The nucleus is divided into functional domains in which
chromosomes occupancy at different regions is associated with divergent transcriptional activity
[379]. The non-uniform compartment of the nuclear interior enables highly-organized structures to
establish chromatin territories based on gene activity and density; gene-rich regions are typically
located in the nuclear center and gene-poor chromatin in the periphery [380].
(2) Chromosomal interactions. The identification of cis-regulatory modules located far from
the promoters they regulate has led to the discovery of looping as the predominant mechanism for
enhancer-promoter interactions [381]. Long-range chromatin communication includes interactions
between regulatory sequences of a single locus [382], among elements within a gene complex
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[383], and between chromosomes [384]. Technological advances utilizing proximity-ligation
followed by deep-sequencing [385] and high-resolution microscopy [386] methods will further allow
the elucidation of inter- and intrachromosomal interactions to establish cell type-specific
transcriptional regulation.

II. Discovery of liver transcriptional control
A. Liver-specific gene expression
Studies on transcriptional control were pioneered by the laboratory of James Darnell
starting in the early 1980s [387]. Rat liver nuclei became one of the first mammalian systems used
to investigate gene expression regulation due to the large number of available cells and the
relatively pure cell types, where hepatocytes constitute approximately 80% of the liver mass [388]
and 60% of liver cell number [389]. Liver-specific gene sequences were isolated via the extraction
of polyadenylated (poly(A)) RNA, reverse transcription into cDNA, and recombination with
antibiotic-resistant E. coli plasmids [390]. DNA from individual colonies was used as a template to
hybridize with nascent, radiolabeled mRNA isolated from rat liver nuclei [390]. The hybridization
signals from liver nuclear RNA is at least 10 times stronger than those from non-liver cells,
suggesting a differential abundance of tissue-specific mRNA [390]. Further analysis to compare
the transcription rate of liver-enriched mRNA in liver and brain nuclei revealed that transcriptional
regulation plays a primary role in establishing differential gene expression in various terminallydifferentiated cell types [390].

B. Liver-specific regulatory regions
Analysis of liver-enriched genes in human and rodent ensued, unveiling tissue-specific
regulatory regions including proximal promoters and distal enhancers that control the expression
of cell type-specific genes. For instance, the 5’ flanking sequences of rat Alb drives efficient
expression of a reporter gene, chloramphenicol acetyltransferase, preferentially in ALB-expressing
hepatoma cells [391]. The promoter-proximal region of human SERPINA1 that encodes the α133

antitrypsin (AAT) enzyme is sufficient for the transcription in Hep3B, a human hepatoma cell line,
but not in HeLa cells [392]. Similarly, expression of distal enhancers of the mouse Ttr, encoding
transthyretin (TTR), activates β-globulin transcription specifically in human hepatoma cells HepG2
but not in HeLa cells [393]. These observations suggest a combination of cis-regulatory sequences
and trans-acting factors in particular cell types establishes tissue-specific expression regulation.
In addition, two hypotheses concerning cell type-specific transcriptional control through
trans-acting proteins emerged [392,394]. It was proposed that activating factors expressed only in
particular tissues govern gene expression. However, some liver-enriched genes are also
expressed in other cell types, such as Serpina1 in macrophages [395], certain apolipoproteins in
the gut [396], and Ttr in the choroid plexus [397]. This implicates that the activating mechanism in
addition to the distribution of the activating factors exhibits liver specificity [394]. Furthermore, it
was later shown that most, if not all, so-called ‘liver-specific’ transcription factors are also expressed
in other cell types [398–401]. Another line of hypothesis suggested the presence of inhibiting factors
to prevent gene expression in specific tissues [392,394]. This implies that a repressor is required
for each gene to be not expressed in a certain cell type, suggesting a requirement for a large
number of negative factors to restrict transcription in non-expressing tissues. Thus, a more
plausible explanation of tissue-specific transcriptional control is that a unique combination of
several liver-enriched positive and negative trans-acting factors modulate expression in a cell typespecific manner [402]. Various liver-enriched, but not necessarily liver-specific, activators induce
expression [402,403] and repressors inhibit transcription to establish a liver-specific gene
expression profile [404].

C. Liver-specific transcription factors
From the late 1980s to 1990s, the use of DNA sequence affinity chromatography with rat
liver nuclear extracts enabled identification of several transcription factors highly expressed in the
liver, collectively referred to as hepatocyte nuclear factors [398,403,405,406]. DNA sequences of
liver-enriched genes suspected to encompass transcription factor binding sites were used as bait
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to isolate protein-DNA complexes followed by high-performance liquid chromatography (HPLC) to
purify the protein of interest. The partial amino acid sequences of the protein peptides were
determined and used to design primers for PCR amplification from hepatoma cell lines. The
amplified products were then used to screen rat cDNA libraries to obtain clones that encode the
gene sequence of each liver-enriched transcription factor.

III. Hepatocyte nuclear factors
A. HNF1
HNF1 was identified as a nuclear protein that binds to the promoters of fibrinogen α and β
chains, as well as AAT in hepatocytes [405]. The HNF1 subfamily contains two isoforms, HNF1α
and HNF1β. Analysis of the ALB promoter established the requirement of the albumin proximal
factor (APF), later found to be HNF1α, for Alb transcription [407]. HNF1α was initially only detected
in differentiated rat hepatoma cells whereas HNF1β, originally identified as modified APF (vAPF),
was observed in two dedifferentiated rat hepatoma cell lines [407]. Later studies confirmed
expression of HNF1α and HNF1β in the liver, pancreas, intestine, and kidney [399,408], with
HNF1α detected at much higher levels and HNF1β lower except for in the kidney [409,410]. HNF1β
could exhibit broader physiological implications as it is also observed in the lung, testis, and ovary
[401,411].
HNF1 is a member of the POU homeobox gene family [412]. The N-terminal contains the
dimerization domain that allows the homeoproteins to dimerize [409], the DNA-binding domain
consists of a bipartite POU homeodomain [412], and the C-terminal includes different
transactivation domains less conserved within the subfamily, in which HNF1α demonstrates a
higher transactivation potency than that of HNF1β [413]. Analysis of the promoters of various liverenriched genes from rat, mouse, and human predicted the HNF1 consensus binding sequence as
GTTAATNATTAAC [414]; both isoforms share the same DNA-binding motif with different
transcriptional activity [415]. The homeoproteins form homo- and heterodimers within the subfamily
[409,410], where HNF1α is able to dimerize without binding to the DNA recognition sequence.
35

Additionally, a dimerization cofactor of HNF1α, DCoH, selectively stabilizes the homodimers and
assembles a tetrameric complex to enhance the trans-activating ability of HNF1α [416].
Sequence homology analysis determined additional HNF1α target genes including Alb
[407], Ttr [414], Afp [414,417], Apoa2 that produces apolipoprotein A-II (ApoA-II) [418], and Apob,
encoding the protein ApoB-100 [419]. Genome-wide analysis of HNF1α footprinting with chromatin
immunoprecipitation (ChIP) followed by high-throughput sequencing (ChIP-seq) further identified
HNF1α targets crucial for liver synthetic functions, such as carbohydrates, cholesterol,
apolipoproteins, CYP450, and serum proteins [420]. Similar to HNF1α, HNF1β occupies the Alb
proximal promoter to activate transcription [409]. Additional HNF1β targets determined through loss
of HNF1β include Slco1a1 that encodes the member 1a1 of the solute carrier organic anion
transporter family (OATP-1) for bile acid reabsorption, and Acadvl, the very long-chain-acylCoenzyme A dehydrogenase (VCLAD) required for fatty acid oxidation [421].
During development, HNF1β is first detected on E4.5 in the endoderm of the foregut, while
HNF1α expression is activated later on E8.5 in the yolk sac [422]. HNF1α and HNF1β are also
present on E10.5 after the initiation of hepatocyte lineage in the liver primordia and continue to be
expressed throughout embryonic development [423]. These observations suggest that HNF1β
participates in the initial transcriptional activation of genes in the visceral endoderm, and the later
activation of HNF1α could be required to maintain target gene expression for liver function [422].
Hnf1a transcript levels gradually decrease at the late period of embryonic liver development while
Hnf1b increases [424].
Hnf1a-/- mice die around weaning due to hepatic dysfunction, phenylketonuria, and renal
Fanconi syndrome [425]. HNF1α-deficient livers are enlarged with decreased Alb expression but a
compensatory increase of HNF1β partially rescues the expression of ALB, AAT, and fibrinogen
[425]. Since HNF1α deletion is not embryonically lethal, it is likely not required for specification of
the hepatocyte cell lineage but important for the expression of differentiated liver function genes.
HNF1β-deficient mice die by E7.5 due to the lack of extraembryonic endoderm
development [426]. Hnf1b-/- tetraploid complementation established that HNF1β activity is required
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for visceral endoderm differentiation to direct the expression of HNF4 and other endoderm marker
genes [408]. Further tetraploid embryo complement analysis showed that Hnf1b-/- mice do not form
the hepatic bud and lack expression of liver-enriched genes [427]. Conditional HNF1β ablation
using the Hnf1bF/F;AlfpCre mouse causes abnormal gallbladder and intrahepatic bile duct formation,
resulting in severe growth retardation and jaundice; liver metabolism was also affected, with
downregulation of genes involved in bile acid sensing and fatty acid oxidation [421]. These studies
implicate that HNF1β is required for endoderm commitment, hepatic specification, and bile duct
morphogenesis during liver organogenesis.
Altogether, HNF1 proteins are important in establishing mature hepatic functions and
appropriate bile duct differentiation. Interestingly, heterozygous human HNF1 mutations do not
cause abnormalities in the liver but rather dysfunctions of the pancreatic islets; HNF1α mutations
lead to autosomal dominant maturity-onset diabetes of the young type 3 (MODY3) [428] and HNF1β
mutations result in MODY5 [429].

B. HNF3/FOXA3
HNF3 proteins were described due to their ability to occupy TTR and AAT promoters at
sites distinct from HNF1 and C/EBP [403]. Ttr contains two recognition sequences for HNF3 within
150 bp upstream of the transcriptional start site. Mutation of the most 3’ HNF3 binding site results
in decreased Ttr expression, despite all other enhancer and promoter sequences being intact,
indicating the importance of HNF3 for Ttr transcriptional activation [403]. The HNF3 family consists
of three members identified from the purification of distinct protein-DNA complexes that bind to the
mouse Ttr promoter, HNF3α, 3β, and 3γ [430–432]. The DNA-binding domains of all three
members are highly conserved and share 90% amino acid similarity that matches the sequences
of the Drosophila Fox nuclear protein [433]. Therefore, HNF3 proteins were renamed according to
the nomenclature of all forkhead transcription factors to ‘FOXA’ [434]. The FOXA proteins are
functionally redundant in the liver [435], of which FOXA3 exhibits the highest expression in adult
hepatocytes [436].
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FOXA proteins are members of the FOX family [430] and belong to the FOXA subfamily
[434]. The forkhead box DNA binding domain is comprised of three α-helices flanked by two
winged-like loops, thus the DNA recognition sequence is also referred to as the winged-helix
domain [437]. All FOXA proteins share up to 95% sequence similarity in the DNA binding domain
flanked by the nuclear localization sequence [438]. Outside of the FOX domain, the N and C termini
also demonstrate high sequence conservation, and functional analysis of FOXA2 revealed their
activity as transcriptional activators [432,438]. Within these domains, regions II, III, and IV
contribute to transactivation, where the activity of region IV is dependent on the other two [432].
Analysis of FOXA binding sites in Ttr and Serpina1 regulatory regions indicated the consensus
sequence as TATTAGAYTTWG, where Y is C/T and W is A/T [403]. FOXA proteins bind to DNA
as monomers [439].
Other hepatocyte-specific genes regulated by FOXA proteins include the Alb enhancer
[404] and promoter [440], the Afp distal enhancer [441], the Apob promoter [442], and the Pfkfb1
proximal promoter that controls the expression of 6-phosphofructo-2-kinase/fructose-2,6bisphosphatase 1 (PFK/FBPase 1) [443]. Furthermore, the structure of the winged-helix domain is
similar to that of linker histones H1 and H5, proteins that induce DNA compaction with the
nucleosome core to repress gene expression [437]. FOXA proteins are able to bind DNA on the
nucleosome core to displace linker histones and increase chromatin accessibility, leading to
transcriptional activation [444]; hence, FOXA proteins are also known as ‘pioneer factors’.
FOXA2 is expressed on E6.5 in the node at the anterior primitive streak and is the first
member of the FOXA subfamily to be expressed [445]. Its expression persists throughout the
development of endoderm-derived tissues such as the liver, pancreas, and the intestine, and
continues into adulthood [445]. FOXA1 displays a similar expression pattern as that of FOXA2 but
is detected later on E7.0 in the primitive endoderm, whereas FOXA3 is expressed starting on E8.5
during hindgut differentiation [445].
Foxa1-/- embryos develop to term but have severe postnatal growth retardation and die
between postnatal day 2 (P2) to P12 [446]. FOXA1-deficient mice experience hypoglycemia and
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changes in islet glucagon gene expression, but no liver phenotype is observed prior to death [446],
suggesting that FOXA1 is not required for early mouse development but is central to the regulation
of glucose homeostasis.
FOXA2 deletion is embryonically lethal by E11 due to the lack of node and notochord
formation, causing death prior to the formation of liver bud [447,448]. Conditional FOXA2 ablation
with the Foxa2F/F;AlbCre mouse does not induce any significant disruption of the liver phenotype or
cause apparent changes in gene expression, indicating that FOXA2 is dispensable in maintaining
hepatocytes at a differentiated state [435]. However, Foxa2F/F;AlfpCre livers fail to integrate
transcriptional response during prolonged fasting since expression of gluconeogenic enzymes
typically activated during fasting is not induced, as seen in the cases of Pck1 that encodes the
cytosolic

phosphoenolpyruvate

carboxykinase

(PEPCK-C),

Tat

that

produces

tyrosine

aminotransferase (TAT), and Igfbp1, encoding insulin-like growth factor-binding protein 1 (IGFBP1) [449]. Whole-body FOXA1 deletion and endoderm-specific ablation of FOXA2 with the Foxa1-/;Foxa2F/F;Foxa3Cre mouse showed a lack of liver bud formation and loss of hepatoblast marker Afp,
indicating that FOXA1 and 2 are required for hepatognesis during embryonic development [22].
Furthermore, combinatorial deletion of FOXA1 and 2 in the liver through Foxa1F/F;Foxa2F/F;AlfpCre
mice causes bile duct expansion and proliferation, leading to biliary tree hyperplasia while liver
differentiation is unaffected [450]. In short, these studies indicate that FOXA2 is required for early
embryonic development prior to liver differentiation as well as bile duct maintenance, and FOXA1
and 2 are essential for liver bud specification.
FOXA3 ablation results in a 50-70% decrease in the expression of several hepatocytespecific genes, including Pck1, Tat, and Tf (Trf) that encodes transferrin along with a compensatory
increase of FOXA1 and 2 [451]. Additionally, Foxa3-/- mice exhibit hypoglycemia after prolonged
fasting that associates with a decreased liver expression of Slc2a2 (Glut2), encoding the type 2
glucose transporter (GLUT-2) [452]. While FOXA3 deletion is not sufficient to cause severe liver
function defects, it is required for mediating fasting glucose homeostasis.
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During the acute phase after PHx, Foxa1 expression is dramatically decreased followed
by the downregulation of its target gene Ttr, whereas Foxa3 level fluctuates minimally, suggesting
that FOXA1, but not 3, is regulated by proliferative signals during liver regeneration [453]. On the
other hand, both Foxa2 and Foxa3 expression are significantly reduced in CCl4-induced liver injury
[454,455]. Furthermore, injection of AAV8-TBG-Cre into Foxa2F/F mice exacerbates CCl4-induced
liver fibrosis while FOXA2 overexpression alleviates collagen deposition and reduces ER stress,
indicating the hepatoprotective potential of FOXA2 during liver injury [455].

C. HNF4
HNF4 was identified as a nuclear protein with distinct recognition properties from C/EBP,
HNF1, and FOXA in its binding to the promoters of TTR and AAT [403]. HNF4 proteins include
three isoforms, HNF4α, 4β, and 4γ, but HNF4β is not detected in human or mouse [456]. HNF4α
is expressed in the liver, kidney, pancreas, small intestine, colon, and testis [400], while HNF4γ is
observed in all tissues mentioned above except for the liver [400]. HNF4α is transcriptionally
regulated through two developmentally-controlled promoters P1 and P2 that are separated by more
than 45 kilobases (kb) [457]. Differential promoter usage combined with alternative splicing
produces six P1 isoforms, HNF4α1 to α6, and three P2 isoforms, HNFα7 to α12 [400,457,458].
However, the impact of HNF4α isoforms on the transcriptional control of downstream targets
remains largely unknown.
HNF4 belongs to the nuclear hormone receptor superfamily that includes receptors for
steroids, retinoids, thyroid hormones, and vitamin D [459,460]. Originally classified as an orphan
member of the superfamily due to the lack of defined ligands, it was later observed that fatty acylCoA thioesters modulate HNF4 activity [461] and linoleic acid acts as the endogenous HNF4α
ligand [462]. HNF4α displays the conventional modular structure of nuclear receptors that
encompasses six functional regions A-F [460]. The N terminal contains the less conserved A/B
region with the activation function 1 (AF-1) domain that acts as a constitutive autonomous
transactivator [463]. Region C encodes the highly-conserved DNA-binding domain with two zinc
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fingers [459] and is responsible for dimerization on the DNA [464]. Region D refers to a hinge that
connects regions C and E [460], in which region E represents a conserved ligand-binding domain
that contributes to protein dimerization in the absence of DNA binding [464]. The ligand-binding
domain also prevents heterodimerization with RXRα and potentially other nuclear receptors that
share similar DNA recognition sequences [465]. Additionally, region E consists of a second
activation domain AF-2 with ligand-dependent transcriptional activity, providing an additional layer
of HNF4α regulation [463]. Region F is located at the C-terminus and contains a unique repressive
feature of the nuclear receptor superfamily to inhibit AF-2 [463]. Together, AF-1 and AF-2 activate
transcription in a cell type-independent manner [463]. All HNF4α isoforms share the same DNAbinding domain and 90% of protein structure homology. The main difference between P1 and P2
classes is the lack of AF-1 at the N-terminus in P2 isoforms [466]. Finally, the zinc finger motifs
bind to the hormone response elements located in promoters exclusively as homodimers to
modulate transcription of HNF4α target genes [464,467].
Initial analysis of the HNF4 binding sites at regulatory regions of Ttr, Serpina1, and Apoc3,
which encodes Apoc-III, suggested the consensus sequence as KGCWARGKYCAY, where K is
G/T, W is A/T, R is A/G, and Y is C/T [459]. Later analyses demonstrated that HNF4 recognizes
repeats of half-site motifs AGGTCA separated by one or two nucleotides [465], as well as a
sequence of NNNNCAAAGTCCA [468]. HNF4α regulates gene expression involved in glucose,
cholesterol, and fatty acid metabolism through binding to promoters of apolipoproteins Apoa1 [469],
Apob [470], and Apoc3 [470,471], as well as Hnf1a [459], Tf [472], and F7 that produces the human
coagulation factor VII [473].
HNF4α mRNA is detected as early as E4.5 in the primitive endoderm of the blastocyte
[474]; expression persists throughout liver development until adulthood to maintain hepatocytes at
a differentiated state [466]. HNF4α ablation is embryonically lethal due to the lack of extraembryonic
tissue development past E5.0 [475]. Tetraploid rescue of Hnf4a-/- embryos displays liver
specification without full differentiation that lacks expression of a number of liver marker genes such
as Alb, Afp, Tf, apolipoproteins Apoa1, Apoa4, Apob, Apoc2, and Apoc3, Nr1i2 (Pxr), Pah that
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produces phenylalanine-4-hydroxylase (PAH), and liver-type fatty acid-binding protein (L-FABP)
encoded by Fabp1 [476]. Hnf4aF/F;AlfpCre mice fail to undergo fetal liver epithelial transformation
due to the lack of expression involved in cell adhesion and cell junction assembly [477]. On E18.5,
HNF4α-deficient embryonic hepatocytes also demonstrate decreased gene expression related to
glucose homeostasis including Pck1, Gys2 that encodes the liver glycogen synthase, and G6pc
that produces glucose-6-phosphatase (G6Pase) [478]. Conditional HNF4α deletion with
Hnf4aF/F;AlbCre results in lipid accumulation with reduced serum cholesterol and triglyceride, while
serum bile acid level is increased, coinciding with the reduction of Apob, Fabp1, Slco1a1, and
Slc10a1 (Ntcp) that

encodes the sodium/bile acid cotransporter [479]. Furthermore,

Hnf4aF/F;AlbCreERT2 mice treated with tamoxifen to remove HNF4α from mature hepatocytes exhibit
elevated hepatocyte proliferation with increased expression of cell cycle genes [349]. Together,
these studies utilizing transgenic mice suggest the requirement of HNF4α from early liver
development for the establishment of epithelial morphology to maintenance of the mature
hepatocyte phenotype including lipid, bile acid, cholesterol, and glucose homeostasis through
gluconeogenesis and glycogen synthesis. Similar to that observed for HNF1, heterozygous HNF4α
mutation affects the pancreas and causes autosomal dominant MODY1 in humans, with no obvious
phenotypic deficiencies observed in the liver [480].
HNF4α activity is modulated through post-translational modifications. Phosphorylation of
tyrosine residues is necessary for proper nuclear compartment localization, as well as the
maintenance of DNA-binding activity and transactivation ability [481]. Additionally, cyclic AMP
(cAMP) response element-binding protein (CBP) acetylation of lysine residues within the nuclear
localization sequence is required for nuclear retention, DNA sequence binding, and target gene
activation [482].

D. HNF6
HNF6 was identified via the protein-DNA complex formed with Pfkfb1 [483], which encodes
a bifunctional enzyme that synthesizes and degrades the key regulator of glycolysis, fructose 2,642

bisphosphate [484]. Analysis of the Pfkfb1 promoter identified two cis-acting sequences that
account for approximately 50% of the transcriptional activity [406]. DNA-affinity labeling from rat
liver nuclear proteins with the sequence from site IV of the Pfkfb1 promoter was utilized to extract
and purify a liver-specific factor originally identified as LP4 and later renamed HNF6 [483]. The
HNF6 subfamily includes two isoforms HNF6α and HNF6β that differ by the linker sequence
between the cut domain and the homeodomain [483]. Both isoforms display transactivating abilities,
but the DNA-binding affinity depends on the target gene sequence [485].
HNF6 belongs to the ONECUT homeodomain family that includes HNF6 (OC1), OC2, and
OC3 [483]. CUT homeodomain proteins were initially described in the Drosophila cut gene [486]
and the mammalian homologs mclox gene [487], both consisting of three CUT domains.
Interestingly, HNF6 only exhibits a single CUT domain, hence the nomenclature as ‘ONECUT’
homeodomain [485]. The N terminus contains the STP box, a serine/threonine/proline-enriched
region, that functions as a transcriptional activator [483]; the C terminus encompasses the bipartite
DNA-binding domain formed by the CUT domain (CD) and the homeodomain (HD) [485]. Both
HNF6 isoforms bind DNA as monomers and do not form heterodimers [485].
Comparison of HNF6 binding sites of liver-enriched genes including Afp, Hnf3b, Pck1, and
Ttr determined the consensus sequence as DWRTCMATND, where D is not C, W is A/T, R is A/G,
M is A/C [485]. In addition to controlling Foxa2 [488] and Hnf4a [489] expression, HNF6 activates
the promoters of various liver function genes including Ttr [490], Afp [485], and Gck that encodes
glucokinase (GCK) [491].
HNF6 is expressed at early developmental stages in the liver, pancreas, and neurons,
suggesting its importance in regulating various differentiation programs [489]. HNF6 is detected on
E9 prior to liver differentiation and continues to be expressed in the liver and the extrahepatic biliary
system throughout development [489]. Hnf6-/- embryos lack the gallbladder primordium, resulting
in abnormal morphology of extrahepatic bile ducts and perturbed development of intrahepatic bile
ducts [492]. HNF6-deficient mice exhibit abnormal bile duct morphogenesis with increased
mortality between P1-10 likely due to increased cholestasis that results in liver necrosis [492]. Hnf643

/-

mice also display reduced HNF1β expression in the biliary epithelial cells during development

[492]. Hnf6F/F;AlbCre mice demonstrate normal intrahepatic bile duct morphology with no indication
of liver injury as measured by serum AST, ALT, and total bilirubin levels [493]. Nonetheless, a later
study examining conditional Hnf6 ablation in the adult mouse liver through AAV8-TBG-Cre injection
into Hnf6F/F mice showed severe hepatosteatosis with the induction of genes involved in oxidationreduction and lipid metabolism [494]. Furthermore, ectopic HNF6 overexpression via adenovirus
prior to PHx leads to an increased number of replicating hepatocytes entering S phase as well as
upregulation of the mitogen TGFα, cell cycle regulator cyclin D1, and the transcription factor
FOXM1 [495]. These observations implicate a crucial role of HNF6 during liver development and
cholangiocyte differentiation, as well as its importance in transcriptional repression of lipid
metabolic genes and the stimulation of hepatocyte proliferation during liver regeneration.
HNF6 expression can be elevated by growth hormone [496] through increased STAT5 and
HNF4α occupancy [497] in conjunction with the displacement of C/EBPα at the HNF6 promoter
[498].

E. C/EBP
C/EBP was discovered as a heat-stable nuclear protein to selectively bind to the CCAAT
motif of several viral promoters [499] and viral enhancer core elements [500] in the rat liver nuclei
[501]. The C/EBP subfamily consists of several isoforms including C/EBPα, C/EBPβ, C/EBPγ,
C/EBPδ, C/EBPε, and C/EBPζ, but only the first three are enriched in the liver [502], with C/EBPα
the most predominant isoform expressed in adult hepatocytes [503].
C/EBPα, originally named C/EBP, was identified through analysis of Alb, Ttr, and Serpina1
promoters and the simian virus 40 (SV40) core C enhancer element [297,298]. C/EBPβ was
described as a nuclear factor to activate IL6 transcription after IL1 induction, hence its original
nomenclature, NF-IL6 [504]. C/EBPβ also binds to regulatory regions of several acute-phase genes
including TNF and IL8, indicating its importance to regulate acute inflammatory responses [504].
C/EBPγ was purified as a protein to bind the B cell-specific enhancer and promoter regions of the
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immunoglobulin heavy chain (IgH) [505]. Subsequent structural analysis of C/EBPγ demonstrated
the lack of transactivating domain observed in C/EBPα and β, suggesting the unlikelihood of
C/EBPγ as a direct transcriptional activator or repressor [506]. Rather, C/EBPγ functions as a
transdominant negative inhibitor and heterodimerizes with C/EBPα or β to repress their
transcriptional activity [506].
C/EBP proteins belong to a larger structural category of the basic leucine zipper (bZIP)
family of transcription factors [507], one of the most conserved groups of eukaryotic transcription
factors that include JUN, FOS, and cAMP-responsive element-binding (CREB) proteins [502]. The
C/EBP subfamily exhibits modular structures that contain an N-terminal transactivating region
[508], a basic DNA-binding domain, and a C-terminal leucine zipper [508]; all C/EBP isoforms share
over 90% of sequence homology at the bZIP domain [501,507,509]. C/EBP binds to the DNA as
homo- or heterodimers and forms intrafamilial heterodimers to recognize the same consensus
sequence, with the exception of C/EBPζ [505,507,510].
The consensus motif for C/EBP proteins is RTTGCGYAAY, where R is A/G and Y is C/T
[511]. Other than Alb and Ttr, C/EBPα also regulates the expression of liver-specific or -enriched
genes including Pck1 [512], Tf [472], Slc2a2 [513], Igf1 that produces the insulin-like growth factor
I (IGF-1) [514], F9 that encodes the coagulation factor IX [515], and several CYP450 genes [442].
C/EBPβ controls metabolic gene production such as Cyp2d5 [516], Pck1 [517], Aldh1a1 that
encodes the cytosolic aldehyde dehydrogenase (RALDH 1) [518], Ca3 (Car3) that produces
carbonic anhydrase 3 (CA-III) [518], and several other genes encoding acute-phase proteins during
inflammation such as serum amyloid A (SAA) [519] and C-reactive protein (CRP) [520].
C/EBP transcription factors are pivotal for a variety of functions including cell proliferation,
differentiation,

metabolism,

inflammation,

tumorigenesis,

and

apoptosis,

particularly

in

hepatocytes, adipocytes, and hematopoietic cells [521]. C/EBPα expression is detected on E9.5 in
the mouse endoderm in the liver primordium, while C/EBPβ expression is detected between E13.5
and E14.5 in the liver [522]. Cebpa-/- mice fail to store hepatic glycogen and die within 8 hours after
birth due to hypoglycemia associated with reduced or delayed gene expression of Gys2 and two
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gluconeogenic enzymes, PEPCK and G6Pase [523]. Injection of AAV-Cre into CebpaF/F mice to
remove up to 90% of C/EBPα expression in the adult liver demonstrated decreased expression of
bilirubin UDP-glucuronosyltransferase (UGT), an enzyme required for bilirubin conjugation and
detoxification [524], leading to adult-onset jaundice [525]. Expression of Pck1, Gys2, and F9 was
also decreased in the adult mouse liver with conditional C/EBPα ablation [525]. These experiments
demonstrate the importance of C/EBPα as a central role for gluconeogenesis, glycogen synthesis,
and bilirubin homeostasis in the liver.
The role of C/EBPβ in metabolic regulation is complex. Half of Cebpb-/- mice exhibit
steadystate glucose homeostasis but demonstrate fasting hypoglycemia and impaired hepatic
glucose production. The other half die at birth due to hypoglycemia attributed to the absence of
PEPCK expression followed by the inability to mobilize glycogen stores [517]. In mice injected with
concanavalin A to induce immune-mediated liver injury, C/EBPβ nuclear expression is increased
as early as 1 h and mRNA levels increased 4 h after liver injury, but returns to normal before
entering S phase [526]. C/EBPβ-deficient mice display decreased DNA synthesis and suppression
of immediate-early growth response genes, Mkp1 and Egr1, 1 h post-PHx [239]. Furthermore,
Cebpb-/- livers also show sustained hypoglycemia in conjunction with dysregulation of genes
important for hepatic gluconeogenesis after PHx [239], suggesting the significance of C/EBPβ for
glucose homeostasis after profound metabolic stress such as PHx.

IV. Regulatory circuits of liver-enriched transcription factors
The liver-enriched transcription factors form a cooperative network to establish
transcriptional control and to synergistically interact with one another to maintain a hepatocytespecific gene expression profile [527,528]. Of all transcription factors highly-expressed in
hepatocytes, HNF1α and HNF4α deficiency correlate with the lack of liver-specific gene expression
in dedifferentiated hepatomas and hepatocyte-fibroblast hybrids [527]. Furthermore, HNF1α and
HNF4α reexpression correspond to the transcription of hepatocyte-specific genes in hybrid cells
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[529]. These observations led to the hypothesis that HNF1α and HNF4α are the primary
transcriptional regulators to maintain the differentiated hepatic phenotype.
In particular, several independent observations suggest that HNF4α could function as the
master regulator that sits atop the transcriptional cascade during hepatocyte differentiation
[459,474]. (1) HNF4α mRNA is detected as early as E4.5 in the primitive endoderm of the blastocyte
[474], preceding the expression of HNF1α on E8.5 [422]. (2) HNF4α is able to overcome the
repression in dedifferentiated hepatoma cells to induce expression of epithelial marker genes
[530,531]. (3) HNF4α transcriptionally activates HNF1α [459]. (4) Hnfa-/- mice are embryonically
lethal due to the lack of extraembryonic tissue development [475] while Hnf1a-/- mice are viable at
birth and die around weaning due to hepatic dysfunction [425]. (5) HNF4α occupies around 12% of
the hepatocyte genome as determined with human DNA microarray, while HNF1α targets 1.6%
and HNF6 1.4%, implying that HNF4α contributes to the regulation of a large portion of liver gene
expression [420].
Later studies revealed the complex regulation between liver-enriched transcription factors
and proposed that the interplay of hepatocyte nuclear factors presumably resembles a regulatory
circuitry, rather than a linear hierarchy [527], in a context-dependent manner [420] summarized in
Figure 1.3.
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SPECIFIC AIMS
In summary, liver regeneration encompasses crosstalk from different cell types,
interactions of various signaling pathways, and modulation of the chromatin architecture to initiate
complex networks of transcriptional regulation. While the regenerative response is well described
in PHx, it is less evident in injury models. Hence, the goal of this thesis is to utilize unbiased
transcriptome- and epigenome-wide techniques to identify regulators of liver regeneration following
acute injury. I hypothesize that investigating the modifications of gene expression and chromatin
accessibility via cell type-specific analyses of regenerating hepatocytes in the Fah-/- model will
enable the identification of essential factors of liver repopulation.
In Specific Aim 1, I propose to perform transcriptomic profiling of regenerating hepatocytes
to identify drivers of liver proliferation. With the combination of the translating ribosome affinity
purification (TRAP) system [532] and the Fah-/- model, regenerating hepatocytes will be explicitly
isolated followed by high-throughput RNA-sequencing (TRAP-seq) to interrogate gene expression
alterations during liver repopulation. Overexpression and inhibition studies will be carried out to
investigate the functional significance of genes of interest as promoters of hepatocyte replication
following acute liver injury.
In Specific Aim 2, I will assess the assotiation of chromatin accessibility modification and
gene expression regulation during the repopulation process. With the implementation of the '
isolation of nuclei tagged in specific cell types' (INTACT) method [533] in the Fah-/- mouse,
regenerating hepatocyte nuclei will be labeled and sorted followed by the 'assay for transposase
accessible chromatin with high-throughput sequencing' (ATAC-seq) [534] to elucidate changes in
the chromatin landscape. I propose to integrate multiomic datasets to identify crucial transcription
factors and regulatory networks that underlie the regenerative process.
This thesis combines a mouse model reflective of human diseases, systematic in vivo
analyses, and functional validation of genes and transcription factors during liver regeneration. By
addressing these aims, I expect to identify novel therapeutic targets and critical regulators to
enhance liver regeneration following acute injury.
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FIGURES
Figure 0.1. Schematic representation of a liver lobule.

The liver consists of various cell types including hepatocytes, cholangiocytes, stellate cells, Kupffer
cells, and sinusoidal endothelial cells. The portal triad is located in zone one and contains the bile
duct, hepatic artery, and portal vein, whereas the central vein resides in zone three. Together, the
portal vein and the hepatic artery move through the sinusoid toward the central vein to provide
blood supply to the liver. On the contrary, bile acids move from zone three to zone one in the bile
duct.
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Figure 0.2. Regulation of the cell cycle by cyclin proteins and cyclin-dependent kinases (CDK).

The cell cycle is tightly controlled by the rise and fall of cyclin proteins that lead to the activation of
CDKs to promote progression through cell cycle checkpoints.

50

Figure 0.3. Liver-enriched transcription factors form a complex regulatory network.

HNF4α activates HNF1α expression [459,535]. HNF1α negatively autoregulates its own expression
[536] and inhibits HNF4α via suppression of the AF2- domain [537]. HNF1α also binds to a 3’
enhancer site to activate FOXA3 transcription [538]. HNF6 activates FOXA2 [488] and HNF4α
[489], while FOXA2 is required for FOXA1 expression [539]. Additionally, FOXA1 and 2 compete
for FOXA motifs on HNF1α and HNF4α, in which FOXA1 represses while FOXA2 induces HNF1α
and HNF4α transcription [539]. Finally, C/EBPα binds to the FOXA2 promoter for transcriptional
activation [540].

51

REFERENCES
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.

Jungermann K, Kietzmann T. Zonation of parenchymal and nonparenchymal metabolism in
liver. Annu Rev Nutr. 1996;16: 179–203.
Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017;27: R1147–R1151.
Williams RT. Comparative patterns of drug metabolism. Fed Proc. 1967;26: 1029–1039.
Dimski DS. Ammonia metabolism and the urea cycle: function and clinical implications. J Vet
Intern Med. 1994;8: 73–78.
Lester R, Schmid R. BILIRUBIN METABOLISM. N Engl J Med. 1964;270: 779–786.
Vlahcevic ZR, Heuman DM, Hylemon PB. Regulation of bile acid synthesis. Hepatology.
1991;13: 590–600.
Stanger BZ. Cellular Homeostasis and Repair in the Mammalian Liver. Annu Rev Physiol.
2015;77: 179–200.
Strazzabosco M. New insights into cholangiocyte physiology. J Hepatol. 1997;27: 945–952.
Wardle EN. Kupffer cells and their function. Liver. 1987;7: 63–75.
Kawada N. The hepatic perisinusoidal stellate cell. Histol Histopathol. 1997;12: 1069–1080.
Reichen J. The Role of the Sinusoidal Endothelium in Liver Function. News Physiol Sci.
1999;14: 117–121.
Kiernan F. The Anatomy and Physiology of the Liver [Internet]. Proceedings of the Royal
Society of London. 1830. pp. 211–212. doi:10.1098/rspl.1830.0129
Gebhardt R, Hovhannisyan A. Organ patterning in the adult stage: the role of Wnt/beta-catenin
signaling in liver zonation and beyond. Dev Dyn. 2010;239: 45–55.
Jungermann K, Katz N. Functional specialization of different hepatocyte populations. Physiol
Rev. 1989;69: 708–764.
Tam PP, Behringer RR. Mouse gastrulation: the formation of a mammalian body plan. Mech
Dev. 1997;68: 3–25.
Zorn AM, Wells JM. Vertebrate endoderm development and organ formation. Annu Rev Cell
Dev Biol. 2009;25: 221–251.
Tremblay KD, Zaret KS. Distinct populations of endoderm cells converge to generate the
embryonic liver bud and ventral foregut tissues. Dev Biol. 2005;280: 87–99.
Bort R, Signore M, Tremblay K, Martinez Barbera JP, Zaret KS. Hex homeobox gene controls
the transition of the endoderm to a pseudostratified, cell emergent epithelium for liver bud
development. Dev Biol. 2006;290: 44–56.
Jung J, Zheng M, Goldfarb M, Zaret KS. Initiation of mammalian liver development from
endoderm by fibroblast growth factors. Science. 1999;284: 1998–2003.
Rossi JM, Dunn NR, Hogan BL, Zaret KS. Distinct mesodermal signals, including BMPs from
the septum transversum mesenchyme, are required in combination for hepatogenesis from
the endoderm. Genes Dev. 2001;15: 1998–2009.
Bossard P, Zaret KS. GATA transcription factors as potentiators of gut endoderm
differentiation. Development. 1998;125: 4909–4917.
Lee CS, Friedman JR, Fulmer JT, Kaestner KH. The initiation of liver development is
dependent on Foxa transcription factors. Nature. 2005;435: 944–947.
Si-Tayeb K, Lemaigre FP, Duncan SA. Organogenesis and development of the liver. Dev Cell.
2010;18: 175–189.
Shiojiri N. Enzymo- and immunocytochemical analyses of the differentiation of liver cells in the
prenatal mouse. J Embryol Exp Morphol. 1981;62: 139–152.
Cascio S, Zaret KS. Hepatocyte differentiation initiates during endodermal-mesenchymal
interactions prior to liver formation. Development. 1991;113: 217–225.
Clotman F, Jacquemin P, Plumb-Rudewiez N, Pierreux CE, Van der Smissen P, Dietz HC, et
al. Control of liver cell fate decision by a gradient of TGF beta signaling modulated by Onecut
transcription factors. Genes Dev. 2005;19: 1849–1854.
Gordillo M, Evans T, Gouon-Evans V. Orchestrating liver development. Development.
2015;142: 2094–2108.
52

28. Macdonald RA. “Lifespan” of liver cells. Autoradio-graphic study using tritiated thymidine in
normal, cirrhotic, and partially hepatectomized rats. Arch Intern Med. 1961;107: 335–343.
29. Zajicek G, Oren R, Weinreb M. The streaming liver. Liver. 1985;5: 293–300.
30. Furuyama K, Kawaguchi Y, Akiyama H, Horiguchi M, Kodama S, Kuhara T, et al. Continuous
cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and
intestine. Nat Genet. 2011;43: 34–41.
31. Bralet MP, Branchereau S, Brechot C, Ferry N. Cell lineage study in the liver using retroviral
mediated gene transfer. Evidence against the streaming of hepatocytes in normal liver. Am J
Pathol. 1994;144: 896–905.
32. Magami Y, Azuma T, Inokuchi H, Kokuno S, Moriyasu F, Kawai K, et al. Cell proliferation and
renewal of normal hepatocytes and bile duct cells in adult mouse liver. Liver. 2002;22: 419–
425.
33. Carpentier R, Suñer RE, van Hul N, Kopp JL, Beaudry J-B, Cordi S, et al. Embryonic ductal
plate cells give rise to cholangiocytes, periportal hepatocytes, and adult liver progenitor cells.
Gastroenterology. 2011;141: 1432–8, 1438.e1–4.
34. Malato Y, Naqvi S, Schürmann N, Ng R, Wang B, Zape J, et al. Fate tracing of mature
hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest. 2011;121: 4850–
4860.
35. Wang B, Zhao L, Fish M, Logan CY, Nusse R. Self-renewing diploid Axin2(+) cells fuel
homeostatic renewal of the liver. Nature. 2015;524: 180–185.
36. Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver cirrhosis
mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014;12:
145.
37. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J
Hepatol. 2019;70: 151–171.
38. Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related
mortality in the United States. Gastroenterology. 2013;145: 375–82.e1–2.
39. Mokdad AH, Forouzanfar MH, Daoud F, Mokdad AA, El Bcheraoui C, Moradi-Lakeh M, et al.
Global burden of diseases, injuries, and risk factors for young people’s health during 19902013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2016;387:
2383–2401.
40. Stein E, Cruz-Lemini M, Altamirano J, Ndugga N, Couper D, Abraldes JG, et al. Heavy daily
alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden
worldwide. J Hepatol. 2016;65: 998–1005.
41. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al. Drinking habits as
cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut. 1997;41:
845–850.
42. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for
alcoholic liver disease. Hepatology. 1997;25: 108–111.
43. You M, Crabb DW. Recent advances in alcoholic liver disease II. Minireview: molecular
mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol. 2004;287: G1–6.
44. You M, Fischer M, Deeg MA, Crabb DW. Ethanol induces fatty acid synthesis pathways by
activation of sterol regulatory element-binding protein (SREBP). J Biol Chem. 2002;277:
29342–29347.
45. Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor alpha
(PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic
lipid metabolism in ethanol-fed mice. J Biol Chem. 2003;278: 27997–28004.
46. You M, Matsumoto M, Pacold CM, Cho WK, Crabb DW. The role of AMP-activated protein
kinase in the action of ethanol in the liver. Gastroenterology. 2004;127: 1798–1808.
47. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360: 2758–2769.
48. Brunt EM, Wong VW-S, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver
disease. Nat Rev Dis Primers. 2015;1: 15080.

53

49. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of
nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and
outcomes. Hepatology. 2016;64: 73–84.
50. Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, et al. Diagnostic
modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated
fibrosis. Hepatology. 2018;68: 349–360.
51. Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, et
al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and
nonalcoholic steatohepatitis. Hepatology. 2018;68: 361–371.
52. Younossi ZM. The epidemiology of nonalcoholic steatohepatitis. Clin Liver Dis. 2018;11: 92–
94.
53. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte
apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis.
Gastroenterology. 2003;125: 437–443.
54. Upton J-P, Austgen K, Nishino M, Coakley KM, Hagen A, Han D, et al. Caspase-2 cleavage
of BID is a critical apoptotic signal downstream of endoplasmic reticulum stress. Mol Cell Biol.
2008;28: 3943–3951.
55. Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F, et al. Adaptation of
hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis.
Cell Metab. 2015;21: 739–746.
56. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, et al. The nuclear factor HMGB1
mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med. 2005;201: 1135–
1143.
57. Imaeda AB, Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M, Sutterwala FS, et al.
Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3
inflammasome. J Clin Invest. 2009;119: 305–314.
58. Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease:
mechanisms and clinical relevance. Gastroenterology. 2014;147: 765–783.e4.
59. Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, Kwasny MM, et al. Susceptibility
to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis.
Liver Int. 2008;28: 1026–1033.
60. Wehr A, Baeck C, Ulmer F, Gassler N, Hittatiya K, Luedde T, et al. Pharmacological inhibition
of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in
chronic hepatic injury. PLoS One. 2014;9: e112327.
61. Tosello-Trampont A-C, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells
trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor
necrosis factor-α production. J Biol Chem. 2012;287: 40161–40172.
62. Leroux A, Ferrere G, Godie V, Cailleux F, Renoud M-L, Gaudin F, et al. Toxic lipids stored by
Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of
steatohepatitis. J Hepatol. 2012;57: 141–149.
63. Teratani T, Tomita K, Suzuki T, Oshikawa T, Yokoyama H, Shimamura K, et al. A highcholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in
hepatic stellate cells. Gastroenterology. 2012;142: 152–164.e10.
64. Tomita K, Teratani T, Suzuki T, Shimizu M, Sato H, Narimatsu K, et al. Free cholesterol
accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic
steatohepatitis in mice. Hepatology. 2014;59: 154–169.
65. Lee WM. Etiologies of acute liver failure. Semin Liver Dis. 2008;28: 142–152.
66. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal
products because of adverse drug reactions: a systematic review of the world literature. BMC
Med. 2016;14: 10.
67. Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis.
2002;22: 137–144.

54

68. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global
burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study
2013. The Lancet. 2016. pp. 1081–1088.
69. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.
Nat Med. 2013;19: 859–868.
70. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol.
2006;1: 23–61.
71. Trey C, Davidson CS. The management of fulminant hepatic failure. Prog Liver Dis. 1970;3:
282–298.
72. Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369: 2525–2534.
73. Reuben A, Koch DG, Lee WM, Acute Liver Failure Study Group. Drug-induced acute liver
failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52: 2065–2076.
74. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in
cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44: 217–231.
75. Popper H. Pathologic aspects of cirrhosis. A review. Am J Pathol. 1977;87: 228–264.
76. Fleming KM, Aithal GP, Card TR, West J. All-cause mortality in people with cirrhosis compared
with the general population: a population-based cohort study. Liver Int. 2012;32: 79–84.
77. D’Amico G, Pasta L, Morabito A, D’Amico M, Caltagirone M, Malizia G, et al. Competing risks
and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment
Pharmacol Ther. 2014;39: 1180–1193.
78. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and
evaluation. Am Fam Physician. 2006;74: 756–762.
79. Cancer of the Liver and Intrahepatic Bile Duct - Cancer Stat Facts. In: SEER [Internet]. [cited
6 Sep 2019]. Available: https://seer.cancer.gov/statfacts/html/livibd.html
80. Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, et al. Populationattributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J
Gastroenterol. 2013;108: 1314–1321.
81. de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution
of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62: 1190–1200.
82. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing
indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.
Hepatology. 2014;59: 2188–2195.
83. Sánchez Alvarado A. Regeneration in the metazoans: why does it happen? Bioessays.
2000;22: 578–590.
84. Morgan TH. Experimental studies of the regeneration of Planaria maculata [Internet]. Archiv
für Entwickelungsmechanik der Organismen. 1898. pp. 364–397. doi:10.1007/bf02161491
85. Muneoka K, Allan CH, Yang X, Lee J, Han M. Mammalian regeneration and regenerative
medicine. Birth Defects Res C Embryo Today. 2008;84: 265–280.
86. Michalopoulos GK, DeFrances MC. Liver regeneration. Science. 1997;276: 60–66.
87. Power C, Rasko JEJ. Whither Prometheus’ Liver? Greek Myth and the Science of
Regeneration. Ann Intern Med. 2008;149: 421.
88. Francavilla A, Ove P, Polimeno L, Coetzee M, Makowka L, Barone M, et al. Regulation of liver
size and regeneration: importance in liver transplantation. Transplant Proc. 1988;20: 494–497.
89. Farber E. Similarities in the sequence of early histological changes induced in the liver of the
rat by ethionine, 2-acetylamino-fluorene, and 3’-methyl-4-dimethylaminoazobenzene. Cancer
Res. 1956;16: 142–148.
90. Stöcker E, Wullstein HK, Bräu G. [Capacity of regeneration in liver epithelia of juvenile,
repeated partially hepatectomized rats. Autoradiographic studies after continous infusion of
3H-thymidine (author’s transl)]. Virchows Arch B Cell Pathol. 1973;14: 93–103.
91. Overturf K, al-Dhalimy M, Ou CN, Finegold M, Grompe M. Serial transplantation reveals the
stem-cell-like regenerative potential of adult mouse hepatocytes. Am J Pathol. 1997;151:
1273–1280.

55

92. Kam I, Lynch S, Svanas G, Todo S, Polimeno L, Francavilla A, et al. Evidence that host size
determines liver size: studies in dogs receiving orthotopic liver transplants. Hepatology.
1987;7: 362–366.
93. Madrahimov N, Dirsch O, Broelsch C, Dahmen U. Marginal Hepatectomy in the Rat. Ann Surg.
2006;244: 89–98.
94. Higgins GM, Anderson RM. Experimental pathology of liver: restoration of liver in white rat
following partial surgical removal. Arch pathol. 1931;12: 186–202.
95. Taub R. Liver regeneration: from myth to mechanism [Internet]. Nature Reviews Molecular
Cell Biology. 2004. pp. 836–847. doi:10.1038/nrm1489
96. Fausto N. Liver regeneration. J Hepatol. 2000;32: 19–31.
97. Grisham JW. A morphologic study of deoxyribonucleic acid synthesis and cell proliferation in
regenerating rat liver; autoradiography with thymidine-H3. Cancer Res. 1962;22: 842–849.
98. Krawitt EL, Betel I, Potter VR. A study of the cytidine kinase pathway of nucleotide
biosynthesis in regenerating rat liver. Biochim Biophys Acta. 1969;174: 763–765.
99. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology. 2006;43: S45–53.
100. Palmes D, Spiegel H-U. Animal models of liver regeneration. Biomaterials. 2004;25: 1601–
1611.
101. Kim PTW, Testa G. Living donor liver transplantation in the USA. Hepatobiliary Surg Nutr.
2016;5: 133–140.
102. Michalopoulos GK. Liver regeneration after partial hepatectomy: critical analysis of
mechanistic dilemmas. Am J Pathol. 2010;176: 2–13.
103. Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and
preconditioning. Am J Physiol Gastrointest Liver Physiol. 2003;284: G15–26.
104. Jaeschke H, Farhood A. Neutrophil and Kupffer cell-induced oxidant stress and ischemiareperfusion injury in rat liver. Am J Physiol. 1991;260: G355–62.
105. Zwacka RM, Zhou W, Zhang Y, Darby CJ, Dudus L, Halldorson J, et al. Redox gene therapy
for ischemia/reperfusion injury of the liver reduces AP1 and NF-kappaB activation. Nat Med.
1998;4: 698–704.
106. Pritchard MT, Apte U. Models to Study Liver Regeneration [Internet]. Liver Regeneration.
2015. pp. 15–40. doi:10.1016/b978-0-12-420128-6.00002-6
107. Colletti LM, Remick DG, Burtch GD, Kunkel SL, Strieter RM, Campbell DA Jr. Role of tumor
necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion
injury in the rat. J Clin Invest. 1990;85: 1936–1943.
108. Lentsch AB, Yoshidome H, Kato A, Warner RL, Cheadle WG, Ward PA, et al. Requirement
for interleukin-12 in the pathogenesis of warm hepatic ischemia/reperfusion injury in mice.
Hepatology. 1999;30: 1448–1453.
109. Jaeschke H, Farhood A, Smith CW. Neutrophils contribute to ischemia/reperfusion injury in
rat liver in vivo. FASEB J. 1990;4: 3355–3359.
110. Lentsch AB, Yoshidome H, Cheadle WG, Miller FN, Edwards MJ. Chemokine involvement in
hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and
KC. Hepatology. 1998;27: 1172–1177.
111. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental
model for cirrhosis in the rat. Br J Exp Pathol. 1984;65: 305–311.
112. Polimeno L, Azzarone A, Zeng QH, Panella C, Subbotin V, Carr B, et al. Cell proliferation and
oncogene expression after bile duct ligation in the rat: evidence of a specific growth effect on
bile duct cells. Hepatology. 1995;21: 1070–1078.
113. Michalopoulos GK, Barua L, Bowen WC. Transdifferentiation of rat hepatocytes into biliary
cells after bile duct ligation and toxic biliary injury. Hepatology. 2005;41: 535–544.
114. Keppler DO, Pausch J, Decker K. Selective uridine triphosphate deficiency induced by Dgalactosamine in liver and reversed by pyrimidine nucleotide precursors. Effect on ribonucleic
acid synthesis. J Biol Chem. 1974;249: 211–216.
115. Liehr H, Grün M, Seelig HP, Seelig R, Reutter W, Heine WD. On the pathogenesis of
galactosamine hepatitis. Indications of extrahepatocellular mechanisms responsible for liver
cell death. Virchows Arch B Cell Pathol. 1978;26: 331–344.
56

116. Kuhlmann WD, Peschke P. Hepatic progenitor cells, stem cells, and AFP expression in models
of liver injury. Int J Exp Pathol. 2006;87: 343–359.
117. Abdul-Hussain SK, Mehendale HM. Ongoing hepatocellular regeneration and resiliency
toward galactosamine hepatotoxicity. Arch Toxicol. 1992;66: 729–742.
118. Badger DA, Sauer JM, Hoglen NC, Jolley CS, Sipes IG. The role of inflammatory cells and
cytochrome P450 in the potentiation of CCl4-induced liver injury by a single dose of retinol.
Toxicol Appl Pharmacol. 1996;141: 507–519.
119. Kim SG, Chung HC, Cho JY. Molecular mechanism for alkyl sulfide-modulated carbon
tetrachloride-induced hepatotoxicity: the role of cytochrome P450 2E1, P450 2B and
glutathione S-transferase expression. J Pharmacol Exp Ther. 1996;277: 1058–1066.
120. Wong FW, Chan WY, Lee SS. Resistance to carbon tetrachloride-induced hepatotoxicity in
mice which lack CYP2E1 expression. Toxicol Appl Pharmacol. 1998;153: 109–118.
121. Brattin WJ, Glende EA Jr, Recknagel RO. Pathological mechanisms in carbon tetrachloride
hepatotoxicity. J Free Radic Biol Med. 1985;1: 27–38.
122. Armendariz-Borunda J, Katai H, Jones CM, Seyer JM, Kang AH, Raghow R. Transforming
growth factor beta gene expression is transiently enhanced at a critical stage during liver
regeneration after CCl4 treatment. Lab Invest. 1993;69: 283–294.
123. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and
cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology.
1996;24: 233–240.
124. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, et al. Mechanisms
of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced
hepatic expression of metalloproteinase inhibitors. J Clin Invest. 1998;102: 538–549.
125. Fitzhugh OG, Nelson AA. Liver Tumors in Rats Fed Thiourea or Thioacetamide. Science.
1948;108: 626–628.
126. Gupta DN. Acute changes in the liver after administration of thioacetamide. J Pathol Bacteriol.
1956;72: 183–192.
127. Müller A, Machnik F, Zimmermann T, Schubert H. Thioacetamide-induced cirrhosis-like liver
lesions in rats--usefulness and reliability of this animal model. Exp Pathol. 1988;34: 229–236.
128. Wang T, Shankar K, Ronis MJ, Mehendale HM. Potentiation of thioacetamide liver injury in
diabetic rats is due to induced CYP2E1. J Pharmacol Exp Ther. 2000;294: 473–479.
129. Kang JS, Wanibuchi H, Morimura K, Wongpoomchai R, Chusiri Y, Gonzalez FJ, et al. Role of
CYP2E1 in thioacetamide-induced mouse hepatotoxicity. Toxicol Appl Pharmacol. 2008;228:
295–300.
130. Hunter AL, Holscher MA, Neal RA. Thioacetamide-induced hepatic necrosis. I. Involvement
of the mixed-function oxidase enzyme system. J Pharmacol Exp Ther. 1977;200: 439–448.
131. Gallagher CH, Gupta DN, Judah JD, Rees KR. Biochemical changes in liver in acute
thioacetamide intoxication. J Pathol Bacteriol. 1956;72: 193–201.
132. Díez-Fernández C, Sanz N, Alvarez AM, Zaragoza A, Cascales M. Influence of
aminoguanidine on parameters of liver injury and regeneration induced in rats by a necrogenic
dose of thioacetamide. Br J Pharmacol. 1998;125: 102–108.
133. Theocharis SE, Margeli AP, Agapitos EV, Mykoniatis MG, Kittas CN, Davaris PS. Effect of
hepatic stimulator substance administration on tissue regeneration due to thioacetamideinduced liver injury in rats. Scand J Gastroenterol. 1998;33: 656–663.
134. Díez-Fernández C, Boscá L, Fernández-Simón L, Alvarez A, Cascales M. Relationship
between genomic DNA ploidy and parameters of liver damage during necrosis and
regeneration induced by thioacetamide. Hepatology. 1993;18: 912–918.
135. Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: Summary of a
workshop. Hepatology. 2008;47: 1401–1415.
136. Cummings AJ, King ML, Martin BK. A kinetic study of drug elimination: the excretion of
paracetamol and its metabolites in man. Br J Pharmacol Chemother. 1967;29: 150–157.
137. Potter WZ, Davis DC, Mitchell JR, Jollow DJ, Gillette JR, Brodie BB. Acetaminophen-induced
hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol Exp
Ther. 1973;187: 203–210.
57

138. Jollow DJ, Mitchell JR, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-induced
hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther. 1973;187: 195–
202.
139. Nakagawa H, Maeda S, Hikiba Y, Ohmae T, Shibata W, Yanai A, et al. Deletion of apoptosis
signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun
N-terminal kinase activation. Gastroenterology. 2008;135: 1311–1321.
140. Bajt ML, Farhood A, Lemasters JJ, Jaeschke H. Mitochondrial bax translocation accelerates
DNA fragmentation and cell necrosis in a murine model of acetaminophen hepatotoxicity. J
Pharmacol Exp Ther. 2008;324: 8–14.
141. Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-induced
hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther. 1973;187: 185–194.
142. Jaeschke H, Bajt ML. Intracellular signaling mechanisms of acetaminophen-induced liver cell
death. Toxicol Sci. 2006;89: 31–41.
143. Dalhoff K, Laursen H, Bangert K, Poulsen HE, Anderson ME, Grunnet N, et al. Autoprotection
in acetaminophen intoxication in rats: the role of liver regeneration. Pharmacol Toxicol.
2001;88: 135–141.
144. Zieve L, Anderson WR, Dozeman R, Draves K, Lyftogt C. Acetaminophen liver injury:
sequential changes in two biochemical indices of regeneration and their relationship to
histologic alterations. J Lab Clin Med. 1985;105: 619–624.
145. Grompe M, al-Dhalimy M, Finegold M, Ou CN, Burlingame T, Kennaway NG, et al. Loss of
fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype
of lethal albino mice. Genes Dev. 1993;7: 2298–2307.
146. Kelsey G, Ruppert S, Beermann F, Grund C, Tanguay RM, Schütz G. Rescue of mice
homozygous for lethal albino deletions: implications for an animal model for the human liver
disease tyrosinemia type 1. Genes Dev. 1993;7: 2285–2297.
147. Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tyrosinemia. Proc Natl
Acad Sci U S A. 1977;74: 4641–4645.
148. Jorquera R, Tanguay RM. The mutagenicity of the tyrosine metabolite, fumarylacetoacetate,
is enhanced by glutathione depletion. Biochem Biophys Res Commun. 1997;232: 42–48.
149. Jorquera R, Tanguay RM. Cyclin B-dependent kinase and caspase-1 activation precedes
mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis. FASEB J. 1999;13:
2284–2298.
150. Kvittingen EA, Brodtkorb E. The pre- and post-natal diagnosis of tyrosinemia type I and the
detection of the carrier state by assay of fumarylacetoacetase. Scand J Clin Lab Invest Suppl.
1986;184: 35–40.
151. Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the
human cancer transcriptome. Science. 2017;357. doi:10.1126/science.aan2507
152. Russo PA, Mitchell GA, Tanguay RM. Tyrosinemia: a review. Pediatr Dev Pathol. 2001;4:
212–221.
153. Laberge C. Hereditary tyrosinemia in a French Canadian isolate. Am J Hum Genet. 1969;21:
36–45.
154. De Braekeleer M, Larochelle J. Genetic epidemiology of hereditary tyrosinemia in Quebec and
in Saguenay-Lac-St-Jean. Am J Hum Genet. 1990;47: 302–307.
155. Heyer E. One founder/one gene hypothesis in a new expanding population: Saguenay
(Quebec, Canada). Hum Biol. 1999;71: 99–109.
156. St-Louis M, Tanguay RM. Mutations in the fumarylacetoacetate hydrolase gene causing
hereditary tyrosinemia type I: overview. Hum Mutat. 1997;9: 291–299.
157. Kvittingen EA. Hereditary tyrosinemia type I--an overview. Scand J Clin Lab Invest Suppl.
1986;184: 27–34.
158. Russo P, O’Regan S. Visceral pathology of hereditary tyrosinemia type I. Am J Hum Genet.
1990;47: 317–324.
159. Larochelle J, Privé L, Saidi M, Bélanger M, Tremblay M, Claveau JC, et al. [Hereditary
tyrosinemia with tyrosiluria. Study of 44 cases in infants]. Union Med Can. 1968;97: 762–772.
160. Larochelle J, Privé L, Bélanger M, Bélanger L, Tremblay M, Claveau JC, et al. [Hereditary
58

tyrosinemia. I. Clinical and biological study of 62 cases]. Pediatrie. 1973;28: 5–18.
161. Dehner LP, Snover DC, Sharp HL, Ascher N, Nakhleh R, Day DL. Hereditary tyrosinemia type
I (chronic form): pathologic findings in the liver. Hum Pathol. 1989;20: 149–158.
162. van Spronsen FJ, Berger R, Smit GP, de Klerk JB, Duran M, Bijleveld CM, et al. Tyrosinaemia
type I: orthotopic liver transplantation as the only definitive answer to a metabolic as well as
an oncological problem. J Inherit Metab Dis. 1989;12 Suppl 2: 339–342.
163. Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in the chronic form of
hereditary tyrosinemia. J Pediatr. 1976;88: 434–438.
164. Haber BA, Chuang E, Lee W, Taub R. Variable gene expression within human tyrosinemia
type 1 liver may reflect region-specific dysplasia. Hepatology. 1996;24: 65–71.
165. Kvittingen EA, Talseth T, Halvorsen S, Jakobs C, Hovig T, Flatmark A. Renal failure in adult
patients with hereditary tyrosinaemia type I. J Inherit Metab Dis. 1991;14: 53–62.
166. Mitchell G, Larochelle J, Lambert M, Michaud J, Grenier A, Ogier H, et al. Neurologic crises
in hereditary tyrosinemia. N Engl J Med. 1990;322: 432–437.
167. Perry TL. Tyrosinemia associated with hypermethioninemia and islet cell hyperplasia. Can
Med Assoc J. 1967;97: 1067–1075.
168. Esquivel CO, Mieles L, Marino IR, Todo S, Makowka L, Ambrosino G, et al. Liver
transplantation for hereditary tyrosinemia in the presence of hepatocellular carcinoma.
Transplant Proc. 1989;21: 2445–2446.
169. Paradis K, Weber A, Seidman EG, Larochelle J, Garel L, Lenaerts C, et al. Liver
transplantation for hereditary tyrosinemia: the Quebec experience. Am J Hum Genet. 1990;47:
338–342.
170. Lock EA, Ellis MK, Gaskin P, Robinson M, Auton TR, Provan WM, et al. From toxicological
problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a
drug. J Inherit Metab Dis. 1998;21: 498–506.
171. Holme E, Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione). J Inherit Metab Dis. 1998;21: 507–517.
172. Barkaoui E, Debray D, Habès D, Ogier H, Bernard O. [Favorable outcome of treatment with
NTBC of acute liver insufficiency disclosing hereditary tyrosinemia type I]. Arch Pediatr.
1999;6: 540–544.
173. Ellis MK, Whitfield AC, Gowans LA, Auton TR, Provan WM, Lock EA, et al. Inhibition of 4hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione. Toxicol Appl
Pharmacol. 1995;133: 12–19.
174. Grompe M, Lindstedt S, al-Dhalimy M, Kennaway NG, Papaconstantinou J, Torres-Ramos
CA, et al. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model
of hereditary tyrosinaemia type I. Nat Genet. 1995;10: 453–460.
175. Endo F, Awata H, Katoh H, Matsuda I. A nonsense mutation in the 4-hydroxyphenylpyruvic
acid dioxygenase gene (Hpd) causes skipping of the constitutive exon and hypertyrosinemia
in mouse strain III. Genomics. 1995;25: 164–169.
176. Overturf K, Al-Dhalimy M, Tanguay R, Brantly M, Ou CN, Finegold M, et al. Hepatocytes
corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia
type I. Nat Genet. 1996;12: 266–273.
177. Overturf K, Al-Dhalimy M, Manning K, Ou CN, Finegold M, Grompe M. Ex vivo hepatic gene
therapy of a mouse model of Hereditary Tyrosinemia Type I. Hum Gene Ther. 1998;9: 295–
304.
178. Overturf K, al-Dhalimy M, Ou CN, Finegold M, Tanguay R, Lieber A, et al. Adenovirusmediated gene therapy in a mouse model of hereditary tyrosinemia type I. Hum Gene Ther.
1997;8: 513–521.
179. Paulk NK, Wursthorn K, Wang Z, Finegold MJ, Kay MA, Grompe M. Adeno-associated virus
gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology. 2010;51:
1200–1208.
59

180. Montini E, Held PK, Noll M, Morcinek N, Al-Dhalimy M, Finegold M, et al. In vivo correction of
murine tyrosinemia type I by DNA-mediated transposition. Mol Ther. 2002;6: 759–769.
181. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, et al. Genome editing with Cas9
in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. 2014;32: 551–553.
182. Wangensteen KJ, Wilber A, Keng VW, He Z, Matise I, Wangensteen L, et al. A facile method
for somatic, lifelong manipulation of multiple genes in the mouse liver. Hepatology. 2008;47:
1714–1724.
183. Wang AW, Wangensteen KJ, Wang YJ, Zahm AM, Moss NG, Erez N, et al. TRAP-seq
identifies cystine/glutamate antiporter as a driver of recovery from liver injury. J Clin Invest.
2018;128: 2297–2309.
184. Wuestefeld T, Pesic M, Rudalska R, Dauch D, Longerich T, Kang T-W, et al. A Direct in vivo
RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell. 2013;153: 389–
401.
185. Wangensteen KJ, Zhang S, Greenbaum LE, Kaestner KH. A genetic screen reveals Foxa3
and TNFR1 as key regulators of liver repopulation. Genes Dev. 2015;29: 904–909.
186. Wangensteen KJ, Wang YJ, Dou Z, Wang AW, Mosleh-Shirazi E, Horlbeck MA, et al.
Combinatorial genetics in liver repopulation and carcinogenesis with a in vivo CRISPR
activation platform. Hepatology. 2018;68: 663–676.
187. Zahm AM, Wang AW, Wang YJ, Schug J, Wangensteen KJ, Kaestner KH. A high-content in
vivo screen to identify microRNA epistasis in the repopulating mouse liver [Internet].
doi:10.1101/664847
188. Kjeldgaard NO, Ploug J. Urokinase an activator of plasminogen from human urine. II.
Mechanism of plasminogen activation. Biochim Biophys Acta. 1957;24: 283–289.
189. Heckel JL, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Neonatal bleeding in transgenic
mice expressing urokinase-type plasminogen activator. Cell. 1990;62: 447–456.
190. Sandgren EP, Palmiter RD, Heckel JL, Daugherty CC, Brinster RL, Degen JL. Complete
hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene.
Cell. 1991;66: 245–256.
191. Rhim JA, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Replacement of diseased mouse
liver by hepatic cell transplantation. Science. 1994;263: 1149–1152.
192. Rhim JA, Sandgren EP, Palmiter RD, Brinster RL. Complete reconstitution of mouse liver with
xenogeneic hepatocytes. Proc Natl Acad Sci U S A. 1995;92: 4942–4946.
193. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, et al. Hepatitis C virus
replication in mice with chimeric human livers. Nat Med. 2001;7: 927–933.
194. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, et al. Near completely
humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol.
2004;165: 901–912.
195. Dandri M, Burda MR, Török E, Pollok JM, Iwanska A, Sommer G, et al. Repopulation of mouse
liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology. 2001;33:
981–988.
196. Wilson JW, Leduc EH. Role of cholangioles in restoration of the liver of the mouse after dietary
injury. J Pathol Bacteriol. 1958;76: 441–449.
197. Demetris AJ, Seaberg EC, Wennerberg A, Ionellie J, Michalopoulos G. Ductular reaction after
submassive necrosis in humans. Special emphasis on analysis of ductular hepatocytes. Am
J Pathol. 1996;149: 439–448.
198. Grisham JW, Porta EA. ORIGIN AND FATE OF PROLIFERATED HEPATIC DUCTAL CELLS
IN THE RAT: ELECTRON MICROSCOPIC AND AUTORADIOGRAPHIC STUDIES. Exp Mol
Pathol. 1964;3: 242–261.
199. Gerber MA, Thung SN, Shen S, Stromeyer FW, Ishak KG. Phenotypic characterization of
hepatic proliferation. Antigenic expression by proliferating epithelial cells in fetal liver, massive
hepatic necrosis, and nodular transformation of the liver. Am J Pathol. 1983;110: 70–74.
200. Peraino C, Fry RJ, Staffeldt E. Reduction and enhancement by phenobarbital of
hepatocarcinogenesis induced in the rat by 2-acetylaminofluorene. Cancer Res. 1971;31:
1506–1512.
60

201. Tatematsu M, Ho RH, Kaku T, Ekem JK, Farber E. Studies on the proliferation and fate of oval
cells in the liver of rats treated with 2-acetylaminofluorene and partial hepatectomy. Am J
Pathol. 1984;114: 418–430.
202. DeBaun JR, Rowley JY, Miller EC, Miller JA. Sulfotransferase activation of N-hydroxy-2acetylaminofluorene in rodent livers susceptible and resistant to this carcinogen. Proc Soc
Exp Biol Med. 1968;129: 268–273.
203. Evarts RP, Nagy P, Marsden E, Thorgeirsson SS. A precursor-product relationship exists
between oval cells and hepatocytes in rat liver. Carcinogenesis. 1987;8: 1737–1740.
204. Petersen BE, Zajac VF, Michalopoulos GK. Hepatic oval cell activation in response to injury
following chemically induced periportal or pericentral damage in rats. Hepatology. 1998;27:
1030–1038.
205. Tephly TR, Gibbs AH, De Matteis F. Studies on the mechanism of experimental porphyria
produced by 3,5-diethoxycarbonyl-1,4-dihydrocollidine. Role of a porphyrin-like inhibitor of
protohaem ferro-lyase. Biochem J. 1979;180: 241–244.
206. Preisegger KH, Factor VM, Fuchsbichler A, Stumptner C, Denk H, Thorgeirsson SS. Atypical
ductular proliferation and its inhibition by transforming growth factor beta1 in the 3,5diethoxycarbonyl-1,4-dihydrocollidine mouse model for chronic alcoholic liver disease. Lab
Invest. 1999;79: 103–109.
207. Faktor VM, Engel’gardt NV, Iazova AK, Lazareva MN, Poltoranina VS, Rudinskaia TD.
[Common antigens of oval cells and cholangiocytes in the mouse. Their detection by using
monoclonal antibodies]. Ontogenez. 1990;21: 625–632.
208. Lemire JM, Shiojiri N, Fausto N. Oval cell proliferation and the origin of small hepatocytes in
liver injury induced by D-galactosamine. Am J Pathol. 1991;139: 535–552.
209. Okabe M, Tsukahara Y, Tanaka M, Suzuki K, Saito S, Kamiya Y, et al. Potential hepatic stem
cells reside in EpCAM+ cells of normal and injured mouse liver. Development. 2009;136:
1951–1960.
210. Sackett SD, Li Z, Hurtt R, Gao Y, Wells RG, Brondell K, et al. Foxl1 is a marker of bipotential
hepatic progenitor cells in mice. Hepatology. 2009;49: 920–929.
211. Shin S, Walton G, Aoki R, Brondell K, Schug J, Fox A, et al. Foxl1-Cre-marked adult hepatic
progenitors have clonogenic and bilineage differentiation potential. Genes Dev. 2011;25:
1185–1192.
212. Shinozuka H, Lombardi B, Sell S, Iammarino RM. Early histological and functional alterations
of ethionine liver carcinogenesis in rats fed a choline-deficient diet. Cancer Res. 1978;38:
1092–1098.
213. Akhurst B, Croager EJ, Farley-Roche CA, Ong JK, Dumble ML, Knight B, et al. A modified
choline-deficient, ethionine-supplemented diet protocol effectively induces oval cells in mouse
liver. Hepatology. 2001;34: 519–522.
214. Yao ZM, Vance DE. The active synthesis of phosphatidylcholine is required for very low
density lipoprotein secretion from rat hepatocytes. J Biol Chem. 1988;263: 2998–3004.
215. Aoyama Y, Yasui H, Ashida K. Effect of dietary protein and amino acids in a choline-deficient
diet on lipid accumulation in rat liver. J Nutr. 1971;101: 739–745.
216. Lombardi B. Effects of choline deficiency on rat hepatocytes. Fed Proc. 1971;30: 139–142.
217. Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem. 1992;61: 441–
470.
218. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation,
deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36: 131–149.
219. Koff A, Cross F, Fisher A, Schumacher J, Leguellec K, Philippe M, et al. Human cyclin E, a
new cyclin that interacts with two members of the CDC2 gene family. Cell. 1991;66: 1217–
1228.
220. Lew DJ, Dulić V, Reed SI. Isolation of three novel human cyclins by rescue of G1 cyclin (Cln)
function in yeast. Cell. 1991;66: 1197–1206.
221. Xiong Y, Connolly T, Futcher B, Beach D. Human D-type cyclin. Cell. 1991;65: 691–699.
222. Lehner CF, O’Farrell PH. Expression and function of Drosophila cyclin A during embryonic
cell cycle progression. Cell. 1989;56: 957–968.
61

223. Pines J, Hunter T. Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein
regulation in the cell cycle and for interaction with p34cdc2. Cell. 1989;58: 833–846.
224. Rabes HM, Iseler G, Czichos S, Tuczek HV. Synchronization of hepatocellular DNA synthesis
in regenerating rat liver by continuous infusion of hydroxyurea. Cancer Res. 1977;37: 1105–
1111.
225. Webber EM, Godowski PJ, Fausto N. In vivo response of hepatocytes to growth factors
requires an initial priming stimulus. Hepatology. 1994;19: 489–497.
226. Mead JE, Braun L, Martin DA, Fausto N. Induction of replicative competence (“priming”) in
normal liver. Cancer Res. 1990;50: 7023–7030.
227. Fausto N. Growth factors in liver development, regeneration and carcinogenesis. Prog Growth
Factor Res. 1991;3: 219–234.
228. Fausto N, Laird AD, Webber EM. Liver regeneration. 2. Role of growth factors and cytokines
in hepatic regeneration. The FASEB Journal. 1995;9: 1527–1536.
229. Michalopoulos GK. Liver regeneration: molecular mechanisms of growth control. FASEB J.
1990;4: 176–187.
230. Decker K. Biologically active products of stimulated liver macrophages (Kupffer cells). Eur J
Biochem. 1990;192: 245–261.
231. Akerman P, Cote P, Yang SQ, McClain C, Nelson S, Bagby GJ, et al. Antibodies to tumor
necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol.
1992;263: G579–85.
232. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, et al. Liver failure
and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 1996;274:
1379–1383.
233. Webber EM, Bruix J, Pierce RH, Fausto N. Tumor necrosis factor primes hepatocytes for DNA
replication in the rat. Hepatology. 1998;28: 1226–1234.
234. Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by tumor necrosis factor:
deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl
Acad Sci U S A. 1997;94: 1441–1446.
235. Kirillova I, Chaisson M, Fausto N. Tumor necrosis factor induces DNA replication in hepatic
cells through nuclear factor kappaB activation. Cell Growth Differ. 1999;10: 819–828.
236. Geiger T, Andus T, Klapproth J, Hirano T, Kishimoto T, Heinrich PC. Induction of rat acutephase proteins by interleukin 6 in vivo. Eur J Immunol. 1988;18: 717–721.
237. Wuestefeld T, Klein C, Streetz KL, Betz U, Lauber J, Buer J, et al. Interleukin-6/glycoprotein
130-dependent pathways are protective during liver regeneration. J Biol Chem. 2003;278:
11281–11288.
238. Thompson NL, Mead JE, Braun L, Goyette M, Shank PR, Fausto N. Sequential protooncogene
expression during rat liver regeneration. Cancer Res. 1986;46: 3111–3117.
239. Greenbaum LE, Li W, Cressman DE, Peng Y, Ciliberto G, Poli V, et al. CCAAT enhancerbinding protein beta is required for normal hepatocyte proliferation in mice after partial
hepatectomy. J Clin Invest. 1998;102: 996–1007.
240. Haber BA, Mohn KL, Diamond RH, Taub R. Induction patterns of 70 genes during nine days
after hepatectomy define the temporal course of liver regeneration. J Clin Invest. 1993;91:
1319–1326.
241. Li W, Liang X, Leu JI, Kovalovich K, Ciliberto G, Taub R. Global changes in interleukin-6dependent gene expression patterns in mouse livers after partial hepatectomy. Hepatology.
2001;33: 1377–1386.
242. Matsumoto T, O’Malley K, Efron PA, Burger C, McAuliffe PF, Scumpia PO, et al. Interleukin6 and STAT3 protect the liver from hepatic ischemia and reperfusion injury during ischemic
preconditioning. Surgery. 2006;140: 793–802.
243. Bruccoleri A, Gallucci R, Germolec DR, Blackshear P, Simeonova P, Thurman RG, et al.
Induction of early-immediate genes by tumor necrosis factor alpha contribute to liver repair
following chemical-induced hepatotoxicity. Hepatology. 1997;25: 133–141.

62

244. Katz A, Chebath J, Friedman J, Revel M. Increased sensitivity of IL-6-deficient mice to carbon
tetrachloride hepatotoxicity and protection with an IL-6 receptor-IL-6 chimera. Cytokines Cell
Mol Ther. 1998;4: 221–227.
245. Chiu H, Gardner CR, Dambach DM, Durham SK, Brittingham JA, Laskin JD, et al. Role of
tumor necrosis factor receptor 1 (p55) in hepatocyte proliferation during acetaminopheninduced toxicity in mice. Toxicol Appl Pharmacol. 2003;193: 218–227.
246. James LP, Lamps LW, McCullough S, Hinson JA. Interleukin 6 and hepatocyte regeneration
in acetaminophen toxicity in the mouse. Biochem Biophys Res Commun. 2003;309: 857–863.
247. Fujita J, Marino MW, Wada H, Jungbluth AA, Mackrell PJ, Rivadeneira DE, et al. Effect of TNF
gene depletion on liver regeneration after partial hepatectomy in mice. Surgery. 2001;129:
48–54.
248. Hayashi H, Nagaki M, Imose M, Osawa Y, Kimura K, Takai S, et al. Normal liver regeneration
and liver cell apoptosis after partial hepatectomy in tumor necrosis factor-alpha-deficient mice.
Liver Int. 2005;25: 162–170.
249. Sakamoto T, Liu Z, Murase N, Ezure T, Yokomuro S, Poli V, et al. Mitosis and apoptosis in
the liver of interleukin-6-deficient mice after partial hepatectomy. Hepatology. 1999;29: 403–
411.
250. Blindenbacher A, Wang X, Langer I, Savino R, Terracciano L, Heim MH. Interleukin 6 is
important for survival after partial hepatectomy in mice. Hepatology. 2003;38: 674–682.
251. McGowan JA, Strain AJ, Bucher NL. DNA synthesis in primary cultures of adult rat
hepatocytes in a defined medium: effects of epidermal growth factor, insulin, glucagon, and
cyclic-AMP. J Cell Physiol. 1981;108: 353–363.
252. Brenner DA, Koch KS, Leffert HL. Transforming growth factor-alpha stimulates protooncogene c-jun expression and a mitogenic program in primary cultures of adult rat
hepatocytes. DNA. 1989;8: 279–285.
253. Mead JE, Fausto N. Transforming growth factor alpha may be a physiological regulator of liver
regeneration by means of an autocrine mechanism. Proc Natl Acad Sci U S A. 1989;86: 1558–
1562.
254. Strain AJ, Ismail T, Tsubouchi H, Arakaki N, Hishida T, Kitamura N, et al. Native and
recombinant human hepatocyte growth factors are highly potent promoters of DNA synthesis
in both human and rat hepatocytes. J Clin Invest. 1991;87: 1853–1857.
255. Breider MA, Bleavins MR, Reindel JF, Gough AW, de la Iglesia FA. Cellular hyperplasia in
rats following continuous intravenous infusion of recombinant human epidermal growth factor.
Vet Pathol. 1996;33: 184–194.
256. Roos F, Ryan AM, Chamow SM, Bennett GL, Schwall RH. Induction of liver growth in normal
mice by infusion of hepatocyte growth factor/scatter factor. Am J Physiol. 1995;268: G380–6.
257. Webber EM, Wu JC, Wang L, Merlino G, Fausto N. Overexpression of transforming growth
factor-alpha causes liver enlargement and increased hepatocyte proliferation in transgenic
mice. Am J Pathol. 1994;145: 398–408.
258. Skov Olsen P, Boesby S, Kirkegaard P, Therkelsen K, Almdal T, Poulsen SS, et al. Influence
of epidermal growth factor on liver regeneration after partial hepatectomy in rats. Hepatology.
1988;8: 992–996.
259. Mars WM, Zarnegar R, Michalopoulos GK. Activation of hepatocyte growth factor by the
plasminogen activators uPA and tPA. Am J Pathol. 1993;143: 949–958.
260. Schirmacher P, Geerts A, Jung W, Pietrangelo A, Rogler CE, Dienes HP. The role of Ito cells
in the biosynthesis of HGF-SF in the liver. EXS. 1993;65: 285–299.
261. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, et al. Extracellular
proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter
factor. EMBO J. 1992;11: 4825–4833.
262. Lindroos PM, Zarnegar R, Michalopoulos GK. Hepatocyte growth factor (hepatopoietin A)
rapidly increases in plasma before DNA synthesis and liver regeneration stimulated by partial
hepatectomy and carbon tetrachloride administration. Hepatology. 1991;13: 743–750.

63

263. Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK, et al.
Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded
by the proto-oncogene c-MET. Oncogene. 1991;6: 501–504.
264. Tomiya T, Ogata I, Yamaoka M, Yanase M, Inoue Y, Fujiwara K. The mitogenic activity of
hepatocyte growth factor on rat hepatocytes is dependent upon endogenous transforming
growth factor-alpha. Am J Pathol. 2000;157: 1693–1701.
265. Diehl AM, Rai RM. Liver regeneration 3: Regulation of signal transduction during liver
regeneration. FASEB J. 1996;10: 215–227.
266. Brenner DA. Signal transduction during liver regeneration [Internet]. Journal of
Gastroenterology and Hepatology. 1998. pp. S93–S95. doi:10.1111/jgh.1998.13.s1.93
267. Shimizu M, Hara A, Okuno M, Matsuno H, Okada K, Ueshima S, et al. Mechanism of retarded
liver regeneration in plasminogen activator-deficient mice: impaired activation of hepatocyte
growth factor after Fas-mediated massive hepatic apoptosis. Hepatology. 2001;33: 569–576.
268. Burr AW, Toole K, Chapman C, Hines JE, Burt AD. Anti-hepatocyte growth factor antibody
inhibits hepatocyte proliferation during liver regeneration. J Pathol. 1998;185: 298–302.
269. Borowiak M, Garratt AN, Wüstefeld T, Strehle M, Trautwein C, Birchmeier C. Met provides
essential signals for liver regeneration. Proc Natl Acad Sci U S A. 2004;101: 10608–10613.
270. Huh C-G, Factor VM, Sánchez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth
factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl
Acad Sci U S A. 2004;101: 4477–4482.
271. Elder JB, Williams G, Lacey E, Gregory H. Cellular localisation of human
urogastrone/epidermal growth factor. Nature. 1978;271: 466–467.
272. Olsen PS, Poulsen SS, Kirkegaard P. Adrenergic effects on secretion of epidermal growth
factor from Brunner’s glands. Gut. 1985;26: 920–927.
273. Argast GM, Campbell JS, Brooling JT, Fausto N. Epidermal growth factor receptor
transactivation mediates tumor necrosis factor-induced hepatocyte replication. J Biol Chem.
2004;279: 34530–34536.
274. Gruppuso PA, Mead JE, Fausto N. Transforming growth factor receptors in liver regeneration
following partial hepatectomy in the rat. Cancer Res. 1990;50: 1464–1469.
275. UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res.
2019;47: D506–D515.
276. Scheving LA, Stevenson MC, Taylormoore JM, Traxler P, Russell WE. Integral role of the
EGF receptor in HGF-mediated hepatocyte proliferation. Biochem Biophys Res Commun.
2002;290: 197–203.
277. Russell WE, Kaufmann WK, Sitaric S, Luetteke NC, Lee DC. Liver regeneration and
hepatocarcinogenesis in transforming growth factor-alpha-targeted mice. Mol Carcinog.
1996;15: 183–189.
278. Natarajan A, Wagner B, Sibilia M. The EGF receptor is required for efficient liver regeneration.
Proc Natl Acad Sci U S A. 2007;104: 17081–17086.
279. Nagy P, Evarts RP, McMahon JB, Thorgeirsson SS. Role of TGF-beta in normal differentiation
and oncogenesis in rat liver. Mol Carcinog. 1989;2: 345–354.
280. Hyytiäinen M, Taipale J, Heldin CH, Keski-Oja J. Recombinant latent transforming growth
factor beta-binding protein 2 assembles to fibroblast extracellular matrix and is susceptible to
proteolytic processing and release. J Biol Chem. 1998;273: 20669–20676.
281. Bissell DM, Roulot D, George J. Transforming growth factor beta and the liver. Hepatology.
2001;34: 859–867.
282. Braun L, Mead JE, Panzica M, Mikumo R, Bell GI, Fausto N. Transforming growth factor beta
mRNA increases during liver regeneration: a possible paracrine mechanism of growth
regulation. Proc Natl Acad Sci U S A. 1988;85: 1539–1543.
283. Chari RS, Price DT, Sue SR, Meyers WC, Jirtle RL. Down-regulation of transforming growth
factor beta receptor type I, II, and III during liver regeneration. Am J Surg. 1995;169: 126–31;
discussion 131–2.
284. Houck KA, Michalopoulos GK. Altered responses of regenerating hepatocytes to
norepinephrine and transforming growth factor type beta. J Cell Physiol. 1989;141: 503–509.
64

285. Houck KA, Cruise JL, Michalopoulos G. Norepinephrine modulates the growth-inhibitory effect
of transforming growth factor-beta in primary rat hepatocyte cultures. J Cell Physiol. 1988;135:
551–555.
286. Macías-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL. MADR2 is a
substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation
and signaling. Cell. 1996;87: 1215–1224.
287. Zhang Y, Feng X, We R, Derynck R. Receptor-associated Mad homologues synergize as
effectors of the TGF-beta response. Nature. 1996;383: 168–172.
288. Reynisdóttir I, Polyak K, Iavarone A, Massagué J. Kip/Cip and Ink4 Cdk inhibitors cooperate
to induce cell cycle arrest in response to TGF-beta. Genes Dev. 1995;9: 1831–1845.
289. Koff A, Ohtsuki M, Polyak K, Roberts JM, Massagué J. Negative regulation of G1 in
mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science. 1993;260:
536–539.
290. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, et al. p27Kip1, a cyclinCdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.
Genes Dev. 1994;8: 9–22.
291. Carr BI, Hayashi I, Branum EL, Moses HL. Inhibition of DNA synthesis in rat hepatocytes by
platelet-derived type beta transforming growth factor. Cancer Res. 1986;46: 2330–2334.
292. Russell WE, Coffey RJ Jr, Ouellette AJ, Moses HL. Type beta transforming growth factor
reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl
Acad Sci U S A. 1988;85: 5126–5130.
293. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, et al. Hepatic expression
of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue
lesions. Proc Natl Acad Sci U S A. 1995;92: 2572–2576.
294. Oe S, Lemmer ER, Conner EA, Factor VM, Levéen P, Larsson J, et al. Intact signaling by
transforming growth factor beta is not required for termination of liver regeneration in mice.
Hepatology. 2004;40: 1098–1105.
295. Yasuda H, Mine T, Shibata H, Eto Y, Hasegawa Y, Takeuchi T, et al. Activin A: an autocrine
inhibitor of initiation of DNA synthesis in rat hepatocytes. J Clin Invest. 1993;92: 1491–1496.
296. Kogure K, Omata W, Kanzaki M, Zhang YQ, Yasuda H, Mine T, et al. A single intraportal
administration of follistatin accelerates liver regeneration in partially hepatectomized rats.
Gastroenterology. 1995;108: 1136–1142.
297. Lichtsteiner S, Wuarin J, Schibler U. The interplay of DNA-binding proteins on the promoter
of the mouse albumin gene. Cell. 1987;51: 963–973.
298. Costa RH, Grayson DR, Xanthopoulos KG, Darnell JE Jr. A liver-specific DNA-binding protein
recognizes multiple nucleotide sites in regulatory regions of transthyretin, alpha 1-antitrypsin,
albumin, and simian virus 40 genes. Proc Natl Acad Sci U S A. 1988;85: 3840–3844.
299. Mischoulon D, Rana B, Bucher NL, Farmer SR. Growth-dependent inhibition of CCAAT
enhancer-binding protein (C/EBP alpha) gene expression during hepatocyte proliferation in
the regenerating liver and in culture. Mol Cell Biol. 1992;12: 2553–2560.
300. Greenbaum LE, Cressman DE, Haber BA, Taub R. Coexistence of C/EBP alpha, beta, growthinduced proteins and DNA synthesis in hepatocytes during liver regeneration. Implications for
maintenance of the differentiated state during liver growth. J Clin Invest. 1995;96: 1351–1365.
301. Umek RM, Friedman AD, McKnight SL. CCAAT-enhancer binding protein: a component of a
differentiation switch. Science. 1991;251: 288–292.
302. Timchenko NA, Wilde M, Nakanishi M, Smith JR, Darlington GJ. CCAAT/enhancer-binding
protein alpha (C/EBP alpha) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1)
protein. Genes Dev. 1996;10: 804–815.
303. Timchenko NA, Harris TE, Wilde M, Bilyeu TA, Burgess-Beusse BL, Finegold MJ, et al.
CCAAT/enhancer binding protein alpha regulates p21 protein and hepatocyte proliferation in
newborn mice. Mol Cell Biol. 1997;17: 7353–7361.
304. Timchenko NA, Wilde M, Darlington GJ. C/EBPalpha regulates formation of S-phase-specific
E2F-p107 complexes in livers of newborn mice. Mol Cell Biol. 1999;19: 2936–2945.
65

305. Timchenko NA, Wilde M, Iakova P, Albrecht JH, Darlington GJ. E2F/p107 and E2F/p130
complexes are regulated by C/EBPalpha in 3T3-L1 adipocytes. Nucleic Acids Res. 1999;27:
3621–3630.
306. Wang H, Iakova P, Wilde M, Welm A, Goode T, Roesler WJ, et al. C/EBPalpha arrests cell
proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell. 2001;8: 817–828.
307. Wang H, Goode T, Iakova P, Albrecht JH, Timchenko NA. C/EBPalpha triggers proteasomedependent degradation of cdk4 during growth arrest. EMBO J. 2002;21: 930–941.
308. Johnson PF. Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription
factors. J Cell Sci. 2005;118: 2545–2555.
309. Soriano HE, Kang DC, Finegold MJ, Hicks MJ, Wang ND, Harrison W, et al. Lack of C/EBP
alpha gene expression results in increased DNA synthesis and an increased frequency of
immortalization of freshly isolated mice [correction of rat] hepatocytes. Hepatology. 1998;27:
392–401.
310. Flodby P, Barlow C, Kylefjord H, Ahrlund-Richter L, Xanthopoulos KG. Increased hepatic cell
proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein
alpha. J Biol Chem. 1996;271: 24753–24760.
311. Harvey KF, Pfleger CM, Hariharan IK. The Drosophila Mst ortholog, hippo, restricts growth
and cell proliferation and promotes apoptosis. Cell. 2003;114: 457–467.
312. Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G. Hippo promotes proliferation arrest and
apoptosis in the Salvador/Warts pathway. Nat Cell Biol. 2003;5: 914–920.
313. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a universal
size-control mechanism in Drosophila and mammals. Cell. 2007;130: 1120–1133.
314. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the
Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev.
2007;21: 2747–2761.
315. Wang C, Zhang L, He Q, Feng X, Zhu J, Xu Z, et al. Differences in Yes-associated protein
and mRNA levels in regenerating liver and hepatocellular carcinoma. Mol Med Rep. 2012;5:
410–414.
316. Grijalva JL, Huizenga M, Mueller K, Rodriguez S, Brazzo J, Camargo F, et al. Dynamic
alterations in Hippo signaling pathway and YAP activation during liver regeneration. Am J
Physiol Gastrointest Liver Physiol. 2014;307: G196–204.
317. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, et al. YAP1 increases
organ size and expands undifferentiated progenitor cells. Curr Biol. 2007;17: 2054–2060.
318. Zhou D, Conrad C, Xia F, Park J-S, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte
quiescence and suppress hepatocellular carcinoma development through inactivation of the
Yap1 oncogene. Cancer Cell. 2009;16: 425–438.
319. Apte U, Gkretsi V, Bowen WC, Mars WM, Luo J-H, Donthamsetty S, et al. Enhanced liver
regeneration following changes induced by hepatocyte-specific genetic ablation of integrinlinked kinase. Hepatology. 2009;50: 844–851.
320. Donthamsetty S, Bowen W, Mars W, Bhave V, Luo J-H, Wu C, et al. Liver-specific ablation of
integrin-linked kinase in mice results in enhanced and prolonged cell proliferation and
hepatomegaly after phenobarbital administration. Toxicol Sci. 2010;113: 358–366.
321. Liu B, Bell AW, Paranjpe S, Bowen WC, Khillan JS, Luo J-H, et al. Suppression of liver
regeneration and hepatocyte proliferation in hepatocyte-targeted glypican 3 transgenic mice.
Hepatology. 2010;52: 1060–1067.
322. Lin C-W, Mars WM, Paranjpe S, Donthamsetty S, Bhave VS, Kang L-I, et al. Hepatocyte
proliferation and hepatomegaly induced by phenobarbital and 1,4-bis [2-(3,5dichloropyridyloxy)] benzene is suppressed in hepatocyte-targeted glypican 3 transgenic
mice. Hepatology. 2011;54: 620–630.
323. Assy N, Spira G, Paizi M, Shenkar L, Kraizer Y, Cohen T, et al. Effect of vascular endothelial
growth factor on hepatic regenerative activity following partial hepatectomy in rats. J Hepatol.
1999;30: 911–915.

66

324. Ding B-S, Nolan DJ, Butler JM, James D, Babazadeh AO, Rosenwaks Z, et al. Inductive
angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature.
2010;468: 310–315.
325. Scher CD, Stone ME, Stiles CD. Platelet-derived growth factor prevents G0 growth arrest.
Nature. 1979;281: 390–392.
326. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte
growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun. 1984;122:
1450–1459.
327. Housley RM, Morris CF, Boyle W, Ring B, Biltz R, Tarpley JE, et al. Keratinocyte growth factor
induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal
tract. J Clin Invest. 1994;94: 1764–1777.
328. Strain AJ, McGuinness G, Rubin JS, Aaronson SA. Keratinocyte growth factor and fibroblast
growth factor action on DNA synthesis in rat and human hepatocytes: modulation by heparin.
Exp Cell Res. 1994;210: 253–259.
329. Ito N, Kawata S, Tamura S, Kiso S, Tsushima H, Damm D, et al. Heparin-binding EGF-like
growth factor is a potent mitogen for rat hepatocytes. Biochem Biophys Res Commun.
1994;198: 25–31.
330. Huang W, Ma K, Zhang J, Qatanani M, Cuvillier J, Liu J, et al. Nuclear receptor-dependent
bile acid signaling is required for normal liver regeneration. Science. 2006;312: 233–236.
331. Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, et al. Platelet-derived serotonin
mediates liver regeneration. Science. 2006;312: 104–107.
332. Bucher ML, Swaffield MN. Regulation of hepatic regeneration in rats by synergistic action of
insulin and glucagon. Proc Natl Acad Sci U S A. 1975;72: 1157–1160.
333. Starzl TE, Watanabe K, Porter KA, Putnam CW. Effects of insulin, glucagon, and
insuling/glucagon infusions on liver morphology and cell division after complete portacaval
shunt in dogs. Lancet. 1976;1: 821–825.
334. Cruise JL, Houck KA, Michalopoulos GK. Induction of DNA synthesis in cultured rat
hepatocytes through stimulation of alpha 1 adrenoreceptor by norepinephrine. Science.
1985;227: 749–751.
335. Cruise JL, Knechtle SJ, Bollinger RR, Kuhn C, Michalopoulos G. Alpha 1-adrenergic effects
and liver regeneration. Hepatology. 1987;7: 1189–1194.
336. Mastellos D, Papadimitriou JC, Franchini S, Tsonis PA, Lambris JD. A novel role of
complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver
regeneration. J Immunol. 2001;166: 2479–2486.
337. Colletti LM, Green M, Burdick MD, Kunkel SL, Strieter RM. Proliferative effects of CXC
chemokines in rat hepatocytes in vitro and in vivo. Shock. 1998;10: 248–257.
338. Hogaboam CM, Bone-Larson CL, Steinhauser ML, Lukacs NW, Colletti LM, Simpson KJ, et
al. Novel CXCR2-dependent liver regenerative qualities of ELR-containing CXC chemokines.
FASEB J. 1999;13: 1565–1574.
339. Tan X, Behari J, Cieply B, Michalopoulos GK, Monga SPS. Conditional deletion of betacatenin reveals its role in liver growth and regeneration. Gastroenterology. 2006;131: 1561–
1572.
340. Sekine S, Gutiérrez PJA, Lan BY-A, Feng S, Hebrok M. Liver-specific loss of beta-catenin
results in delayed hepatocyte proliferation after partial hepatectomy. Hepatology. 2007;45:
361–368.
341. Köhler C, Bell AW, Bowen WC, Monga SP, Fleig W, Michalopoulos GK. Expression of Notch1 and its ligand Jagged-1 in rat liver during liver regeneration. Hepatology. 2004;39: 1056–
1065.
342. Walesky C, Apte U. Mechanisms of Termination of Liver Regeneration [Internet]. Liver
Regeneration. 2015. pp. 103–111. doi:10.1016/b978-0-12-420128-6.00007-5
343. Imai T, Jiang M, Kastner P, Chambon P, Metzger D. Selective ablation of retinoid X receptor
alpha in hepatocytes impairs their lifespan and regenerative capacity. Proc Natl Acad Sci U S
A. 2001;98: 4581–4586.
67

344. Anderson SP, Yoon L, Richard EB, Dunn CS, Cattley RC, Corton JC. Delayed liver
regeneration in peroxisome proliferator-activated receptor-alpha-null mice. Hepatology.
2002;36: 544–554.
345. Rao MS, Peters JM, Gonzalez FJ, Reddy JK. Hepatic regeneration in peroxisome proliferatoractivated receptor alpha-null mice after partial hepatectomy. Hepatol Res. 2002;22: 52–57.
346. Dai G, He L, Bu P, Wan Y-JY. Pregnane X receptor is essential for normal progression of liver
regeneration. Hepatology. 2008;47: 1277–1287.
347. Turmelle YP, Shikapwashya O, Tu S, Hruz PW, Yan Q, Rudnick DA. Rosiglitazone inhibits
mouse liver regeneration. FASEB J. 2006;20: 2609–2611.
348. Yamamoto Y, Ono T, Dhar DK, Yamanoi A, Tachibana M, Tanaka T, et al. Role of peroxisome
proliferator-activated receptor-gamma (PPARgamma) during liver regeneration in rats. J
Gastroenterol Hepatol. 2008;23: 930–937.
349. Bonzo JA, Ferry CH, Matsubara T, Kim J-H, Gonzalez FJ. Suppression of hepatocyte
proliferation by hepatocyte nuclear factor 4α in adult mice. J Biol Chem. 2012;287: 7345–
7356.
350. Song G, Sharma AD, Roll GR, Ng R, Lee AY, Blelloch RH, et al. MicroRNAs control hepatocyte
proliferation during liver regeneration. Hepatology. 2010;51: 1735–1743.
351. Kuboki S, Shin T, Huber N, Eismann T, Galloway E, Schuster R, et al. Hepatocyte signaling
through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia/reperfusion
in mice. Hepatology. 2008;48: 1213–1223.
352. Van Sweringen HL, Sakai N, Tevar AD, Burns JM, Edwards MJ, Lentsch AB. CXC chemokine
signaling in the liver: impact on repair and regeneration. Hepatology. 2011;54: 1445–1453.
353. Yamada Y, Webber EM, Kirillova I, Peschon JJ, Fausto N. Analysis of liver regeneration in
mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not
type 2 receptor. Hepatology . 1998. pp. 959–970.
354. Vogel G. Development. Two unexpected players add twists to liver’s comeback story. Science.
2006. p. 178.
355. Español-Suñer R, Carpentier R, Van Hul N, Legry V, Achouri Y, Cordi S, et al. Liver progenitor
cells yield functional hepatocytes in response to chronic liver injury in mice. Gastroenterology.
2012;143: 1564–1575.e7.
356. Huch M, Dorrell C, Boj SF, van Es JH, Li VSW, van de Wetering M, et al. In vitro expansion
of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature. 2013;494: 247–
250.
357. Yanger K, Knigin D, Zong Y, Maggs L, Gu G, Akiyama H, et al. Adult hepatocytes are
generated by self-duplication rather than stem cell differentiation. Cell Stem Cell. 2014;15:
340–349.
358. Lu W-Y, Bird TG, Boulter L, Tsuchiya A, Cole AM, Hay T, et al. Hepatic progenitor cells of
biliary origin with liver repopulation capacity. Nat Cell Biol. 2015;17: 971–983.
359. Shin S, Upadhyay N, Greenbaum LE, Kaestner KH. Ablation of Foxl1-Cre-labeled hepatic
progenitor cells and their descendants impairs recovery of mice from liver injury.
Gastroenterology. 2015;148: 192–202.e3.
360. Raven A, Lu W-Y, Man TY, Ferreira-Gonzalez S, O’Duibhir E, Dwyer BJ, et al. Cholangiocytes
act as facultative liver stem cells during impaired hepatocyte regeneration. Nature. 2017;547:
350–354.
361. Grompe M, Laconi E, Shafritz DA. Principles of therapeutic liver repopulation. Semin Liver
Dis. 1999;19: 7–14.
362. Nicolas CT, Hickey RD, Chen HS, Mao SA, Lopera Higuita M, Wang Y, et al. Concise Review:
Liver Regenerative Medicine: From Hepatocyte Transplantation to Bioartificial Livers and
Bioengineered Grafts. Stem Cells. 2017;35: 42–50.
363. Lelli KM, Slattery M, Mann RS. Disentangling the many layers of eukaryotic transcriptional
regulation. Annu Rev Genet. 2012;46: 43–68.
364. Istrail S, Davidson EH. Logic functions of the genomic cis-regulatory code. Proc Natl Acad Sci
U S A. 2005;102: 4954–4959.
68

365. Gill G. Regulation of the initiation of eukaryotic transcription. Essays Biochem. 2001;37: 33–
43.
366. Narlikar GJ, Fan H-Y, Kingston RE. Cooperation between complexes that regulate chromatin
structure and transcription. Cell. 2002;108: 475–487.
367. Xu L, Glass CK, Rosenfeld MG. Coactivator and corepressor complexes in nuclear receptor
function. Curr Opin Genet Dev. 1999;9: 140–147.
368. Courey AJ. Cooperativity in transcriptional control. Curr Biol. 2001;11: R250–2.
369. Moretti R, Ansari AZ. Expanding the specificity of DNA targeting by harnessing cooperative
assembly. Biochimie. 2008;90: 1015–1025.
370. Badis G, Berger MF, Philippakis AA, Talukder S, Gehrke AR, Jaeger SA, et al. Diversity and
complexity in DNA recognition by transcription factors. Science. 2009;324: 1720–1723.
371. Benayoun BA, Veitia RA. A post-translational modification code for transcription factors:
sorting through a sea of signals. Trends Cell Biol. 2009;19: 189–197.
372. Luger K, Mäder AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the
nucleosome core particle at 2.8 A resolution. Nature. 1997;389: 251–260.
373. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293: 1074–1080.
374. Felsenfeld G, Groudine M. Controlling the double helix. Nature. 2003;421: 448–453.
375. Bai L, Morozov AV. Gene regulation by nucleosome positioning. Trends Genet. 2010;26: 476–
483.
376. Wang X, Bai L, Bryant GO, Ptashne M. Nucleosomes and the accessibility problem. Trends
Genet. 2011;27: 487–492.
377. Bhutani N, Burns DM, Blau HM. DNA demethylation dynamics. Cell. 2011;146: 866–872.
378. Bártová E, Krejcí J, Harnicarová A, Galiová G, Kozubek S. Histone modifications and nuclear
architecture: a review. J Histochem Cytochem. 2008;56: 711–721.
379. Zorn C, Cremer C, Cremer T, Zimmer J. Unscheduled DNA synthesis after partial UV
irradiation of the cell nucleus. Distribution in interphase and metaphase. Exp Cell Res.
1979;124: 111–119.
380. Vaquerizas JM, Akhtar A, Luscombe NM. Large-scale nuclear architecture and transcriptional
control. Subcell Biochem. 2011;52: 279–295.
381. Krivega I, Dean A. Enhancer and promoter interactions-long distance calls. Curr Opin Genet
Dev. 2012;22: 79–85.
382. Agelopoulos M, McKay DJ, Mann RS. Developmental regulation of chromatin conformation
by Hox proteins in Drosophila. Cell Rep. 2012;1: 350–359.
383. Noordermeer D, Leleu M, Splinter E, Rougemont J, De Laat W, Duboule D. The dynamic
architecture of Hox gene clusters. Science. 2011;334: 222–225.
384. Schoenfelder S, Sexton T, Chakalova L, Cope NF, Horton A, Andrews S, et al. Preferential
associations between co-regulated genes reveal a transcriptional interactome in erythroid
cells. Nat Genet. 2010;42: 53–61.
385. Dekker J, Rippe K, Dekker M, Kleckner N. Capturing chromosome conformation. Science.
2002;295: 1306–1311.
386. Jones SA, Shim S-H, He J, Zhuang X. Fast, three-dimensional super-resolution imaging of
live cells. Nat Methods. 2011;8: 499–508.
387. Darnell JE Jr. Variety in the level of gene control in eukaryotic cells. Nature. 1982;297: 365–
371.
388. Greengard O, Federman M, Knox WE. Cytomorphometry of developing rat liver and its
application to enzymic differentiation. J Cell Biol. 1972;52: 261–272.
389. Jungermann K, Katz N. Functional hepatocellular heterogeneity. Hepatology. 1982;2: 385–
395.
390. Derman E, Krauter K, Walling L, Weinberger C, Ray M, Darnell JE Jr. Transcriptional control
in the production of liver-specific mRNAs. Cell. 1981;23: 731–739.
391. Ott MO, Sperling L, Herbomel P, Yaniv M, Weiss MC. Tissue-specific expression is conferred
by a sequence from the 5’ end of the rat albumin gene. EMBO J. 1984;3: 2505–2510.
392. Ciliberto G, Dente L, Cortese R. Cell-specific expression of a transfected human alpha 1antitrypsin gene. Cell. 1985;41: 531–540.
69

393. Costa RH, Lai E, Darnell JE Jr. Transcriptional control of the mouse prealbumin (transthyretin)
gene: both promoter sequences and a distinct enhancer are cell specific. Mol Cell Biol. 1986;6:
4697–4708.
394. Cereghini S, Raymondjean M, Carranca AG, Herbomel P, Yaniv M. Factors involved in control
of tissue-specific expression of albumin gene. Cell. 1987;50: 627–638.
395. Cohen AB. Interrelationships between the human alveolar macrophage and alpha-1antitrypsin. J Clin Invest. 1973;52: 2793–2799.
396. Green PH, Lefkowitch JH, Glickman RM, Riley JW, Quinet E, Blum CB. Apolipoprotein
localization and quantitation in the human intestine. Gastroenterology. 1982;83: 1223–1230.
397. Dickson PW, Aldred AR, Marley PD, Bannister D, Schreiber G. Rat choroid plexus specializes
in the synthesis and the secretion of transthyretin (prealbumin). Regulation of transthyretin
synthesis in choroid plexus is independent from that in liver. J Biol Chem. 1986;261: 3475–
3478.
398. Baumhueter S, Mendel DB, Conley PB, Kuo CJ, Turk C, Graves MK, et al. HNF-1 shares
three sequence motifs with the POU domain proteins and is identical to LF-B1 and APF.
Genes Dev. 1990;4: 372–379.
399. Kuo CJ, Conley PB, Hsieh CL, Francke U, Crabtree GR. Molecular cloning, functional
expression, and chromosomal localization of mouse hepatocyte nuclear factor 1. Proc Natl
Acad Sci U S A. 1990;87: 9838–9842.
400. Drewes T, Senkel S, Holewa B, Ryffel GU. Human hepatocyte nuclear factor 4 isoforms are
encoded by distinct and differentially expressed genes. Mol Cell Biol. 1996;16: 925–931.
401. Coffinier C, Barra J, Babinet C, Yaniv M. Expression of the vHNF1/HNF1beta homeoprotein
gene during mouse organogenesis. Mech Dev. 1999;89: 211–213.
402. De Simone V, Cortese R. Transcriptional regulation of liver-specific gene expression. Curr
Opin Cell Biol. 1991;3: 960–965.
403. Costa RH, Grayson DR, Darnell JE Jr. Multiple hepatocyte-enriched nuclear factors function
in the regulation of transthyretin and alpha 1-antitrypsin genes. Mol Cell Biol. 1989;9: 1415–
1425.
404. Herbst RS, Friedman N, Darnell JE Jr, Babiss LE. Positive and negative regulatory elements
in the mouse albumin enhancer. Proc Natl Acad Sci U S A. 1989;86: 1553–1557.
405. Courtois G, Morgan JG, Campbell LA, Fourel G, Crabtree GR. Interaction of a liver-specific
nuclear factor with the fibrinogen and alpha 1-antitrypsin promoters. Science. 1987;238: 688–
692.
406. Lemaigre FP, Durviaux SM, Rousseau GG. Identification of regulatory sequences and proteinbinding sites in the liver-type promoter of a gene encoding 6-phosphofructo-2-kinase/fructose2,6-bisphosphatase. Mol Cell Biol. 1991;11: 1099–1106.
407. Cereghini S, Blumenfeld M, Yaniv M. A liver-specific factor essential for albumin transcription
differs between differentiated and dedifferentiated rat hepatoma cells. Genes Dev. 1988;2:
957–974.
408. Coffinier C, Thépot D, Babinet C, Yaniv M, Barra J. Essential role for the homeoprotein
vHNF1/HNF1beta in visceral endoderm differentiation. Development. 1999;126: 4785–4794.
409. Rey-Campos J, Chouard T, Yaniv M, Cereghini S. vHNF1 is a homeoprotein that activates
transcription and forms heterodimers with HNF1. EMBO J. 1991;10: 1445–1457.
410. Mendel DB, Hansen LP, Graves MK, Conley PB, Crabtree GR. HNF-1 alpha and HNF-1 beta
(vHNF-1) share dimerization and homeo domains, but not activation domains, and form
heterodimers in vitro. Genes Dev. 1991;5: 1042–1056.
411. Reber M, Cereghini S. Variant hepatocyte nuclear factor 1 expression in the mouse genital
tract. Mech Dev. 2001;100: 75–78.
412. Frain M, Swart G, Monaci P, Nicosia A, Stämpfli S, Frank R, et al. The liver-specific
transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain. Cell.
1989;59: 145–157.
413. Hayashi Y, Wang W, Ninomiya T, Nagano H, Ohta K, Itoh H. Liver enriched transcription
factors and differentiation of hepatocellular carcinoma. Mol Pathol. 1999;52: 19–24.
70

414. Courtois G, Baumhueter S, Crabtree GR. Purified hepatocyte nuclear factor 1 interacts with a
family of hepatocyte-specific promoters. Proc Natl Acad Sci U S A. 1988;85: 7937–7941.
415. Kuo CJ, Mendel DB, Hansen LP, Crabtree GR. Independent regulation of HNF-1 alpha and
HNF-1 beta by retinoic acid in F9 teratocarcinoma cells. EMBO J. 1991;10: 2231–2236.
416. Mendel DB, Khavari PA, Conley PB, Graves MK, Hansen LP, Admon A, et al. Characterization
of a cofactor that regulates dimerization of a mammalian homeodomain protein. Science.
1991;254: 1762–1767.
417. Jose-Estanyol M, Danan JL. A liver-specific factor and nuclear factor I bind to the rat alphafetoprotein promoter. J Biol Chem. 1988;263: 10865–10871.
418. Chambaz J, Cardot P, Pastier D, Zannis VI, Cladaras C. Promoter elements and factors
required for hepatic transcription of the human ApoA-II gene. J Biol Chem. 1991;266: 11676–
11685.
419. Brooks AR, Levy-Wilson B. Hepatocyte nuclear factor 1 and C/EBP are essential for the
activity of the human apolipoprotein B gene second-intron enhancer. Mol Cell Biol. 1992;12:
1134–1148.
420. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, et al. Control of
pancreas and liver gene expression by HNF transcription factors. Science. 2004;303: 1378–
1381.
421. Coffinier C, Gresh L, Fiette L, Tronche F, Schütz G, Babinet C, et al. Bile system
morphogenesis defects and liver dysfunction upon targeted deletion of HNF1beta.
Development. 2002;129: 1829–1838.
422. Cereghini S, Ott MO, Power S, Maury M. Expression patterns of vHNF1 and HNF1
homeoproteins in early postimplantation embryos suggest distinct and sequential
developmental roles. Development. 1992;116: 783–797.
423. Ott MO, Rey-Campos J, Cereghini S, Yaniv M. vHNF1 is expressed in epithelial cells of distinct
embryonic origin during development and precedes HNF1 expression. Mech Dev. 1991;36:
47–58.
424. Nagy P, Bisgaard HC, Thorgeirsson SS. Expression of hepatic transcription factors during
liver development and oval cell differentiation. J Cell Biol. 1994;126: 223–233.
425. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, et al. Hepatocyte nuclear
factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi
syndrome. Cell. 1996;84: 575–585.
426. Barbacci E, Reber M, Ott MO, Breillat C, Huetz F, Cereghini S. Variant hepatocyte nuclear
factor 1 is required for visceral endoderm specification. Development. 1999;126: 4795–4805.
427. Lokmane L, Haumaitre C, Garcia-Villalba P, Anselme I, Schneider-Maunoury S, Cereghini S.
Crucial role of vHNF1 in vertebrate hepatic specification. Development. 2008;135: 2777–2786.
428. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, et al. Mutations in the
hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3).
Nature. 1996;384: 455–458.
429. Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, Cockburn BN, et al. Mutation in
hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet. 1997;17:
384–385.
430. Lai E, Prezioso VR, Smith E, Litvin O, Costa RH, Darnell JE Jr. HNF-3A, a hepatocyteenriched transcription factor of novel structure is regulated transcriptionally. Genes Dev.
1990;4: 1427–1436.
431. Lai E, Prezioso VR, Tao WF, Chen WS, Darnell JE Jr. Hepatocyte nuclear factor 3 alpha
belongs to a gene family in mammals that is homologous to the Drosophila homeotic gene
fork head. Genes Dev. 1991;5: 416–427.
432. Pani L, Overdier DG, Porcella A, Qian X, Lai E, Costa RH. Hepatocyte nuclear factor 3 beta
contains two transcriptional activation domains, one of which is novel and conserved with the
Drosophila fork head protein. Mol Cell Biol. 1992;12: 3723–3732.
433. Lai E, Clark KL, Burley SK, Darnell JE Jr. Hepatocyte nuclear factor 3/fork head or “winged
helix” proteins: a family of transcription factors of diverse biologic function. Proc Natl Acad Sci
U S A. 1993;90: 10421–10423.
71

434. Kaestner KH, Knochel W, Martinez DE. Unified nomenclature for the winged helix/forkhead
transcription factors. Genes Dev. 2000;14: 142–146.
435. Sund NJ, Ang SL, Sackett SD, Shen W, Daigle N, Magnuson MA, et al. Hepatocyte nuclear
factor 3beta (Foxa2) is dispensable for maintaining the differentiated state of the adult
hepatocyte. Mol Cell Biol. 2000;20: 5175–5183.
436. Friedman JR, Kaestner KH. The Foxa family of transcription factors in development and
metabolism. Cell Mol Life Sci. 2006;63: 2317–2328.
437. Clark KL, Halay ED, Lai E, Burley SK. Co-crystal structure of the HNF-3/fork head DNArecognition motif resembles histone H5. Nature. 1993;364: 412–420.
438. Qian X, Costa RH. Analysis of hepatocyte nuclear factor-3 beta protein domains required for
transcriptional activation and nuclear targeting. Nucleic Acids Res. 1995;23: 1184–1191.
439. Marsden I, Jin C, Liao X. Structural changes in the region directly adjacent to the DNA-binding
helix highlight a possible mechanism to explain the observed changes in the sequencespecific binding of winged helix proteins 1 1Edited by P. E. Wright. J Mol Biol. 1998;278: 293–
299.
440. Liu JK, DiPersio CM, Zaret KS. Extracellular signals that regulate liver transcription factors
during hepatic differentiation in vitro. Mol Cell Biol. 1991;11: 773–784.
441. Groupp ER, Crawford N, Locker J. Characterization of the distal alpha-fetoprotein enhancer,
a strong, long distance, liver-specific activator. J Biol Chem. 1994;269: 22178–22187.
442. Schrem H. Liver-Enriched Transcription Factors in Liver Function and Development. Part I:
The Hepatocyte Nuclear Factor Network and Liver-Specific Gene Expression. Pharmacol Rev.
2002;54: 129–158.
443. Lemaigre FP, Durviaux SM, Rousseau GG. Liver-specific factor binding to the liver promoter
of a 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene. J Biol Chem. 1993;268:
19896–19905.
444. Cirillo LA, McPherson CE, Bossard P, Stevens K, Cherian S, Shim EY, et al. Binding of the
winged-helix transcription factor HNF3 to a linker histone site on the nucleosome. EMBO J.
1998;17: 244–254.
445. Monaghan AP, Kaestner KH, Grau E, Schütz G. Postimplantation expression patterns indicate
a role for the mouse forkhead/HNF-3 alpha, beta and gamma genes in determination of the
definitive endoderm, chordamesoderm and neuroectoderm. Development. 1993;119: 567–
578.
446. Kaestner KH, Katz J, Liu Y, Drucker DJ, Schütz G. Inactivation of the winged helix transcription
factor HNF3alpha affects glucose homeostasis and islet glucagon gene expression in vivo.
Genes Dev. 1999;13: 495–504.
447. Ang S-L, Rossant J. HNF-3β is essential for node and notochord formation in mouse
development. Cell. 1994;78: 561–574.
448. Weinstein DC, Ruiz i Altaba A, Chen WS, Hoodless P, Prezioso VR, Jessell TM, et al. The
winged-helix transcription factor HNF-3 beta is required for notochord development in the
mouse embryo. Cell. 1994;78: 575–588.
449. Zhang L, Rubins NE, Ahima RS, Greenbaum LE, Kaestner KH. Foxa2 integrates the
transcriptional response of the hepatocyte to fasting. Cell Metab. 2005;2: 141–148.
450. Li Z, White P, Tuteja G, Rubins N, Sackett S, Kaestner KH. Foxa1 and Foxa2 regulate bile
duct development in mice. J Clin Invest. 2009;119: 1537–1545.
451. Kaestner KH, Hiemisch H, Schütz G. Targeted disruption of the gene encoding hepatocyte
nuclear factor 3gamma results in reduced transcription of hepatocyte-specific genes. Mol Cell
Biol. 1998;18: 4245–4251.
452. Shen W, Scearce LM, Brestelli JE, Sund NJ, Kaestner KH. Foxa3 (hepatocyte nuclear factor
3gamma ) is required for the regulation of hepatic GLUT2 expression and the maintenance of
glucose homeostasis during a prolonged fast. J Biol Chem. 2001;276: 42812–42817.
453. Qian X, Samadani U, Porcella A, Costa RH. Decreased expression of hepatocyte nuclear
factor 3 alpha during the acute-phase response influences transthyretin gene transcription.
Mol Cell Biol. 1995;15: 1364–1376.
72

454. Nakamura T, Akiyoshi H, Shiota G, Isono M, Nakamura K, Moriyama M, et al.
Hepatoprotective action of adenovirus-transferred HNF-3gamma gene in acute liver injury
caused by CCl(4). FEBS Lett. 1999;459: 1–4.
455. Wang W, Yao L-J, Shen W, Ding K, Shi P-M, Chen F, et al. FOXA2 alleviates CCl-induced
liver fibrosis by protecting hepatocytes in mice. Sci Rep. 2017;7: 15532.
456. O’Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, et al. Reference
sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional
annotation. Nucleic Acids Res. 2016;44: D733–45.
457. Thomas H, Jaschkowitz K, Bulman M, Frayling TM, Mitchell SM, Roosen S, et al. A distant
upstream promoter of the HNF-4alpha gene connects the transcription factors involved in
maturity-onset diabetes of the young. Hum Mol Genet. 2001;10: 2089–2097.
458. Huang J, Levitsky LL, Rhoads DB. Novel P2 promoter-derived HNF4α isoforms with different
N-terminus generated by alternate exon insertion. Exp Cell Res. 2009;315: 1200–1211.
459. Sladek FM, Zhong WM, Lai E, Darnell JE. Liver-enriched transcription factor HNF-4 is a novel
member of the steroid hormone receptor superfamily. Genes Dev. 1990;4: 2353–2365.
460. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, et al. The nuclear
receptor superfamily: the second decade. Cell. 1995;83: 835–839.
461. Hertz R, Magenheim J, Berman I, Bar-Tana J. Fatty acyl-CoA thioesters are ligands of hepatic
nuclear factor-4α. Nature. 1998;392: 512–516.
462. Yuan X, Ta TC, Lin M, Evans JR, Dong Y, Bolotin E, et al. Identification of an endogenous
ligand bound to a native orphan nuclear receptor. PLoS One. 2009;4: e5609.
463. Hadzopoulou-Cladaras M, Kistanova E, Evagelopoulou C, Zeng S, Cladaras C, Ladias JA.
Functional domains of the nuclear receptor hepatocyte nuclear factor 4. J Biol Chem.
1997;272: 539–550.
464. Jiang G, Nepomuceno L, Hopkins K, Sladek FM. Exclusive homodimerization of the orphan
receptor hepatocyte nuclear factor 4 defines a new subclass of nuclear receptors. Mol Cell
Biol. 1995;15: 5131–5143.
465. Jiang G, Sladek FM. The DNA binding domain of hepatocyte nuclear factor 4 mediates
cooperative, specific binding to DNA and heterodimerization with the retinoid X receptor alpha.
J Biol Chem. 1997;272: 1218–1225.
466. Babeu J-P, Boudreau F. Hepatocyte nuclear factor 4-alpha involvement in liver and intestinal
inflammatory networks. World J Gastroenterol. 2014;20: 22–30.
467. Taraviras S, Monaghan AP, Schütz G, Kelsey G. Characterization of the mouse HNF-4 gene
and its expression during mouse embryogenesis. Mech Dev. 1994;48: 67–79.
468. Fang B, Mane-Padros D, Bolotin E, Jiang T, Sladek FM. Identification of a binding motif
specific to HNF4 by comparative analysis of multiple nuclear receptors. Nucleic Acids Res.
2012;40: 5343–5356.
469. Ginsburg GS, Ozer J, Karathanasis SK. Intestinal apolipoprotein AI gene transcription is
regulated by multiple distinct DNA elements and is synergistically activated by the orphan
nuclear receptor, hepatocyte nuclear factor 4. J Clin Invest. 1995;96: 528–538.
470. Ladias JA, Hadzopoulou-Cladaras M, Kardassis D, Cardot P, Cheng J, Zannis V, et al.
Transcriptional regulation of human apolipoprotein genes ApoB, ApoCIII, and ApoAII by
members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3. J
Biol Chem. 1992;267: 15849–15860.
471. Costa RH, Van Dyke TA, Yan C, Kuo F, Darnell JE Jr. Similarities in transthyretin gene
expression and differences in transcription factors: liver and yolk sac compared to choroid
plexus. Proc Natl Acad Sci U S A. 1990;87: 6589–6593.
472. Schaeffer E, Guillou F, Part D, Zakin MM. A different combination of transcription factors
modulates the expression of the human transferrin promoter in liver and Sertoli cells. J Biol
Chem. 1993;268: 23399–23408.
473. Erdmann D, Heim J. Orphan nuclear receptor HNF-4 binds to the human coagulation factor
VII promoter. J Biol Chem. 1995;270: 22988–22996.

73

474. Duncan SA, Manova K, Chen WS, Hoodless P, Weinstein DC, Bachvarova RF, et al.
Expression of transcription factor HNF-4 in the extraembryonic endoderm, gut, and
nephrogenic tissue of the developing mouse embryo: HNF-4 is a marker for primary endoderm
in the implanting blastocyst. Proceedings of the National Academy of Sciences. 1994;91:
7598–7602.
475. Chen WS, Manova K, Weinstein DC, Duncan SA, Plump AS, Prezioso VR, et al. Disruption of
the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm
and impaired gastrulation of mouse embryos. Genes Dev. 1994;8: 2466–2477.
476. Duncan SA, Nagy A, Chan W. Murine gastrulation requires HNF-4 regulated gene expression
in the visceral endoderm: tetraploid rescue of Hnf-4(-/-) embryos. Development. 1997;124:
279–287.
477. Battle MA, Konopka G, Parviz F, Gaggl AL, Yang C, Sladek FM, et al. Hepatocyte nuclear
factor 4alpha orchestrates expression of cell adhesion proteins during the epithelial
transformation of the developing liver. Proc Natl Acad Sci U S A. 2006;103: 8419–8424.
478. Parviz F, Matullo C, Garrison WD, Savatski L, Adamson JW, Ning G, et al. Hepatocyte nuclear
factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat
Genet. 2003;34: 292–296.
479. Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ. Hepatocyte nuclear factor 4alpha
(nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid
homeostasis. Mol Cell Biol. 2001;21: 1393–1403.
480. Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S, Cox NJ, et al. Mutations in the
hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1).
Nature. 1996;384: 458–460.
481. Ktistaki E, Ktistakis NT, Papadogeorgaki E, Talianidis I. Recruitment of hepatocyte nuclear
factor 4 into specific intranuclear compartments depends on tyrosine phosphorylation that
affects its DNA-binding and transactivation potential. Proceedings of the National Academy of
Sciences. 1995;92: 9876–9880.
482. Soutoglou E, Katrakili N, Talianidis I. Acetylation Regulates Transcription Factor Activity at
Multiple Levels. Mol Cell. 2000;5: 745–751.
483. Lemaigre FP, Durviaux SM, Truong O, Lannoy VJ, Hsuan JJ, Rousseau GG. Hepatocyte
nuclear factor 6, a transcription factor that contains a novel type of homeodomain and a single
cut domain. Proc Natl Acad Sci U S A. 1996;93: 9460–9464.
484. Rider MH, Bertrand L, Vertommen D, Michels PA, Rousseau GG, Hue L. 6-phosphofructo-2kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls
glycolysis. Biochem J. 2004;381: 561–579.
485. Lannoy VJ, Bürglin TR, Rousseau GG, Lemaigre FP. Isoforms of hepatocyte nuclear factor-6
differ in DNA-binding properties, contain a bifunctional homeodomain, and define the new
ONECUT class of homeodomain proteins. J Biol Chem. 1998;273: 13552–13562.
486. Blochlinger K, Bodmer R, Jack J, Jan LY, Jan YN. Primary structure and expression of a
product from cut, a locus involved in specifying sensory organ identity in Drosophila. Nature.
1988;333: 629–635.
487. Neufeld EJ, Skalnik DG, Lievens PM, Orkin SH. Human CCAAT displacement protein is
homologous to the Drosophila homeoprotein, cut. Nat Genet. 1992;1: 50–55.
488. Samadani U, Costa RH. The transcriptional activator hepatocyte nuclear factor 6 regulates
liver gene expression. Mol Cell Biol. 1996;16: 6273–6284.
489. Landry C, Clotman F, Hioki T, Oda H, Picard JJ, Lemaigre FP, et al. HNF-6 is expressed in
endoderm derivatives and nervous system of the mouse embryo and participates to the crossregulatory network of liver-enriched transcription factors. Dev Biol. 1997;192: 247–257.
490. Rausa F, Samadani U, Ye H, Lim L, Fletcher CF, Jenkins NA, et al. The cut-homeodomain
transcriptional activator HNF-6 is coexpressed with its target gene HNF-3 beta in the
developing murine liver and pancreas. Dev Biol. 1997;192: 228–246.
491. Lannoy VJ, Decaux JF, Pierreux CE, Lemaigre FP, Rousseau GG. Liver glucokinase gene
expression is controlled by the onecut transcription factor hepatocyte nuclear factor-6.
Diabetologia. 2002;45: 1136–1141.
74

492. Clotman F, Lannoy VJ, Reber M, Cereghini S, Cassiman D, Jacquemin P, et al. The onecut
transcription factor HNF6 is required for normal development of the biliary tract. Development.
2002;129: 1819–1828.
493. Vanderpool C, Sparks EE, Huppert KA, Gannon M, Means AL, Huppert SS. Genetic
interactions between hepatocyte nuclear factor-6 and Notch signaling regulate mouse
intrahepatic bile duct development in vivo. Hepatology. 2012;55: 233–243.
494. Zhang Y, Fang B, Damle M, Guan D, Li Z, Kim YH, et al. HNF6 and Rev-erbα integrate hepatic
lipid metabolism by overlapping and distinct transcriptional mechanisms. Genes Dev. 2016;30:
1636–1644.
495. Tan Y, Yoshida Y, Hughes DE, Costa RH. Increased expression of hepatocyte nuclear factor
6 stimulates hepatocyte proliferation during mouse liver regeneration. Gastroenterology.
2006;130: 1283–1300.
496. Lahuna O, Fernandez L, Karlsson H, Maiter D, Lemaigre FP, Rousseau GG, et al. Expression
of hepatocyte nuclear factor 6 in rat liver is sex-dependent and regulated by growth hormone.
Proc Natl Acad Sci U S A. 1997;94: 12309–12313.
497. Lahuna O, Rastegar M, Maiter D, Thissen JP, Lemaigre FP, Rousseau GG. Involvement of
STAT5 (signal transducer and activator of transcription 5) and HNF-4 (hepatocyte nuclear
factor 4) in the transcriptional control of the hnf6 gene by growth hormone. Mol Endocrinol.
2000;14: 285–294.
498. Pierreux CE, Stafford J, Demonte D, Scott DK, Vandenhaute J, O’Brien RM, et al.
Antiglucocorticoid activity of hepatocyte nuclear factor-6. Proc Natl Acad Sci U S A. 1999;96:
8961–8966.
499. Graves BJ, Johnson PF, McKnight SL. Homologous recognition of a promoter domain
common to the MSV LTR and the HSV tk gene. Cell. 1986;44: 565–576.
500. Johnson PF, Landschulz WH, Graves BJ, McKnight SL. Identification of a rat liver nuclear
protein that binds to the enhancer core element of three animal viruses. Genes Dev. 1987;1:
133–146.
501. Landschulz WH, Johnson PF, Adashi EY, Graves BJ, McKnight SL. Isolation of a recombinant
copy of the gene encoding C/EBP. Genes Dev. 1988;2: 786–800.
502. Takiguchi M. The C/EBP family of transcription factors in the liver and other organs. Int J Exp
Pathol. 1998;79: 369–391.
503. Diehl AM. Roles of CCAAT/enhancer-binding proteins in regulation of liver regenerative
growth. J Biol Chem. 1998;273: 30843–30846.
504. Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, et al. A nuclear factor for IL-6
expression (NF-IL6) is a member of a C/EBP family. EMBO J. 1990;9: 1897–1906.
505. Roman C, Platero JS, Shuman J, Calame K. Ig/EBP-1: a ubiquitously expressed
immunoglobulin enhancer binding protein that is similar to C/EBP and heterodimerizes with
C/EBP. Genes Dev. 1990;4: 1404–1415.
506. Cooper C, Henderson A, Artandi S, Avitahl N, Calame K. Ig/EBP (C/EBP gamma) is a
transdominant negative inhibitor of C/EBP family transcriptional activators. Nucleic Acids Res.
1995;23: 4371–4377.
507. Williams SC, Cantwell CA, Johnson PF. A family of C/EBP-related proteins capable of forming
covalently linked leucine zipper dimers in vitro. Genes Dev. 1991;5: 1553–1567.
508. Agre P, Johnson PF, McKnight SL. Cognate DNA binding specificity retained after leucine
zipper exchange between GCN4 and C/EBP. Science. 1989;246: 922–926.
509. Landschulz WH, Johnson PF, McKnight SL. The DNA binding domain of the rat liver nuclear
protein C/EBP is bipartite. Science. 1989;243: 1681–1688.
510. Ron D, Habener JF. CHOP, a novel developmentally regulated nuclear protein that dimerizes
with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of
gene transcription. Genes Dev. 1992;6: 439–453.
511. Osada S, Yamamoto H, Nishihara T, Imagawa M. DNA binding specificity of the
CCAAT/enhancer-binding protein transcription factor family. J Biol Chem. 1996;271: 3891–
3896.
75

512. Park EA, Roesler WJ, Liu J, Klemm DJ, Gurney AL, Thatcher JD, et al. The role of the
CCAAT/enhancer-binding protein in the transcriptional regulation of the gene for
phosphoenolpyruvate carboxykinase (GTP). Mol Cell Biol. 1990;10: 6264–6272.
513. Kim JW, Ahn YH. CCAAT/enhancer binding protein regulates the promoter activity of the rat
GLUT2 glucose transporter gene in liver cells. Biochem J. 1998;336 ( Pt 1): 83–90.
514. Nolten LA, van Schaik FM, Steenbergh PH, Sussenbach JS. Expression of the insulin-like
growth factor I gene is stimulated by the liver-enriched transcription factors C/EBP alpha and
LAP. Mol Endocrinol. 1994;8: 1636–1645.
515. Boccia LM, Lillicrap D, Newcombe K, Mueller CR. Binding of the Ets factor GA-binding protein
to an upstream site in the factor IX promoter is a critical event in transactivation. Mol Cell Biol.
1996;16: 1929–1935.
516. Lee YH, Alberta JA, Gonzalez FJ, Waxman DJ. Multiple, functional DBP sites on the promoter
of the cholesterol 7 alpha-hydroxylase P450 gene, CYP7. Proposed role in diurnal regulation
of liver gene expression. J Biol Chem. 1994;269: 14681–14689.
517. Croniger C, Trus M, Lysek-Stupp K, Cohen H, Liu Y, Darlington GJ, et al. Role of the isoforms
of CCAAT/enhancer-binding protein in the initiation of phosphoenolpyruvate carboxykinase
(GTP) gene transcription at birth. J Biol Chem. 1997;272: 26306–26312.
518. Friedman JR, Larris B, Le PP, Peiris TH, Arsenlis A, Schug J, et al. Orthogonal analysis of
C/EBPbeta targets in vivo during liver proliferation. Proc Natl Acad Sci U S A. 2004;101:
12986–12991.
519. Ray A, Ray BK. Serum amyloid A gene expression under acute-phase conditions involves
participation of inducible C/EBP-beta and C/EBP-delta and their activation by phosphorylation.
Mol Cell Biol. 1994;14: 4324–4332.
520. Yiangou M, Paraskeva E, Hsieh CC, Markou E, Victoratos P, Scouras Z, et al. Induction of a
subgroup of acute phase protein genes in mouse liver by hyperthermia. Biochim Biophys Acta.
1998;1396: 191–206.
521. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation.
Biochem J. 2002;365: 561–575.
522. Shiojiri N, Takeshita K, Yamasaki H, Iwata T. Suppression of C/EBP alpha expression in biliary
cell differentiation from hepatoblasts during mouse liver development. J Hepatol. 2004;41:
790–798.
523. Wang ND, Finegold MJ, Bradley A, Ou CN, Abdelsayed SV, Wilde MD, et al. Impaired energy
homeostasis in C/EBP alpha knockout mice. Science. 1995;269: 1108–1112.
524. Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury JR, et al.
Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform
in man. J Biol Chem. 1994;269: 17960–17964.
525. Lee YH, Sauer B, Johnson PF, Gonzalez FJ. Disruption of the c/ebp alpha gene in adult
mouse liver. Mol Cell Biol. 1997;17: 6014–6022.
526. Trautwein C, Rakemann T, Malek NP, Plümpe J, Tiegs G, Manns MP. Concanavalin Ainduced liver injury triggers hepatocyte proliferation. J Clin Invest. 1998;101: 1960–1969.
527. Kuo CJ, Conley PB, Chen L, Sladek FM, Darnell JE Jr, Crabtree GR. A transcriptional
hierarchy involved in mammalian cell-type specification. Nature. 1992;355: 457–461.
528. Nagaki M, Moriwaki H. Transcription factor HNF and hepatocyte differentiation. Hepatol Res.
2008;38: 961–969.
529. Griffo G, Hamon-Benais C, Angrand PO, Fox M, West L, Lecoq O, et al. HNF4 and HNF1 as
well as a panel of hepatic functions are extinguished and reexpressed in parallel in
chromosomally reduced rat hepatoma-human fibroblast hybrids. J Cell Biol. 1993;121: 887–
898.
530. Späth GF, Weiss MC. Hepatocyte nuclear factor 4 expression overcomes repression of the
hepatic phenotype in dedifferentiated hepatoma cells. Mol Cell Biol. 1997;17: 1913–1922.
531. Späth GF, Weiss MC. Hepatocyte Nuclear Factor 4 Provokes Expression of Epithelial Marker
Genes, Acting As a Morphogen in Dedifferentiated Hepatoma Cells. J Cell Biol. 1998;140:
935–946.
76

532. Heiman M, Kulicke R, Fenster RJ, Greengard P, Heintz N. Cell type-specific mRNA purification
by translating ribosome affinity purification (TRAP). Nat Protoc. 2014;9: 1282–1291.
533. Mo A, Mukamel EA, Davis FP, Luo C, Henry GL, Picard S, et al. Epigenomic Signatures of
Neuronal Diversity in the Mammalian Brain. Neuron. 2015;86: 1369–1384.
534. Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native
chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins
and nucleosome position. Nat Methods. 2013;10: 1213–1218.
535. Miura N, Tanaka K. Analysis of the rat hepatocyte nuclear factor (HNF) 1 gene promoter:
synergistic activation by HNF4 and HNF1 proteins. Nucleic Acids Res. 1993;21: 3731–3736.
536. Kritis AA, Ktistaki E, Barda D, Zannis VI, Talianidis I. An indirect negative autoregulatory
mechanism involved in hepatocyte nuclear factor-1 gene expression. Nucleic Acids Res.
1993;21: 5882–5889.
537. Ktistaki E, Talianidis I. Modulation of hepatic gene expression by hepatocyte nuclear factor 1.
Science. 1997;277: 109–112.
538. Hiemisch H, Schütz G, Kaestner KH. Transcriptional regulation in endoderm development:
characterization of an enhancer controlling Hnf3g expression by transgenesis and targeted
mutagenesis. EMBO J. 1997;16: 3995–4006.
539. Duncan SA, Navas MA, Dufort D, Rossant J, Stoffel M. Regulation of a transcription factor
network required for differentiation and metabolism. Science. 1998;281: 692–695.
540. Samadani U, Porcella A, Pani L, Johnson PF, Burch JB, Pine R, et al. Cytokine regulation of
the liver transcription factor hepatocyte nuclear factor-3 beta is mediated by the C/EBP family
and interferon regulatory factor 1. Cell Growth Differ. 1995;6: 879–890.

77

CHAPTER 2
TRAP-SEQ IDENTIFIES CYSTINE/GLUTAMATE ANTIPORTER AS A DRIVER OF
RECOVERY FROM LIVER INJURY

Parts of this chapter were adapted with permission from TRAP-seq identifies cystine/glutamate
antiporter as a driver of recovery from liver injury. Wang AW*, Wangensteen KJ*, Wang YJ, Zahm
AM, Moss NG, Erez N, Kaestner KH. The Journal of Clinical Investigation. 2018;128(6):2297-2309.
doi:10.1172/JCI95120.
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ABSTRACT
Understanding the molecular basis of the regenerative response following hepatic injury
holds promise for improved treatment of liver diseases. Here, we report an innovative method to
profile gene expression specifically in the hepatocytes that regenerate the liver following toxic
injury. We used the Fah-/- mouse, a model of hereditary tyrosinemia, which conditionally undergoes
severe liver injury unless fumarylacetoacetate hydrolase (FAH) expression is reconstituted
ectopically. We used translating ribosome affinity purification followed by high-throughput RNA
sequencing (TRAP-seq) to isolate mRNAs specific to repopulating hepatocytes. We uncovered
upstream regulators and important signaling pathways that are highly enriched in genes changed
in regenerating hepatocytes. Specifically, we found that glutathione metabolism, particularly the
gene Slc7a11 encoding the cystine/glutamate antiporter (xCT), is massively upregulated during
liver regeneration. Furthermore, we show that Slc7a11 overexpression in hepatocytes enhances,
and its suppression inhibits, repopulation following toxic injury. TRAP-seq allows cell type-specific
expression profiling in repopulating hepatocytes and identified xCT, a factor that supports
antioxidant responses during liver regeneration. xCT has potential as a therapeutic target for
enhancing liver regeneration in response to liver injury.
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INTRODUCTION
The liver is the main metabolic organ in the body; it is the nexus for homeostasis of
carbohydrates, proteins, and lipids, and it eliminates waste products by oxidation and reduction,
conjugation, and excretion into the bile. As such, the liver is exposed to environmental toxins that
can severely damage hepatocytes and cause acute liver failure [1]. Animals have conserved the
ability to regenerate the liver parenchyma upon damage [2] and to restore full mass and function
even with the loss of up to 75% of hepatocytes [3].
Liver cells in adult animals are normally quiescent and divide infrequently. With acute tissue
damage, however, mature hepatocytes and cholangiocytes enter the cell cycle and divide [4]. In
addition, hepatocyte proliferation occurs after partial hepatectomy (PHx), a noninflammatory liver
regeneration model in which up to two-thirds of the liver is removed [5]. In rodents, this leads to cell
division in most hepatocytes within hours and expansion of the remnant organ over the course of
1 to 2 weeks, until the entire mass of the liver is restored. Because PHx is relatively easily carried
out in rodents, it has been used to study liver regeneration in mice for decades [5,6]. In fact, many
studies have profiled changes in gene expression during regeneration, and a number of important
genes and pathways have been identified [7–9]. The common theme from these studies is that cellcycle genes are upregulated and metabolic genes are downregulated as hepatocytes divide to
recover from PHx.
Other paradigms to study liver regeneration utilize injury models involving treatment of
animals with hepatotoxins to examine the expression changes of injured liver tissue taken en bloc
[10–12]. However, until now there has been no methodology to distinguish the responses of the
healthy, repopulating liver cells from those of damaged hepatocytes and inflammatory cells. In
clinically relevant hepatic injury, a minority of cells may be protected from the initial insult and thus
poised to drive repopulation [13,14]. It is therefore important to establish which genes in the
repopulating hepatocyte drive regeneration in the setting of widespread injury.
The mouse model of hereditary tyrosinemia, an inborn error of tyrosine metabolism caused
by a deficiency of fumarylacetoacetate hydrolase (FAH) enzyme [14], is useful for studying the
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mechanisms of liver regeneration, since repopulating hepatocytes can be labeled as they divide to
restore liver function after injury. Homozygous null (Fah-/-) mice die at birth with hepatic dysfunction
from toxic metabolites but can be maintained in a healthy state by the drug 2-(2-nitro-4trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) [14]. Alternatively, gene therapy that
restores FAH expression can normalize tyrosine catabolism within hepatocytes and allow liver
repopulation by the corrected cells upon NTBC removal [15]. Our previous work also demonstrated
that transgenes can be coexpressed with FAH and can be used to genetically trace repopulating
hepatocytes over time [15,16].
Here, we use translating ribosome affinity purification (TRAP) [17] followed by highthroughput RNA sequencing (TRAP-seq) to profile the gene expression pattern specific to
repopulating hepatocytes. Slc7a11, encoding the cystine/glutamate antiporter (xCT), was
massively activated in regenerating hepatocytes. xCT imports cystine as a precursor for glutathione
(GSH) synthesis [18,19]. We show that ectopic expression of xCT promotes liver repopulation,
whereas CRISPR/Cas9-mediated mutation of Slc7a11 causes a decrease in replicating
hepatocytes. These findings indicate the functional significance of xCT and suggest that activation
of Slc7a11 could be used clinically to support therapeutic liver regeneration in the setting of acute
liver injury.
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RESULTS
TRAP enables lineage-tracing of repopulating hepatocytes
With the goal of specifically isolating repopulating hepatocytes from the injured liver to
perform RNA-seq, we initially set out to lineage trace repopulating hepatocytes with GFP and
isolate tagged cells by FACS for expression analysis. However, we encountered several problems.
First, the fragility of hepatocytes undergoing repopulation led to poor recovery following liver
perfusion. Second, the large size of the repopulating hepatocytes hampered the yield and purity of
isolated cells by sorting. Finally, the process from organ harvest to cell isolation took more than 2
h, which may have altered the expression profile.
Next, we turned to TRAP-seq (Figure 2.1A), which enables the immunoprecipitation of
ribosome-bound, translating mRNA from cells that express a fusion protein of the ribosomal protein
L10a and GFP (GFP-L10a) [17]. The fusion protein was subcloned into the coexpression vector
pKT2/Fah-mCa//SB [15] to construct pKT2/Fah-Gfp-L10a//SB (TRAP vector), which expresses
FAH together with GFP-L10a. The TRAP vector utilizes the Sleeping Beauty transposon system
for stable plasmid integration into the hepatocyte genome [15]. The TRAP vector was
hydrodynamically injected into Fah-/- mice, and NTBC was withdrawn to induce liver injury and
create pressure for the selection of hepatocytes that stably express FAH to repopulate the liver. An
estimated 0.1% to 1% of hepatocytes integrated the plasmid stably into their genomes [20]. Tissue
was harvested 1 or 4 weeks after injection, and GFP-tagged polysomes were extracted to isolate
translating mRNAs specifically from repopulating hepatocytes (Figure 2.1B). No RNA was
recovered from mice that were not injected with the TRAP vector, indicating the specificity of TRAP
isolation. Three mice in the four-week regeneration group had a greater degree of weight loss
(Figure 2.2), which was suggestive of more severe injury. Indeed, livers from these mice had large
areas lacking GFP staining, indicating a reduced level of initial plasmid uptake (Figure 2.1C).
Hence, we grouped these mice into a separate category termed “4-week regeneration after severe
injury.” Immunofluorescence (IF) analysis of liver sections confirmed that the majority of
proliferating hepatocytes also expressed GFP (Figure 2.1C). Thus, TRAP allows for mRNA
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isolation selectively from hepatocytes repopulating the injured liver, without contamination from
dying hepatocytes or inflammatory cells.

TRAP allows hepatocyte-specific RNA isolation from the quiescent liver
To obtain mRNA from quiescent hepatocytes as a reference for TRAP-seq, we used the
RosaLSL-GFP-L10a mouse, in which expression of GFP-L10a can be activated following Cre expression
[21]. We injected RosaLSL-GFP-L10a mice with hepatocyte-specific AAV8-TBG-Cre [22,23] and
performed TRAP to isolate hepatocyte mRNA 1 week later (Figure 2.1A). IHC of liver tissue from
these mice confirmed that GFP expression was only found in hepatocytes following AAV8-TBGCre injection (Figure 2.1C). GFP and Ki67 colabeling revealed very few actively dividing
hepatocytes (Figure 2.1C), consistent with the quiescent liver state.
High-throughput sequencing of cDNA libraries derived from 16 samples of TRAP-isolated
mRNA obtained, on average, 5.8 million uniquely mapped reads (Supplementary Digital Table 2.1).
As expected in pure hepatic mRNA, the 10 most abundant transcripts in the quiescent animals
were specific to hepatocytes (Table 2.1) [24–26]. Hepatocyte-specific genes such as Alb and Ttr
were highly abundant in hepatocytes from all samples, whereas the biliary epithelium markers
CK19, CK7, CFTR, and PKD2, as well as transcripts from other cell types in the liver, were nearly
undetectable (Table 2.2) [27,28], demonstrating the exquisite specificity of the TRAP method.
TRAP-seq detects differentially expressed genes in repopulating hepatocytes
Differential gene expression analysis identified 6,745 genes that change in expression in
repopulating compared with quiescent hepatocytes (Supplementary Digital Table 2.2); 3,418 were
significantly upregulated and 3,380 downregulated (FDR ≤ 5%) (Figure 2.3A). Hierarchical
clustering of the differentially expressed genes showed a distinct separation between quiescent
and repopulating hepatocytes (Figure 2.3B). Notably, the 4-week regeneration group clustered
closer to the 1-week regeneration group, demonstrating that TRAP-seq allows identification of
different levels of liver regeneration. To establish whether the differentially expressed genes fall
into defined regulatory networks, we used pathway analysis and focused on the highly validated
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Kyoto Encyclopedia of Genes and Genomes (KEGG) network collection [29,30] (Figure 2.3C).
Pathways controlling replication and growth were overrepresented among the upregulated genes,
including those regulating the cell cycle and DNA replication, indicating that genes involved in cell
replication were activated during liver repopulation, as expected. Strikingly, the GSH metabolic
pathway was strongly activated in regenerating hepatocytes, aligning with previous studies
showing that control of oxidative stress plays a crucial role in the regenerative response following
toxic liver injury [31]. Interestingly, metabolic pathways were enriched in both activated and
inhibited genes, reflecting the important metabolic regulation of hepatocytes, although the genes
at play were different in the 2 groups (Supplementary Digital Table 2.3). Upregulated metabolic
genes included redox processes, whereas repressed genes regulate lipid biosynthesis,
corroborating previous findings that hepatocytes limit the activity of metabolic networks to conserve
energy for rapid cell replication and DNA synthesis during regeneration [6].
The key regulatory nodes enriched in differentially expressed genes were analyzed with
Ingenuity Pathway Analysis, which takes into account the degree of change of each gene to
generate putative regulatory networks and predict activation or inhibition of the pathways. We
identified 227 upstream regulators, of which 24 met the following additional filters: (a) significant Zscores (≥2 for predicted activation and ≤2 for predicted inhibition); (b) at least a 2-fold change in
expression; and (c) congruence between the observed fold change and predicted state categories
(Table 2.3). MYC, the most enriched regulator, is a proto-oncogene activated as early as 1 h after
PHx [32] and is also upregulated in liver regeneration induced by carbon tetrachloride and
galactosamine [33]. Previous work had identified MYC as the strongest driver of liver repopulation
in Fah-/- mice in a cDNA overexpression screen of more than 40 genes [16], and its overexpression
also induces spontaneous hepatocellular carcinoma (HCC) development in the Fah-/- mouse model
within 8 weeks [34]. A second upstream regulator of the proliferative response is the transcription
factor FOXM1, which was previously shown to enhance liver repopulation [35]. These results
indicate that we were indeed able to profile the translating mRNA signature specifically in
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repopulating hepatocytes and demonstrate that TRAP-seq is a robust methodology for identifying
enriched pathways and upstream regulators.

Fah-/- and PHx regeneration models share common genetic pathways
Next, we set out to compare the transcriptional changes of regenerating hepatocytes in
Fah-/- mice recovering from toxic injury with those occurring following PHx, a paradigm of noninjury
regeneration. First, we reanalyzed previous RNA-seq data from whole-liver homogenates after PHx
[36] and identified 2,321 differentially expressed genes, 1,449 of which were activated and 872
inhibited (Figure 2.3D). Hierarchical clustering showed a distinct separation of gene regulation at
various time points after PHx (Figure 2.3E). Interestingly, gene expression at 1 h clustered closer
with quiescent hepatocytes, indicating that at this very early time point only a few early-response
genes were transcriptionally regulated. Pathway analysis [29,30] showed enrichment of genes
regulating cell-cycle and DNA synthesis pathways among the upregulated genes and those
regulating immune and metabolic pathways among the downregulated genes (Figure 2.3F).
We compared the gene expression changes between the Fah-/- and PHx models, defining
congruent genes as those regulated in the same direction in both models for at least 1 time point.
We identified a total of 1,236 congruent genes, 790 of which were activated and 446 repressed
(Figure 2.4A). Gene expression changes that occurred at all time points in the Fah-/- repopulation
mice were most similar to the changes observed in the PHx model at later time points (36 or 48 h
after PHx), as shown by the high percentage of congruence. Additionally, we found that the
percentage of congruence was higher among the upregulated genes, indicating a more similar
gene activation pattern in the 2 regeneration models. We discovered that the top upregulated
congruent genes — ranked by mean fold change in Fah-/- mice and subsequently retrieved from
the PHx data set — were associated with GSH metabolism, including the genes Slc7a11 and Gsta1
(Supplementary Digital Table 2.4) [18]. This was confirmed by pathway analysis, in which GSH
metabolism was highly enriched in the congruently upregulated genes, along with cell-cycle, DNA
replication, and DNA repair pathways (Figure 2.4C). Immune response and metabolic pathways
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were enriched among the congruently downregulated genes (Figure 2.4D). Interestingly, the
majority of the congruent genes did not show a significant change 1 h after PHx (Supplementary
Digital Table 2.4), as at this stage, hepatocytes still resembled quiescent hepatocytes, with
activation of only a few immediate early genes [2].
Of note, 2 of the top congruently upregulated genes, Ly6d and Pbk, are not typically
expressed in hepatocytes. The average fragments per kilobase of transcript per million mapped
(FPKM) reads for these genes in the quiescent hepatocytes were 2.7 and 0.01, but increased to
504.4 and 6.6 in regenerating hepatocytes, respectively (Supplementary Digital Table 2.2). Ly6d
expression has been shown to be associated with HCC and liver regeneration after injury [37,38],
while Pbk has been detected in HCC and cholangiocarcinoma [39,40]. This further demonstrates
the sensitivity and specificity of TRAP-seq in detecting expression changes in a unique
subpopulation of the liver — that of the regenerating hepatocytes.
Additionally, we identified genes that were only changed in 1 model but not the other
(unique genes), of which 5,510 were unique to Fah-/- mice, and 1,033 were unique to the PHx model
(Figure 2.4B). Of note, in both models, the percentage of unique genes compared with the total
number of differentially expressed genes was approximately 81%. However, in the Fah-/- mice, upand downregulated genes each constituted 50% of the unique genes, whereas in the PHx model,
the upregulated and downregulated genes made up 64% and 36% of the unique genes,
respectively. To further identify the biological pathways specific to each model, pathway enrichment
analysis was performed on the unique genes [29,30], and overrepresented networks were identified
(Figure 2.4, C and D). In Fah-/- mice, liver injury response categories such as alcoholism and viral
carcinogenesis were uniquely activated, while immune response and metabolic pathways were
uniquely inhibited. On the other hand, no significant pathway activation was unique to the PHx
model, whereas the pancreatic secretion and protein and fat digestion/absorption pathways were
uniquely inhibited. The striking difference in enriched pathways demonstrates the gene expression
signatures that differentiate the 2 regeneration paradigms, in which injury response and immune
modulation are unique to Fah-/- mice and nutrient redistribution is integral to the PHx model.
86

Recently, single-molecule RNA-FISH combined with single-cell RNA-seq (scRNA-seq) has
been applied to reconstruct the spatial heterogeneity and identify novel zonal signature genes
within the quiescent liver [41]. While TRAP-seq utilizes bulk RNA-seq and therefore cannot inform
a spatial resolution of transcriptional changes during regeneration, we compared the expression
profiles of quiescent hepatocytes from TRAP-seq with the scRNA-seq data. We reasoned that since
all hepatocytes express GFP-L10a in the quiescent liver (Figure 2.1C), the isolated transcripts from
TRAPseq should have an equal representation of the genes identified from the 9 different
subpopulations by scRNA-seq. As expected, we found significant overlap between TRAP-seq and
all 9 layers of scRNA-seq, with an average of 10,405 common genes, constituting 90.7% of the
genes detected by TRAP-seq (Figure 2.5). Thus, TRAP-seq enables unbiased RNA isolation from
all layers of hepatocytes.

Slc7a11 is massively upregulated in regenerating hepatocytes
The comparison of the Fah-/- and PHx models revealed Slc7a11 as the most significantly
activated gene in both paradigms, with a remarkable increase of 900-fold in the former and 200fold in the latter (Supplementary Digital Table 2.4). Slc7a11 encodes xCT, a sodium-independent
transporter for cystine import and glutamate export [19]. After entering the cell, cystine is rapidly
reduced to cysteine, a precursor for GSH synthesis necessary for cellular defense against oxidative
stress [18]. Previous studies indicated that deficiency of glutamate-cysteine ligase, the rate-limiting
enzyme in GSH synthesis, leads to decreased hepatocyte proliferation in vitro and delayed
regeneration after PHx [42,43]. However, the role of xCT in liver regeneration has not been studied.
We hypothesized that xCT upregulation supports actively repopulating hepatocytes to defend
against increased oxidative stress during injury and regeneration (Figure 2.6A).
To evaluate the role of xCT in liver regeneration, we first validated our observations from
RNA-seq with quantitative real-time reverse transcription PCR (qRT-PCR) on TRAP-purified mRNA
and confirmed a significant upregulation of Slc7a11 and Gsta1 transcripts in repopulating
hepatocytes (Figure 2.7A). Western blot analysis showed an increase in xCT protein in repopulating
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livers (Figure 2.7B). Of note, there was low xCT expression in the quiescent liver, albeit no mRNA
transcripts were present in hepatocytes. One possibility is that whole-liver homogenate was used
for the protein analysis, and thus xCT protein from other cell types such as macrophages was
detected [19]. Alternatively, the protein stability of Slc7a11 could exceed its RNA turnover rate.
Regardless, the expression of Slc7a11 was significantly activated in the regenerating liver.
We next sought to investigate whether oxidative stress is increased in Fah-/- livers during
regeneration. We used immunohistochemical methods to detect markers of lipid peroxidation
(malondialdehyde and 4-hydroxynonenal) and protein nitration (nitrotyrosine). We observed an
accumulation of redox metabolites in the injured livers compared with healthy, quiescent livers
(Figure 2.7C). These results indicate that Slc7a11 mRNA expression and xCT protein levels are
highly enriched in repopulating hepatocytes in the presence of increased reactive oxygen and
nitrogen species, suggesting a functional role of Slc7a11 in the regulation of liver regeneration.

Ectopic Slc7a11 expression promotes liver regeneration
To examine the functional importance of xCT activation in regenerating hepatocytes, we
constructed plasmids coexpressing Fah and overexpressing Slc7a11 (Fah-Slc7a11) or Gfp (FahGfp). We performed a competition assay, in which equimolar amounts of Fah-Gfp and Fah-Slc7a11
were injected into Fah-/- mice, followed by NTBC withdrawal (Figure 2.6B). After 4 weeks of
repopulation, we observed a 2.5-fold enrichment of Fah-Slc7a11 plasmid relative to the Fah-Gfp
control plasmid by qPCR of extracted liver genomic DNA (Figure 2.6C) as well as
overrepresentation of HA-tagged, xCT-expressing hepatocytes compared with GFP-expressing
cells (Figure 2.6D). These results demonstrate a positive selection for hepatocytes overexpressing
xCT, even above the already striking activation of endogenous Slc7a11.
To test whether Slc7a11 is required for liver regeneration, we used CRISPR/Cas9 to
inactivate Slc7a11 specifically in the repopulating hepatocytes. We coexpressed FAH with either
10 single-guide RNAs (sgRNAs) targeting Slc7a11 exons (Fah-sgSlc7a11) or 10 control sgRNAs
targeting luciferase (Fah-gCtl) and performed hydrodynamic tail-vein injection of these sgRNAs,
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together with adeno-associated virus 8 (AAV8) expressing Staphylococcus aureus Cas9 (SaCas9)
to allow for hepatocyte-specific expression of the SaCas9 nuclease [44], which efficiently
introduces indels comparable to those of Cas9 from S. pyogenes [45] (Figure 2.6E). Liver
repopulation was then carried out for 4 weeks. To quantify and characterize the mutations induced
by CRISPR/Cas9, we extracted genomic DNA from the repopulating livers, PCR amplified exon 1
for Sanger sequencing, and performed tracking of indels by decomposition (TIDE) analysis [46].
We found that the 2 sgRNAs targeting the first exon of Slc7a11 exhibited different mutation
efficiency: 29.5% and 51.6%, respectively (Figure 2.8, A and B). Furthermore, the main mutation
introduced by SaCas9 in either sgRNA was a 5-nucleotide deletion, with an efficacy of 27.9% and
51.6%, respectively. The difference in mutation rate could be due to the slight difference in the
protospacer-associated motif (PAM) sequence (NNGRRT) of the 2 sgRNAs, CTGAGT and
AAGGGT [44]. Nonetheless, TIDE analysis demonstrated that Slc7a11 was mutated through the
expression of SaCas9 in the hepatocytes.
We measured weight changes over the 4-week period of liver repopulation and found no
significant weight differences in mice treated with Slc7a11 sgRNAs compared with those treated
with control sgRNAs (Figure 2.8C). Likewise, we detected no significant difference in the liver
weight to body weight ratio by the end of the 4-week period (Figure 2.8D). However, sgSlc7a11treated mice had smaller FAH repopulation nodules and fewer Ki67/FAH double-positive
hepatocytes compared with sgCtl-treated mice (Figure 2.6F), indicating that Slc7a11 mutation
inhibits replication of FAH-expressing cells during liver injury. It should be noted that these results
are probably an underrepresentation of the true effect of Slc7a11 mutation, as only hepatocytes
homozygous, not those that are heterozygous, for inactivation of Slc7a11 are expected to be at a
growth disadvantage. Furthermore, redundant pathways could compensate for the loss of Slc7a11
[47]. Together, these studies demonstrate the functional importance of xCT during liver
repopulation and show that Slc7a11 overexpression is sufficient to accelerate repopulation,
whereas Slc7a11 inactivation, while not completely abrogating regeneration, hinders hepatocyte
replication.
89

Slc7a11 is transcriptionally activated by ATF4
Finally, we investigated the mechanism of xCT activation during liver repopulation. Several
transcription factors have been shown to regulate Slc7a11 expression in different contexts: nuclear
factor E2-related factor 2 (NRF2) activates xCT during redox stress [48], activating transcription
factor 4 (ATF4) upregulates xCT under ER stress, octamer-binding transcription factor (OCT1)
disinhibits Slc7a11 following ethanol exposure [49], and p53 inhibits xCT under normal tumor
suppression conditions [50]. Additionally, ATF4 is suggested to regulate the basal levels of Slc7a11
expression [51].
We first performed unbiased chromatin accessibility profiling to identify regulatory elements
at the Slc7a11 locus in hepatocytes in the basal and repopulating state. We used the isolation of
nuclei-tagged in specific cell types (INTACT) system to label the nuclei of regenerating hepatocytes
[52]. Specifically, the nuclear envelope protein SUN1 was tagged with GFP [53], and the resulting
fragment was subcloned into the FAH coexpression construct (Fah-Sun1-Gfp). One week after the
Fah-/- mice were repopulated with Fah-Sun1-Gfp, livers were harvested and sorted for GFP-positive
nuclei (Figure 2.9A). As a quiescent control, we injected RosaLSL-Sun1-GFP mice with AAV8-TBG-Cre
and sorted hepatocytes after 1 week (Figure 2.9A). We used the assay for transposase accessible
chromatin using sequencing (ATAC-seq) [54,55] to profile the chromatin landscape changes after
1 week of regeneration. Remarkably, the Slc7a11 promoter is highly accessible in the regenerating
hepatocytes, as indicated by the strong peak present 1 week after regeneration (Figure 2.9B). In
comparison, we observed no peak at the promoter in the quiescent liver, demonstrating a
heterochromatic state in healthy liver cells. This observation coincides with our TRAP-seq analysis,
in which no Slc7a11 transcripts were detected in quiescent hepatocytes, but became highly
abundant in regenerating hepatocytes (Figure 2.7A).
Next, to determine how Slc7a11 is activated, we performed a motif search at the open
chromatin region of the activated promoter and identified a potential NRF2-binding site 39 bases
and 2 potential ATF4-binding sites 39 and 66 bases upstream of the transcriptional start site (Figure
2.9C). To assess whether ATF4 or NRF2 binds to the Slc7a11 promoter during liver repopulation,
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we carried out ChIP-qPCR in quiescent and 4-week regenerating livers. We detected a significant
4-fold enrichment of bound ATF4 at the Slc7a11 promoter in regenerating hepatocytes relative to
that seen in quiescent controls. In contrast, NRF2 binding was undetected in either condition
(Figure 2.9D), suggesting that ATF4, but not NRF2, activates Slc7a11 transcription during liver
repopulation.

91

TABLES
Table 2.1. Top ten abundant transcripts identified in quiescent livers.

Apoc3

22258.99

1-week
regeneration
8284.08

Apoa2

18465.14

8906.01

8600.62

10388.86

Fabp1

14824

15222.48

10529.91

1586.67

Apoc1

12632.39

14177.49

6945.49

15360.81

Apoe

12418.85

6753.43

5936.13

10505.54

Apoc1

11083.99

12446.11

6094.25

13496.84

Alb

10481.08

5141.19

2962.66

9602.19

Trf

6906.36

1267.84

1930.87

3292.12

Gpx1

6150.21

4540.07

5258.64

5562.72

Apoc4

5028.13

4193.01

4623.31

2596.7

Gene

Quiescent

4-week
regeneration
16707.52

4-week regeneration
after severe injury
10378.8

Numbers represent the average fragments per kilobase of transcript per million (FPKM) reads in
each regeneration group.
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Table 2.2. FPKM of cell type-specific transcripts detected by TRAP-seq.

Alb

10481.08

1-week
regeneration
5141.19

Ttr

2639.6

3072.59

1212.62

5454.57

Hepatocyte

Cyp2e1

2424.01

588.72

1418.17

380.48

Hepatocyte

Asgr1

1190.04

865.69

1375.35

654.07

Krt19

0.18

0.16

0.15

1.97

Pkd2

1.28

0.71

0.79

1.56

Krt7

0.22

0

0.22

0.89

Cftr

0

0

0.02

0

Des

1.09

0.33

0.43

0.86

Hepatocyte
Biliary
epithelium
Biliary
epithelium
Biliary
epithelium
Biliary
epithelium
Stellate cell

Acta2

0.41

0.35

0.27

0.34

Stellate cell

Col1a1

0.04

0.42

0.26

1.22

Stellate cell

Cd68

0.92

0.71

0.36

5.9

Kupffer cell

Emr1

0.67

0.28

0.27

0.84

Kupffer cell

Cd163l1

0

0

0

0

Kupffer cell

Clec5a

0

0

0.02

0.05

Kupffer cell

Gene

Quiescent

4-week
regeneration
2962.66

4-week regeneration
after severe injury
9602.19

Hepatocyte
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Cell type

Table 2.3. Upstream regulators predicted by Ingenuity Pathway Analysis.
Upstream
regulator
MYC

Fold
change
3.08

Molecule type

Predicted state

Z-score

P value

Transcription regulator

Activated

4.73

1.15E-24

SREBF1

0.26

Transcription regulator

Inhibited

-3.97

3.32E-16

THRB

0.50

Nuclear receptor

Inhibited

-2.28

4.26E-10

E2F1

2.53

Transcription regulator

Activated

2.59

2.06E-09

FOXM1

15.67

Transcription regulator

Activated

3.23

4.79E-09

EGR1

0.33

Transcription regulator

Inhibited

-2.09

4.33E-08

HBB-B1

0.11

Transporter

Inhibited

-2.07

7.41E-08

SPARC

0.30

Other

Inhibited

-3.62

1.43E-07

CSF1

0.48

Cytokine

Inhibited

-2.95

2.63E-07

HBB-B2

0.11

Other

Inhibited

-2.68

5.31E-07

ERF2

4.85

Transcription regulator

Activated

2.75

9.10E-07

USF2

0.35

Transcription regulator

Inhibited

-2.49

2.40E-06

AGTR1

0.40

GPCR

Inhibited

-2.70

6.04E-06

LMNB1

6.69

Other

Activated

2.56

6.26E-06

CCNE1

3.7

Transcription regulator

Activated

2.07

2.14E-05

MLXIPL

0.40

Transcription regulator

Inhibited

-3.70

3.19E-05

TFEB

0.35

Transcription regulator

Inhibited

-2.05

3.33E-04

S100A6

2.92

Transporter

Activated

2.85

1.20E-03

CTGF

0.44

Growth factor

Inhibited

-2.04

1.26E-03

TAS1R3

0.42

GPCR

Inhibited

-2.14

2.02E-03

IL15

0.37

Cytokine

Inhibited

-2.70

3.28E-03

FASN

0.14

Enzyme

Inhibited

-2.11

1.77E-02

TNK1

0.46

Kinase

Inhibited

-2.83

2.03E-02

MLYCD

0.50

Enzyme

Inhibited

-2.00

2.06E-02

Filter criteria: (a) significant Z-scores (≥2 for predicted activation and ≤2 for predicted inhibition);
(b) at least 2-fold change in expression; and (c) congruence between the observed fold change
and predicted state categories.
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FIGURES
Figure 2.1. Translating ribosome affinity purification (TRAP) enables cell type-specific isolation of
RNA from quiescent and repopulating hepatocytes.

(A) The approach for isolating repopulating hepatocyte RNA with the Fah-/- model involves use of
the FAH expression construct to mediate liver repopulation and the GFP-tagged ribosomal protein
L10a (GFP-L10a) to specifically isolate translating mRNAs with TRAP. Injection of the RosaLSLGFP-L10a mouse with the AAV8-TBG-Cre virus, which has a tropism for hepatocytes and has a
hepatocyte-specific promoter driving Cre expression in nearly all hepatocytes, allows for
immunoprecipitation of translating mRNA from quiescent hepatocytes. (B) Bioanalyzer tracings of
affinity-purified RNA from mice treated with or without the TRAP vector. FU, fluorescence units. (C)
Representative (n = 3) IHC images of GFP show progressive repopulation over time in Fah-/- mice
as well as complete labeling of quiescent hepatocytes in RosaLSL-GFP-L10a mice 1 week after injection
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of AAV8-TBG-Cre. No GFP expression was observed in livers from the uninjected mice. IF of Ki67
and GFP confirmed successful liver repopulation in Fah-/-mice injected with the TRAP vector, as all
Ki67-positive hepatocytes express GFP. IF costaining also showed global GFP-expressing and
rare Ki67-positive hepatocytes, indicating that the control tissue was truly quiescent. Note that a
subset of mice showed only partial repopulation at 4 weeks (4-week regeneration after severe
injury). Scale bars: 1 mm (top) and 100 μm (bottom).
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Figure 2.2. Mice in the 4-week regeneration after severe injury group exhibit significant weight loss.

The proportion of weight loss was normalized to the initial weight prior to plasmid injection and
NTBC removal. Bodyweight was monitored three times per week after induction of liver injury and
regeneration. After four weeks of injury and regeneration, three mice lost ~30% of the starting
weight (blue), significantly different from mice in the 4-week regeneration group that underwent
initial weight loss but restored body weight after four weeks (red). A two-sided, two-tailed Student’s
t-test was used to compare the proportion of body weight in the 4-week regeneration (n=6) and 4week regeneration after severe injury (n=3) groups.
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Figure 2.3. TRAP-seq identifies differentially expressed genes specific to repopulating hepatocytes
in the Fah-/- model.

(A and D) Differential expression analysis identified 6,745 (3,418 upregulated and 3,380
downregulated) and 2,321 (1,449 upregulated and 872 downregulated) genes as being significantly
altered in repopulating hepatocytes in the Fah-/- (A) and PHx (D) models (36), respectively,
compared with quiescent controls. Red, 1-week Fah-/- regeneration and 1 h after PHx; blue, 4-week
Fah-/- regeneration and 36 h after PHx; green, 4-week Fah-/- regeneration after severe injury and
48 h after PHx. (B and E) Hierarchical clustering of differentially expressed genes of quiescent and
repopulating hepatocytes at different time points. (C and F) KEGG pathways significantly enriched
for the sets of activated and repressed genes, respectively, in the Fah-/- (C) and PHx (F) data sets.
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Figure 2.4. Comparison of the Fah-/- TRAP-seq data with RNA-seq data from the PHx model
identifies common and unique characteristics of liver repopulation paradigms.

(A) A total of 1,236 genes were significantly altered in the same direction in both models [36] for at
least 1 time point (congruent genes). Of these genes, 790 were activated and 446 inhibited. Labels
indicate the number of congruent genes at each time point. (B) A total of 5,510 and 1,033 genes
were uniquely changed in the Fah-/- and PHx models, respectively. (C and D) Comparison of the
KEGG pathways enriched for genes upregulated (C) and downregulated (D) in the congruent
(Cong) and unique gene sets.
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Figure 2.5. Comparison of identified transcripts from single-cell RNA-seq (scRNA-seq) [41] shows
significant overlap between TRAP-seq and all nine layers of scRNA-seq.

Genes identified in the quiescent samples from TRAP-seq was compared to that from scRNA-seq.
Bar height indicates the number of overlapping genes identified in two techniques. Line and data
points indicate the percentage overlap from each scRNA-seq layer compared to TRAP-seq. A
hypergeometric test was used to calculate the significance of overlapping genes from the two
sequencing methods.
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Figure 2.6. Slc7a11 enhances hepatocyte repopulation.

(A) The Slc7a11 gene product (xCT) imports cystine, which is used for GSH synthesis to alleviate
oxidative stress. Several GSH metabolic enzymes were significantly (FDR ≤ 5%) upregulated (red)
in repopulating hepatocytes from Fah-/- mice. GSSG, glutathione disulfide; GCL, glutamatecysteine ligase; GSS, glutathione synthetase; GST, glutathione S-transferase; GSR, glutathione
reductase; GPX, glutathione peroxidase. (B) Schematic of the competition assay to determine the
effects of Slc7a11 overexpression on repopulation. (C) The Fah-Slc7a11 plasmid was significantly
enriched after 4 weeks of repopulation. A 1-sample, 2-tailed Student’s t-test was used to compare
the ratio of 2 plasmids before and after repopulation (n = 8). (D) Representative IF staining and
quantification showing a significant increase in xCT-positive hepatocytes. A paired, 2-tailed
Student’s t-test was used to compare HA- and GFP-expressing hepatocytes (n = 5). Scale bar: 100
μm. (E) Schematic of the CRISPR/Cas9 system used to inactivate Slc7a11 in Fah-/- mice. sgCtl,
sgRNAs targeting firefly luciferase. (F) Representative IHC and IF images and quantification
showing a significant reduction in repopulation nodules and replicating hepatocytes in mice treated
101

with sgRNAs targeting Slc7a11 (sgSlc7a11) compared with control mice treated with sgCtl. A 2sample, 2-tailed Student’s t-test was used to compare groups (n = 4 each). Scale bars: 300 μm
(top) and 100 μm (bottom).
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Figure 2.7. Slc7a11 is activated at the transcript and protein levels under increased oxidative stress
during liver regeneration.

(A) Real-time reverse transcription PCR (qRT-PCR) analysis showed continuous upregulation of
Slc7a11 and Gsta1, both involved in GSH metabolism, in repopulating hepatocytes. A two-sample,
two-tailed Student’s t-test was used to compare repopulating and quiescent hepatocytes. * p<0.05,
*** p<0.001 (n=4, quiescent and 1-week regeneration; n=3, 4-week regeneration and 4-week
regeneration after severe injury). (B) Western blot analysis confirmed the activation of xCT in the
regenerating liver. (C) IHC staining of lipid peroxidation markers (malondialdehyde and 4hydroxynonenal) and protein nitration (nitrotyrosine) showed accumulation of redox metabolites in
the injured, repopulating liver compared to healthy, quiescent livers. Scale bar: 100µm.
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Figure 2.8. No significant differences in the weight of mice with Slc7a11 inhibition compared to
control after 4 weeks of repopulation.

(A and B) Mutation analysis of Slc7a11 exon one identified differential indel rates introduced by
two single guide RNAs (sgRNA), sgSlc7a11-1 (A) and sgSlc7a11-2 (B). The x-axis indicates the
number of nucleotides that were inserted or deleted and the y-axis indicates the percentage of
mutation. (C) No weight differences during and after 4 weeks of repopulation and no changes in
liver weight to body weight ratio (D) in mice treated with sgRNA against Slc7a11 (n=4) compared
to control mice (n=4). A two-sample, two-tailed Student’s t-test was used to compare mice treated
with Slc7a11 and control sgRNAs.
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Figure 2.9. Slc7a11 is activated by ATF4 during liver repopulation.

(A) Schematic of our approach utilizing the GFP-labeled nuclear envelope protein SUN1 to isolate
hepatocyte nuclei [53], followed by ATAC-seq [54,55] analysis. (B) ATAC-seq identified an open
chromatin state at the promoter region of Slc7a11 specifically in regenerating hepatocytes (n = 2,
quiescent; n = 4, 1-week regeneration). (C) The open chromatin region of the Slc7a11 promoter
contains binding motifs for NRF2 and ATF4. (D) ChIP-qPCR showed a 4-fold enrichment of ATF4
binding to the Slc7a11 promoter after 4 weeks of liver regeneration, while no enrichment in NRF2
binding was observed. The Wilcoxon rank-sum test was used to compare the differential binding in
regenerating and quiescent livers (n = 3, quiescent; n = 6, 4-week regeneration).
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DISCUSSION
Here, we performed what we believe to be the first expression profile specific to
repopulating hepatocytes by integrating the TRAP assay with the Fah-/- mouse model. We identified
important signaling networks and regulators, including upregulation of the cell-cycle and GSH
metabolic pathways, and several activated transcription factors such as MYC and FOXM1.
Bioinformatics analysis comparing the gene expression of Fah-/- and PHx regeneration models
identified pathways common to both models, i.e., cell cycle and GSH metabolism pathway genes
among the congruently activated genes, and immune response pathway genes among the
congruently inhibited genes. We also observed that liver damage pathways are uniquely
upregulated in Fah-/- mice, while altered biosynthetic activity is a main theme in the PHx model.
A recent study utilizing single-cell technology to reconstruct the spatial heterogeneity of the
liver had identified 9 distinct layers of gene expression profiles in quiescent hepatocytes [41]. We
showed that transcripts identified from TRAP-seq significantly overlapped with those found in
scRNA-seq, regardless of the layer, demonstrating the sensitivity and specificity of TRAP-seq in
isolating transcripts from pure hepatocytes. Nonetheless, there are several differences between
the 2 techniques. First, TRAP-seq utilizes bulk RNA-seq and therefore could not capture the zonal
information by scRNA-seq. Second, TRAP-seq isolates mRNA bound to the ribosomal subunit
L10a and hence only captures the actively translating mRNA. Third, TRAP-seq does not require
cell sorting and therefore bypasses the time-consuming sample preprocessing required for scRNAseq. Previous efforts to isolate intact regenerating hepatocytes after hydrodynamic injection has
been unsuccessful, rendering TRAP-seq a valuable alternative. Future work could apply cell layerspecific expression of GFP-L10a to shed light on the zonal responses to liver injury and
regeneration.
Previous work has demonstrated the importance of controlling oxidative stress during liver
regeneration to allow hepatocyte replication, as an elevation of ROS induces a compensatory
upregulation of GSH to inhibit irreversible cell damage and promote hepatic replication [56]. In
support of the central role of GSH in liver regeneration, inhibition or deficiency of glutamate-cysteine
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ligase, the rate-limiting enzyme in GSH synthesis, leads to downregulation of cyclin expression,
decreased hepatocyte proliferation in vitro, and delayed regeneration after PHx [42,43].
Furthermore, GSH is depleted in acetaminophen-induced liver injury by the toxic metabolite NAPQI
[57], pointing to the importance of GSH detoxification and ROS homeostasis in various regenerative
paradigms.
Importantly, our results indicate that Slc7a11 becomes dramatically activated in
repopulating hepatocytes, and we further show that ectopic expression of xCT concomitantly with
the onset of liver injury promotes regeneration, probably by shielding repopulating hepatocytes
from oxidative stress. These results highlight the therapeutic potential of activating Slc7a11 as a
treatment for acute liver injury. We did not observe any health complications in mice overexpressing
Slc7a11 during the 4-week period of repopulation in the Fah-/- mouse. However, determining
whether this approach is beneficial in managing chronic liver injury and whether long term xCT
activation is safe will require further examination.
Recent studies have found Slc7a11 to be highly expressed in HCC, breast cancer cells,
and gastrointestinal tumors [58–60] and have shown that pharmacological xCT inhibition induces
growth arrest in cancer cells and decreases tumor size in mouse models [59,60]. Therefore, it is
possible that regenerating hepatocytes experience metabolic requirements similar to those seen in
cancer cells to increase GSH availability. This raises the question of the safety of using xCT
antagonists in patients with HCC, as both the growth of cancer cells and regenerating hepatocytes
would be inhibited. Interestingly, in our gene inactivation studies, while a decrease in replicating
hepatocytes during regeneration was observed, Slc7a11 inhibition did not completely abrogate liver
repopulation, and the mice treated with sgRNAs against Slc7a11 were still able to restore full body
weight after 4 weeks of regeneration. This observation is consistent with recent findings that xCT
deficiency alone is not sufficient to induce liver injury but exacerbates injury when combined with
secondary stress such as a high-iron diet [61] or inhibition of the transsulfuration pathway [62]. In
addition, as discussed above, Slc7a11 was probably not inactivated for both alleles in all
regenerating hepatocyte clones. Furthermore, genetic redundancy has been proposed to underlie
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liver regeneration, as loss of any single gene rarely leads to complete inhibition of the regenerative
process [3].
In conclusion, this study demonstrates the feasibility of TRAP-seq for cell type-specific
mRNA isolation of hepatocytes and identifies Slc7a11 as a driver that promotes recovery after
acute liver injury. Likewise, TRAP could be used to label other cell types in the liver to study their
roles in acute liver injury. For instance, by combining the RosaLSL-GFP-L10a mouse with a biliaryspecific Cre or stellate cell-specific Cre transgene, it will be possible to profile the cell type-specific
gene expression for these cells during injury and regeneration.
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MATERIALS AND METHODS
All primer sequences are listed in Supplementary Digital Table 2.5.
Plasmid construction
The plasmid C2-EGFP-L10a was provided by Nathaniel Heintz (The Rockefeller University,
New York, NY, USA). The GFP-L10a coding sequence was amplified by PCR using the primers
L10a-R-BsiWI and MfeI-EGFP-F and subcloned into the vector pKT2/Fah-mCa//SB [15] at the
EcoRI and BsiWI restriction sites. The vector utilizes the Sleeping Beauty (SB) transposon system
to enable the integration of transgene sequences into the genome. The Slc7a11 cDNA was
purchased (MG225346, OriGene) and amplified by PCR with the primers Slc7a11_clone_F1 and
Slc7a11_psmd_bcd-R or Slc7a11-HA_bcd-R to include the HA tag. For the CRISPR/Cas9 studies,
the vector pKT2/Fah-SpCas9//SB [34] was used to replace the SpCas9 with the SaCas9 sgRNA
scaffold and introduce the subcloning site for further sgRNA subcloning using the oligonucleotides
SaCas-9Ins-F and -R and the restriction enzymes SapI and EcoRI to generate the vector
pKT2/Fah-SaCas9//SB. Next, 10 sgRNAs targeting the exon regions of Slc7a11 were designed
with the online CRISPR RGEN Tools [63] and DESKGEN Cloud [64]. Ten sgRNAs against
luciferase were designated as the control, and the oligonucleotides were subcloned into the
pKT2/Fah-SaCas9//SB vector at the SapI restriction sites. For the ATAC-seq study, SUN1-GFP
fragments with EcoRI and BsiWI restriction sites were amplified from the SUN1-GFP plasmid (a
gift of Jeremy Nathans, Johns Hopkins University, Baltimore, MD, USA) with the primers MfeISun1-F and BsiW1-Sun1-R and subcloned into the vector pKT2/Fah-mCa//SB to generate
pKT2/Fah-Sun1-Gfp//SB. Endotoxin-free Maxi-scale DNA extraction and purification were
performed with the GenElute HP Plasmid Maxiprep Kit (MilliporeSigma).

Mouse experiments
Fah-/- mice were maintained on NTBC (Swedish Orphan Biovitrum) in the drinking water
(7.5 mg/l) until hydrodynamic tail-vein injection [15] of 10 μg plasmid, as specified below. For the
TRAP-seq study, pKT2/Fah-Gfp-L10a//SB was injected, and the mice were euthanized 1 week (n
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= 3) or 4 weeks (n = 9) after injection. Likewise, for the overexpression assay, mice were injected
with equimolar amounts of the plasmids pKT2/Fah-Gfp//SB and pKT2/Fah-Slc7a11//SB (n = 3) or
pKT2/Fah-Slc7a11-HA//SB (n = 5) and euthanized 4 weeks after injection. For the CRISPR/Cas9
studies, Mice were injected with either a mixture of 10 pKT2/Fah-sgSlc7a11//SB (n = 4) or
pKT2/Fah-sgCtl//SB (n = 4) in conjunction with 11012 genome copies of AAV8.SaCas9 (Penn
Vector Core [65]) for 4 weeks of repopulation. For the ATAC-seq assay, mice were injected with
pKT2/Fah-Sun1-Gfp//SB (n = 4). One week after plasmid injection, the livers were harvested, and
GFP-positive nuclei were isolated by FACS. Mouse weights were measured 3 times per week over
the course of the repopulation period to ensure successful liver regeneration. RosaLSL-GFP-L10a mice
were purchased from The Jackson Laboratory and used as a healthy control (n = 4) in the TRAPseq study, and the RosaLSL-GFP-L10a mice were provided by Mitchell Lazar (University of
Pennsylvania, Philadelphia, PA, USA) as a quiescent control in the ATAC-seq (n = 2) experiments.
AAV8.TBG.PI.Cre.rBG (Penn Vector Core [65]) was injected into the tail vein of mice at 11011 virus
particles per mouse. Mice were euthanized after 1 week of injection, and the livers were harvested.
All animal studies were performed in 8- to 12-week-old female mice.

Translating RNA isolation
RNA specific for repopulating hepatocytes was isolated by TRAP [17]. Briefly, 200 mg liver
tissue was taken en bloc from mice injected with the TRAP construct and from RosaLSL-GFP-L10a
mice, homogenized with lysis buffer, and incubated with magnetic beads that were conjugated with
anti-GFP antibodies (clones Htz-GFP-19F7 and Htz-GFP-19C8, Memorial Sloan-Kettering
Monoclonal Antibody Facility, New York, New York, USA) to affinity purify RNA that was bound by
the GFP-L10a fusion protein.

IHC and IF
Liver lobes were dissected from mice and fixed with 4% paraformaldehyde, embedded in
paraffin, and sectioned. For IHC, slides were rehydrated and subjected to antigen retrieval in
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sodium citrate (pH 6.0). H2O2 (30%) was used for quenching endogenous peroxidases, and avidin
D and biotin (Vector Laboratories) were used for blocking before incubation with primary antibodies
overnight at 4 °C. The slides were then incubated with biotin-conjugated secondary antibody at 37
°C for 30 min. The avidin-peroxidase complex was incubated at 37 °C for 30 min (VECTASTAIN
Elite Kit, Vector Laboratories). A DAB Substrate Kit for Peroxidase (Vector Laboratories) was used
for development and hematoxylin for counterstaining. For IF, slides were prepared as described
above. Incubation with primary antibodies was done overnight at 4 °C in a humid chamber, followed
by secondary antibody incubation for 2 h at room temperature.

Antibodies
GFP was detected with goat anti-GFP antibody (ab6673, 1:100, Abcam) for IHC and
chicken anti-GFP antibody (GFP-1020, 1:300, Aves Labs) for IF staining. We used rabbit antimouse Ki67 antibody (SP6, 1:300, Thermo Fisher Scientific) and anti-mouse Ki67 antibody
(550609, 1:200, BD Biosciences) to detect proliferating cells, rabbit anti-HA antibody (sc-805,
1:100, Santa Cruz Biotechnology) for Slc7a11-HA-positive hepatocytes, rabbit anti-mouse FAH
antibody (ab81087, 1:500 for IHC and 1:200 for IF, Abcam), and DAPI for nuclear staining.

RNA-seq
RNA integrity was measured using an Agilent RNA 6000 Bioanalyzer (Agilent
Technologies). cDNA libraries were made from isolated RNA with a NEBNext Ultra RNA Library
Prep Kit for Illumina (New England BioLabs) according to the manufacturer’s instructions. Library
quality was measured with an Agilent High Sensitivity DNA Bioanalyzer, and cDNA libraries were
purified and qPCR quantified (Kapa Biosystems). Twenty samples of equimolar libraries were
pooled and sequenced with an Illumina HiSeq 2500.
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RNA-seq data analysis
Fastq files of RNA-seq were processed using the RUM algorithm [66], with support from
the University of Pennsylvania’s Next Generation Sequencing Core [67]. Differential gene
expression analysis was performed using the package edgeR [68] in R software. Differentially
expressed genes were identified with a cutoff of greater than 2-fold change and an FDR of less
than 5%. Congruent genes in Fah-/- and PHx models were defined as genes regulated in the same
direction for at least 1 time point in both models. Quantile-normalized reads were used for
generating the heatmaps with the R package aheatmap, and Venn diagrams were created using
Vennerable. Gene ontology was performed using the Database for Annotation, Visualization, and
Integrated Discovery (DAVID) [29,30]. The top 3,000 upregulated and downregulated genes were
uploaded to DAVID and analyzed using the functional annotation tool. A list of enriched KEGG
pathways was obtained from the functional annotation chart report. The top-10 most significantly
enriched KEGG pathways were selected and sorted according to the Bonferroni-corrected p-value.
In addition, all differentially expressed genes, along with their corresponding fold change, were
uploaded into the Ingenuity Pathway Analysis tool, and functional analysis was performed using
the Core Analysis function. The upstream regulators predicted by Ingenuity Pathway Analysis were
further filtered by (a) genes that were also changed in the RNA-seq analysis by at least 2-fold, (b)
a significant Z-score (≥2 for predicted activation and ≤2 for predicted inhibition), and (c) congruence
between the observed fold change and the predicted activation or inhibition.

Quantitative reverse-transcription with polymerase chain reaction (qRT-PCR)
Extracted RNAs were reverse transcribed to cDNA with SuperScript II Reverse
Transcriptase (Invitrogen, Thermo Fisher Scientific), and qRT-PCR was performed with Slc7a11
primers (Slc7a11-qRTPCR-F and -R), Gsta1 primers (Gsta1-qRTPCR-F and -R), and Tbp primers
(Tbp-qRTPCR-F and -R). Relative expression levels were normalized to Tbp.
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Quantitative PCR (qPCR)
Genomic DNA was extracted from mice injected with equimolar amounts of pKT2/FahGfp//SB (Fah-Gfp) and pKT2/Fah-Slc7a11-HA//SB (Fah-Slc7a11-HA) over a 4-week period with a
DNeasy Blood and Tissue Kit (QIAGEN), followed by ethanol precipitation. qPCR was performed
with PrimeTime primer sets (IDT DNA) Slc7a11 (Slc7a11-qPCR-F, -R, and -P) and Gfp (Gfp-qPCRF, -R, and -P). Standard curves were generated by performing a serial dilution of the input plasmid
with equimolar amounts of Fah-Gfp and Fah-Slc7a11-HA.

Western blotting
Proteins were extracted from whole-liver homogenate with lysis buffer containing 50 mM
Tris, pH 7.5, 0.5 mM EDTA, 150 mM NaCl, 10% glycerol, 1% NP-40, and 1% SDS, supplemented
with 1:100 Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific). The lysates were sonicated
at 30-second intervals for 5 min and electrophoresed on 4% to 12% NuPAGE Precast Gels (Life
Technologies, Thermo Fisher Scientific). A nitrocellulose membrane was used for transfer, and 5%
milk in TBST (TBS plus 0.1% Tween-20) was used to block the membrane at room temperature for
1 h. The anti-mouse xCT antibody (sc-79360, 1:200, Santa Cruz Biotechnology) was diluted in 5%
BSA in TBST and incubated overnight at 4 °C. The membrane was washed with TBST 3 times for
10 min, followed by an HRP-conjugated secondary antibody in 5% milk in TBST for 1 h, and then
exposed to film.

Hepatocyte nuclei isolation and sorting
Livers were harvested and nuclei isolation was performed as previously described [69].
Briefly, liver was dounced in a pestle tissue grinder in 10 ml hypotonic buffer (10 mM Tris-HCl,
pH7.5, 2 mM MgCl2, 3 mM CaCl2) on ice. The homogenate was passed through a 100-μm filter
and sedimented at 400 g at 4 °C for 10 min. The pellet was resuspended in 10 ml hypotonic buffer
with 10% glycerol, and 10 ml lysis buffer (hypotonic buffer, 10% glycerol, 1% IGEPAL CA-630) was
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added dropwise. After 5 min of incubation, the solution was centrifuged at 600 g for 5 min at 4 °C.
The isolated nuclei were washed again in lysis buffer, and nuclei were counted in a hemocytometer.
Isolated hepatocyte nuclei were labeled with an Alexa Fluor 647 anti-GFP antibody
(338006, clone FM264G, 1:25, BioLegend). Immediately before cell sorting, the nuclei suspension
was stained with 2 μg/ml DAPI. GFP– and AF647–double-positive nuclei were sorted using a BD
FACSAria II, after gating for DAPI-positive nuclei. Because of the polyploidy state of the
hepatocytes, only 4n nuclei were collected.

ATAC-seq
Sorted hepatocyte nuclei were tagmented and PCR amplified according to a previously
published ATAC-seq protocol [54,55]. Briefly, 25,000 nuclei were aliquoted, and transposition was
performed at 37 °C for 30 min. The transposition reaction was stopped by Buffer ERC (QIAGEN),
and DNA was purified using the QIAGEN MinElute Reaction Cleanup Kit. Genomic fragments were
preamplified for 5 cycles, and the final amplification cycle was determined by qPCR. The libraries
were size selected with Agencourt AMPure XP beads (Beckman Coulter) and sequenced with an
Illumina HiSeq 4000. ATAC-seq data analysis. Fastq files from ATAC-seq were analyzed with the
pipeline developed by Anshul Kundaje (Stanford University, Stanford, CA, USA) [70]. Briefly, for
each sample, adapters were trimmed and aligned to the genome mm9 with Bowtie. The aligned
bam files of biological replicates were then merged and subjected to peak calling of open chromatin
regions. The parameters for the analysis were -auto_detect_adapter -enable_idr -filt_bam-sample1
-filt_bam-sample2 … -filt_bam-sampleN.

ChIP-qPCR
The Slc7a11 promoter was analyzed, and potential NRF2- and ATF4-binding motifs were
identified with JASPAR [71]. Liver chromatin was prepared as previously described [72]. Briefly,
100 mg liver was fixed and sonicated with a Bioruptor (Diagenode) for 2 rounds of 7.5 min each.
Sheared DNA (10 μg) was then incubated with anti-ATF4 antibody (D4B8, 1:200, Cell Signaling
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Technology) and NRF2 antibodies (D1Z9C, 1:100, Cell Signaling Technology). Immunoprecipitated
DNA was then isolated with phenol:chloroform extraction and subjected to qPCR analysis with the
primers Slc7a11-Nrf2/Atf4-ChIP-qPCR-2F and -2R. Fold enrichment was calculated by
normalization to the average Ct value of Ins (Ins-ChIP-qPCR-F and -R) and Arbp (Arbp-ChIPqPCR-F and -R) compared with input DNA. Sequencing data download. TRAP-seq and ATAC-seq
data have been deposited according to MINSEQE standards in the NCBI’s Gene Expression
Omnibus database (GEO GSE109466) [73]. RNA-seq data from PHx are available in the
ArrayExpress database (accession no.E-MTAB-1612).

Statistics
Unless otherwise indicated, a 2-tailed, 2-sample Student’s t-test was used to analyze the
experimental and control groups in all assays performed in this study. A 2-tailed, 1-sample
Student’s t-test was used to compare the ratio of Fah-Slc7a11 to Fah-Gfp plasmids after liver
repopulation with the injected plasmid mix. A hypergeometric test was used to analyze the
overlapping genes in the scRNA-seq and TRAP-seq experiments. The Wilcoxon rank-sum test was
used to compare the differential binding of NRF2 and ATF4 in the repopulating and quiescent livers.
A P value or FDR of less than 0.05 was considered significant. Individual data are presented as
dot plots, with the mean shown as a horizontal line. Study approval. All animal studies were
reviewed and approved by the IACUC of the Penn Office of Animal Welfare (University of
Pennsylvania).
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CHAPTER 3
CELL TYPE-SPECIFIC EXPRESSION PROFILING IN THE MOUSE LIVER

Parts of this chapter were adapted with permission from Cell type-specific gene expression profiling
in the mouse liver. Wang AW, Zahm AM, Wangensteen KJ. The Journal of Visualized Experiments.
2019;151:e60242.doi:10.3791/60242.
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ABSTRACT
Liver repopulation after injury is a crucial feature of mammals which prevents immediate
organ failure and death after exposure to environmental toxins. A deeper understanding of the
changes in gene expression that occur during the regenerative process could help identify
therapeutic targets to promote the restoration of liver function in the setting of injuries. Nonetheless,
methods to isolate specifically the repopulating hepatocytes are inhibited by a lack of cell markers,
limited cell numbers, and the fragility of these cells. The development of the translating ribosome
affinity purification (TRAP) method in conjunction with the Fah-/- mouse model to recapitulate
repopulation in the setting of liver injury allows gene expression profiling of the repopulating
hepatocytes. With TRAP, cell type-specific translating mRNA is rapidly and efficiently isolated. We
developed a method that utilizes TRAP with affinity-based isolation of translating mRNA from
hepatocytes that selectively express the green fluorescent protein (GFP)-tagged ribosomal protein
(RP) L10A, GFP:RPL10A. TRAP circumvents the long time period required for fluorescenceactivated cell sorting (FACS) that could change the gene expression profile. Furthermore, since
only the repopulating hepatocytes express the GFP:RPL10A fusion protein, the isolated mRNA is
devoid of contamination from the surrounding injured hepatocytes and other cell types in the liver.
The affinity-purified mRNA is of high quality and enables downstream PCR- or high-throughput
sequencing-based analysis of gene expression.
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INTRODUCTION
As the main metabolic organ in vertebrates, the liver is responsible for glucose
homeostasis, serum protein synthesis, bile acid secretion, and xenobiotic metabolism and
detoxification. The liver possesses an extraordinary capacity to regenerate the injured parenchyma
upon exposure to toxins to prevent immediate liver dysfunction [1]. However, failure of regeneration
can occur in the setting of acetaminophen or alcohol overconsumption, which can lead to acute
liver failure [2]. Furthermore, chronic liver injury caused by viral hepatitis infection, fatty liver
disease, and steatohepatitis frequently result in liver fibrosis, cirrhosis, and hepatocellular
carcinoma [3]. The only available curative treatment for end-stage liver disease is transplantation
but is currently limited by organ shortage, preventing efficient treatment for all patients [4]. A better
understanding of the recovery process after toxic liver injury is therefore crucial for the development
of treatments to stimulate regeneration sufficient to rescue function in the diseased organ.
The most broadly-applied model system for the study of liver regeneration is partial
hepatectomy in rodents, in which a large proportion of the liver is resected to stimulate rapid
hepatocyte expansion [5]. However, partial hepatectomy does not recapitulate hepatocyte
expansion following toxic liver injury due to the lack of immune cell infiltration and hepatocyte cell
necrosis often observed in the setting of acute liver injury in humans [6]. A more suitable system to
model this form of organ renewal is the Fah-/- mouse, which lacks functional fumarylacetoacetate
hydrolase (FAH) required for proper tyrosine catabolism, and develops severe liver damage leading
to death [7]. These mice can be maintained in a healthy state indefinitely by treatment with the drug
nitisinone in the drinking water. Alternatively, FAH expression can be restored by transgene
delivery to a subset of hepatocytes, which will expand to repopulate the liver upon nitisinone
removal [8].
To profile the gene expression changes of repopulating hepatocytes, a tool to specifically
isolate these cells in the Fah-/- mouse without contamination from the neighboring injured
hepatocytes and other cell types is required. Unfortunately, fluorescence-assisted cell sorting
(FACS) of hepatocytes is difficult since (1) the fragility of repopulating cells leads to poor recovery
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after liver perfusion, (2) replicating hepatocytes are highly variable in size, making isolation of a
pure population by FACS difficult, and (3) the procedure time from liver perfusion to RNA isolation
is greater than 2 h, hence gene expression profiles may undergo substantial artificial changes prior
to sample acquisition [9].
Alternatively, the expression of epitope-tagged ribosomes specifically in repopulating
hepatocytes enables the rapid isolation of actively translating mRNA bound by ribosomes using
affinity purification immediately after organ harvest with bulk liver tissue lysates. Here, we describe
a protocol to perform translating-ribosome affinity purification (TRAP) [10] followed by highthroughput RNA-sequencing (TRAP-seq) to specifically isolate and profile mRNA in repopulating
hepatocytes in the Fah-/- mouse [9]. Coexpression of green fluorescent protein (GFP)-tagged
ribosomal protein (RP) L10A (GFP:RPL10A) with FAH allows affinity purification of translating
mRNA bound by polysomes containing GFP:RPL10A. This method avoids any cell dissociation
steps, such as liver perfusion to isolate fragile repopulating hepatocytes. Instead, TRAP utilizes
whole organ tissue lysis and antibodies to rapidly extract the RNA specifically from target cells.
Finally, isolation of abundant, high-quality mRNA via TRAP-seq enables downstream applications
such as sequencing analysis to profile the dynamic change of gene expression during the
repopulation process.
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PROTOCOL
All methods that involve the use of mice are consistent with the guidelines provided by the
Institutional Animal Care and Use Committee (IACUC) of the Penn Office of Animal Welfare at
the University of Pennsylvania.

1. Reagent preparation
1.1. Cycloheximide. To make 500 μl of 0.1 g/ml cycloheximide, suspend 50 mg of
cycloheximide in 500 μl of methanol. Cycloheximide can be stored at 4 °C for up to 1 day.
NOTE: Cycloheximide inhibits translation.
CAUTION: cycloheximide is extremely toxic to the environment and can cause congenital
malformation. All wastes and buffers containing cycloheximide should be collected for
proper disposal.
1.2. DTT. To make 1 ml of 1M DTT, suspend 0.15 g of DTT powder in RNase-free water. DTT
can be stored at -20 °C. It is recommended to store 1M DTT in single-use aliquots of 50 μl.
NOTE: DTT is a detergent.
CAUTION: DTT can cause irritation to the skin, eye, and respiratory tract.
1.3. Deoxycholate (DOC). To make 10% DOC, suspend 1 g of DOC in a 50 ml conical tube and
add RNase-free water up to 10 ml. Shake vigorously until the powder is dissolved. The
10% DOC solution is slightly yellow and can be stored at RT for up to 1 year.
NOTE: DOC is used for nuclear lysis.
1.4. GFP antibodies. Aliquot GFP antibodies when using for the first time. Snap freeze the
aliquots and store at -80 °C. It is recommended to store 50 μg of GFP antibodies in singleuse aliquots.
1.5. Biotinylated protein L. Resuspend biotinylated protein L in 1X PBS to make the final
concentration 1 μg/μl. The resuspended solution can be stored at -20 °C for up to 6 months.
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2. Buffer preparation
2.1. BSA buffer. To make 50 ml of 3% BSA buffer, add 1.5 g of IgG- and protease-free BSA
powder into 40 ml of PBS followed by a quick vortex. After the BSA is dissolved, add PBS
to a final volume of 50 ml. The BSA buffer can be stored at 4 °C for up to 6 months.
2.2. Dissection buffer. To make 50 ml of dissection buffer stock, combine 5 ml of 10X HBSS,
125 μl of 1M HEPES, 1750 μl of 1M glucose, and 200 μl of 1M NaHCO3. Add RNase-free
water to a final volume of 50 ml. The dissection buffer stock can be stored at 4 °C for up to
6 months. Immediately prior to use, add 100 μg/ml of 0.1 g/ml cycloheximide and keep on
ice.
2.3. High-salt buffer. To make 50 ml of high-salt buffer stock, add 1 ml of 1M HEPES, 8.75 ml
2M

KCl,

500

μl

1M

MgCl2,

and

500

μl

100%

branched

octylphenoxy

poly(ethyleneoxy)ethanol (IGEPAL) to RNase-free water. The high-salt buffer stock can be
stored at 4 °C for up to 6 months. Immediately prior to use, add 0.5 μl/ml of 1M DTT and 1
μl/ml of 0.1 g/ml cycloheximide. Keep the fresh high-salt buffer on ice.
2.4. Low-salt buffer. To make 50 ml of low-salt buffer stock, add 1 ml of 1M 4-(2-hydroxyethyl)1-piperazineethanesulfonic acid (HEPES), 3.75 ml of 2M KCl, 500 μl of 1M MgCl2, and 500
μl of 100% IGEPAL to 44.25 ml RNase-free water. The low-salt buffer stock can be stored
at 4 °C up to 6 months. Add 0.5 μl/ml of 1M DTT and 1 μl/ml of 0.1 g/ml cycloheximide prior
to use. Keep the fresh low-salt buffer on ice.
2.5. Tissue lysis buffer. To make 50 ml of tissue lysis buffer stock, combine 1 ml of 1M HEPES,
3.75 ml of 2M KCl, and 500 μl of 1M MgCl2. Add RNase-free water to a final of 50 ml. The
dissection buffer stock can be stored at 4 °C up to 6 months. Add 1 tab/ml of EDTA-free
protease inhibitor, 1 μl/ml of 0.1 g/ml cycloheximide, 10 μl/ml of RNase inhibitors each
immediately prior to use. Keep the fresh tissue lysis buffer on ice.
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3. Conjugation of antibodies to magnetic beads
3.1. Antibodies
3.1.1. Calculate the amount of GFP antibodies required for all samples and prepare for one extra
sample. For each sample, 50 μg of each GFP antibody is required.
3.1.2. Thaw GFP antibodies on ice and spin at maximum speed (> 13,000 x g) for 10 min at 4 °C
and transfer supernatants to a new Eppendorf.
NOTE: The antibody preparation step can be performed prior to bead preparation and the
thawed antibodies can be kept on ice. Alternatively, this step can be performed during
incubation of magnetic beads with biotinylated protein L.
3.2. Resuspend magnetic beads
3.2.1. Resuspend magnetic beads by gentle pipetting. For each sample, 150 μl of magnetic bead
is used. Calculate the volume of magnetic bead required for all samples and prepare one
extra.
3.2.2. Transfer the resuspended magnetic beads to a 1.5 or 2 ml Eppendorf. If more than 1 ml is
required for an experiment, split the total amount into equal volumes.
3.2.3. Collect beads on a magnetic stand for > 1 min and remove the supernatant. Remove
Eppendorf from the magnetic stand and add 1 ml PBS followed by pipetting up and down
to wash the beads. Collect beads on a magnetic stand for > 1 min and remove PBS.
3.3. Preparation of protein L-coated beads
3.3.1. Take the amount of biotinylated protein L required for all samples and prepare one extra.
For each sample, 60 μl of biotinylated protein L is used. If protein L is previously
resuspended and stored at -20 °C, thaw on ice.
3.3.2. Add the calculated volume of biotinylated protein L to the resuspended and washed
magnetic beads. Add 1X PBS to make the final volume 1 ml if using a 1.5 ml Eppendorf,
or 1.5 ml if using a 2 ml Eppendorf. Incubate magnetic beads with biotinylated protein L for
35 min at RT on a tube rotator.
NOTE: Antibodies can be prepared at this step during bead incubation with protein L.
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3.3.3. Collect protein L-coated beads on a magnetic stand for > 1 min and remove the
supernatant. Remove the Eppendorf tube from the magnetic stand and add 1 ml of 3%
BSA buffer followed by gentle pipetting for 5 times to wash the protein L-coated beads.
3.3.4. Collect coated beads on a magnetic stand for > 1 min and remove the supernatant. Repeat
the washing steps with 3% BSA for another 4 times (a total of 5 times).
3.4. Antibody binding
3.4.1. Add the calculated amount of GFP antibodies into the protein L-coated beads and incubate
for 1 h at 4 °C on a tube rotator.
NOTE: After antibody incubation, take special care to not vortex or vigorously shake the
affinity matrix as it could disrupt the binding of biotinylated protein L to the magnetic beads.
3.4.2. During incubation, prepare low-salt buffer by calculating the total volume required for all
samples and add 0.5 μl/ml of 1M DTT and 1 μl/ml of 0.1 g/ml cycloheximide to low-salt
buffer stock prior to use. 3 ml of low-salt buffer for washing each tube of GFP-conjugated
beads and 200 μl/sample for resuspension of the GFP-conjugated beads are required.
Fresh low-salt buffer can be kept on ice for a couple of hours.
3.4.3. Collect the affinity matrix on a magnetic stand for > 1 min and remove the supernatant.
Add 1 ml of low-salt buffer and gently pipette up and down to wash the affinity matrix.
3.4.4. Collect the affinity matrix on a magnetic stand for > 1 min and remove low-salt buffer.
Repeat the washing steps with low-salt buffer for another 2 times (a total of 3 times).
3.4.5. Resuspend the beads in low-salt buffer so that each sample has 200 μl of affinity matrix.
3.4.6. The affinity matrix can be stored in 0.02% NaN3 at 4 °C for up to 2 weeks. The affinity
matrix should be quickly washed in low-salt buffer 3 times and resuspended gently on a
tube rotator at 4 °C for at least 10 min if the affinity matrix is prepared within 1 week or
overnight if the affinity matrix is stored for over 1 week.
CAUTION: Sodium azide is extremely toxic to the environment. Contact with acids
produces toxic gas. All wastes should be collected for proper disposal.
NOTE: The protocol can be paused after this step.
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4. Liver tissue lysis
4.1. Buffer preparation and equipment setup
4.1.1. Calculate the number of Eppendorf tubes required, label and chill on ice. Usually, 7 1.5 ml
Eppendorf tubes are required for each sample. 1 for the remaining dissected liver, 4 for 4
ml of homogenized liver lysate, and 2 for transferring supernatants.
4.1.2. Prepare fresh dissection buffer by calculating the total volume required for all samples and
add 1 μl/ml of 0.1 g/ml cycloheximide. Place the fresh dissection buffer on ice to keep cold
throughout the experiment. For each sample, 10 ml of dissection buffer is required.
4.1.3. Prepare fresh lysis buffer by calculating the total volume required for all samples and add
1 tab/10 ml of EDTA-free protease inhibitor, 1 μl/ml of 0.1 g/ml cycloheximide, and 10 μl/ml
of RNase inhibitors each. Keep the lysis buffer on ice throughout the experiment. For each
sample, 4 ml of lysis buffer is required.
4.1.4. Setup the homogenizer apparatus so that the Teflon-glass tubes can be placed on ice
during homogenization of liver pieces. Put 4 ml of cold lysis buffer in the Teflon-glass tubes.
4.2. Repopulating liver homogenization
4.2.1. Euthanize 8-12-week-old Fah-/- mice injected with the TRAP vector and repopulated for
one to four weeks with anesthesia and cervical dislocation according to approved animal
experimental guidelines.
4.2.2. Place mice on a dissection board and spray the abdomen with 70% ethanol. Tent the skin
and peritoneum using forceps and use scissors to make a transverse incision low in the
abdomen and continue to cut with the scissors to make a wide U-shaped peritoneal flap,
with care to not cut the viscera. Flip the peritoneal flap over the sternum to expose the liver.
4.2.3. Carefully remove the liver with scissors and forceps and quickly place the tissue in cold
dissection buffer to rinse. To homogenize frozen tissues, quickly move the desired amount
of liver tissue into Teflon-glass tubes with cold lysis buffer without the tissue thawing.
NOTE: The dissected tissue can be flash-frozen and stored at -80 °C after it is washed with
dissection buffer. The protocol can be paused after this step.
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4.2.4. Weigh the liver on a Petri dish, Isolate 200-500 mg of liver, and transfer to the Teflon-glass
tubes. Place the remaining tissue into a pre-chilled microcentrifuge tube and flash freeze.
NOTE: The amount of tissue used is based on the abundance of the cell type of interest.
4.2.5. Homogenize the tissue in a motor-driven homogenizer starting at 300 rpm to dissociate
hepatocytes from the liver structure for at least 5 strokes. Lower the glass tube each time
but take care to not let the pestle rise above the solution to prevent aeration that could
cause protein denaturation.
4.2.6. Raise the speed to 900 rpm to fully homogenize the liver tissues for at least 12 full strokes.
4.2.7. Transfer the lysate into labeled and pre-chilled Eppendorf tubes, with no more than 1 ml of
lysate per 1.5 ml tube. If 4 ml of lysis buffer is used, keep 1 tube and flash freeze the
remaining 3 tubes.
NOTE: The lysates can be kept on ice for up to 1 h while dissecting the next animal and
preparing fresh lysates. The homogenized liver can be flash-frozen after the lysis step and
stored at -80 °C. There could be a 50% decrease in isolated RNA if frozen lysates are
used. The protocol can be paused after this step.
4.3. Nuclear lysis
4.3.1. Centrifuge the liver lysate at 2,000 x g at 4 °C for 10 min and transfer the supernatant to a
new, prechilled Eppendorf on ice.
4.3.2. Add 1/9 of the supernatant volume of 10% IGEPAL to make a final concentration of 1%
and mix by gently inverting the Eppendorf tubes.
4.3.3. Quickly spin down the Eppendorf tubes and add 1/9 of the sample volume of 10% DOC to
make a final concentration of 1% and mix by gently inverting the Eppendorf tubes. Quickly
spin down the Eppendorf tubes and incubate on ice for 5 min.
4.3.4. Centrifuge the nuclear lysate at 20,000 x g at 4 °C for 10 min and transfer the supernatant
to a new, prechilled Eppendorf on ice.
NOTE: The mitochondria-depleted supernatant can be placed on ice for a couple of hours
while the remaining samples are being collected.
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5. Immunoprecipitation
5.1. For each sample, take out 1% of the total volume of the mitochondria-depleted
supernantant as a pre-immunoprecipitation control to compare target enrichment after
incubation with the affinity matrix. Place the pre-immunoprecipitation controls on a tube
rotator at 4 °C overnight, the same way as the immunoprecipitated samples are processed.
5.2. Add 200 μl of affinity matrix to each sample. Take extra care to resuspend the beads by
gentle pipetting prior to adding the affinity matrix to each sample. Incubate the lysates with
affinity matrix at 4 °C overnight with gentle mixing on a tube rotator.
NOTE: The protocol can be paused for up to a day after this step.

6. RNA isolation
6.1. Removal of unbound background noise
6.1.1. Place the magnetic rack at 4 °C for at least 30 min to pre-chill and keep the rack on ice
throughout the experiment.
6.1.2. Calculate the number of Eppendorf tubes required and pre-chill on ice or at 4 °C. Usually,
each sample requires 1 Eppendorf tube for the final purified RNA.
6.1.3. Quickly spin down the supernant incubated with the affinity matrix and collect the beads by
placing on the magnetic rack for at least 1 min. Collect or discard the supernatant that
contains the unbound fraction in additional Eppendorf tubes.
NOTE: The collected supernatant can be flash-frozen and stored at -80 °C to compare with
the bound fraction for transcript enrichment after purification.
6.1.4. Prepare high-salt buffer by adding 0.5 μl/ml of 1M DTT and 1 μl/ml of 0.1 g/ml
cycloheximide to high-salt buffer stock. 5 ml of high-salt buffer is required for each sample.
6.1.5. Add 1 ml of fresh high-salt buffer to each tube followed by gentle pipetting for at least 5
times without introducing bubbles.
NOTE: Insufficient washing could introduce backgrounds of unbound transcripts while the
introduction of bubbles could accelerate RNA degradation.
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6.1.6. Collect beads on a magnetic stand for > 1 min and remove the supernatant. Repeat the
washing steps with high-salt buffer for another 4 times (a total of 5 times).
6.1.7. Remove remaining high-salt buffer and remove Eppendorf tubes from the magnetic stand
and place at RT for 5 min to warm up.
6.2. RNA isolation with column-based kits
6.2.1. Resuspend the beads in 100 μl of lysis buffer with β-mercaptoethanol, both provided in the
RNA isolation kit.
NOTE: Any RNA isolation and purification kit that contains the denaturant guanidine
thiocyanate in the lysis buffer can be used to release bound RNA from the affinity matrix.
RNA extraction should be processed at room temperature since guanidine thiocyanate can
crystallize at low temperatures.
6.2.2. Vortex the beads and buffer for at least 5 sec at the highest speed, quickly spin down to
collect the buffer on the side of the Eppendorf and incubate the beads at RT for 10 min to
release the bead-bound RNA into the lysis buffer.
6.2.3. Collect beads on a magnetic stand for > 1 min and collect the supernatant to proceed
immediately to RNA cleanup according to the RNA purification protocol as specified in the
kit.
NOTE: The supernatant containing the eluted RNA in lysis buffer can also be stored at -80
°C for up to 1 month prior to cleanup. To proceed after storage, warm up the tubes to RT
upon thawing.
6.2.4. To achieve maximum quality of the isolated RNA, perform all optional steps including
DNase digestion and all RNA elution steps. Heat up the elution buffer provided by the RNA
isolation kit or RNase-free water to 60 °C for maximum RNA recovery.
NOTE: The isolated RNA can be stored at -20 °C for up to 1 month or -80 °C for several
years. The protocol can be paused after this step.

131

7. Optional RNA quality analysis (recommended)
7.1. Assess RNA quality using a Bioanalyzer and quantity with a Nanodrop to determine if
repeating the immunoprecipitation process is required to obtain ample and high-quality
RNA.
NOTE: The optimal RNA quality for high-throughput sequencing should follow protocols
specified by individual library preparation kits and sequencing platforms.

8. Downstream applications
NOTE: Total RNA isolated by the TRAP protocol can be used in a number of standard
downstream applications, including RNA-seq (TRAP-seq) and reverse transcription and
quantitative PCR (RT-qPCR).
8.1. RNA-seq. Prepare cDNA sequencing libraries using commercial RNA-seq kits with oligo
d(T)-based enrichment of polyadenylated (poly(A)) transcripts. Alternatively, if the total
RNA quality is lower than recommended for poly(A) enrichment, use rRNA depletion
modules. However, expect to see more rRNA alignment after sequencing.
8.2. RT-qPCR. Standard reverse transcription and quantitative PCR protocols can be used
following TRAP.
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REPRESENTATIVE RESULTS
To profile gene expression in repopulating hepatocytes of the Fah-/- mouse, Gfp:Rpl10a
fusion and Fah transgenes are co-delivered within a transposon-containing plasmid [8] (TRAP
vector) to livers by hydrodynamic injection (Figure 3.1A). The removal of nitisinone induces a toxic
liver injury that creates a selection pressure for hepatocytes stably expressing FAH to repopulate
the injured parenchyma [9]. Immunofluorescence staining confirms the co-expression of FAH and
the GFP:RPL10A fusion protein in repopulating hepatocytes after two weeks of liver repopulation
(Figure 3.1B).
In the following representative experiment, TRAP-seq was performed using quiescent and
repopulating mouse hepatocytes. First, to obtain GFP-tagged ribosomes from quiescent
hepatocytes, transgenic RosaLSL-GFP-L10A mice were injected with AAV8-TBG-Cre 7 days prior to
sacrifice to induce GFP:RPL10A expression in all hepatocytes [11]. We also processed a liver
sample collected from a wild type mouse as a negative control to ensure isolation of translating
mRNA was specific, meaning RNA could only be extracted from mice expressing GFP:RPL10A.
The concentration of isolated RNA correlated with the number of cells expressing the fusion protein;
the quiescent sample displays the highest yield since all hepatocytes express GFP:RPL10A after
AAV8-TBG-Cre injection (Figure 3.2A). Conversely, barely any RNA was detectable in wild type
controls that did not possess the GFP:RPL10A transgene, indicating the TRAP procedure is highly
specific and has a low background. When TRAP was used on liver tissues undergoing repopulation
with GFP:RPL10A-transduced hepatocytes, abundant, high-quality RNA was obtained while no
RNA trace was detected via Bioanalyzer for the negative control sample (Figure 3.2B).
Downstream gene expression analysis can be carried out via RT-qPCR or RNA-seq on
TRAP-isolated RNA. Gsta1 encodes glutathione S-transferase that plays an important role in the
metabolism of glutathione, the main detoxifying peptide to protect cellular oxidative stress damage
[12]. Gsta1 expression is induced by over 10-fold in repopulating hepatocytes as compared to
quiescent hepatocytes, while no CT cycle was detected with TRAP-isolated RNA from the wild type
mouse due to the lack of input RNA (Figure 3.3A). Note that RNA quality can greatly impact gene
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expression analysis. In the case of RNA-seq experiments, assessment of RNA quality should be
performed according to the recommendations of the library preparation kit and the sequencing
platform (Figure 3.3B). A Bioanalyzer is often used to determine the RNA integrity number (RIN),
with a high RIN correlating with a higher rate of mRNA alignments to the genome (Figure 3.3B,
left), whereas a lower RIN leading to a higher rate of ribosomal reads, indicating mRNA degradation
(Figure 3.3B, right). Figures 3.3C and D demonstrate that TRAP-seq can identify differential gene
expression in quiescent and repopulating hepatocytes. For instance, Alb expression is inhibited
and Afp expression is activated during liver repopulation, reflecting that the regenerating
hepatocytes assume a less differentiated state to inhibit liver metabolic functions during
repopulation [9,13].
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TABLES
Table 3.1. Materials for the TRAP-seq protocol.
Name of Material/ Equipment

Company
DWK Life Sciences
(Wheaton)
Agilent
Memorial SloanKettering Antibody &
Bioresource Core
Jackson
ImmunoResearch

Catalog Number

Roche

11836170001

Millipore Sigma

C7698

D-Glucose, Dextrose

Fisher Scientific

D16

Deoxycholic acid, DOC

Millipore Sigma

D2510

DL-Dithiothreitol

Millipore Sigma

D9779

Thermo Fisher Scientific

65602

Fisher Scientific

FB0875712

Thermo Fisher Scientific

14065-056

Thermo Fisher Scientific

AAJ16924AE

Millipore Sigma

I8896

Millipore Sigma

M8266

Fisher Scientific

A452

Thermo Fisher Scientific

VV-83061-00

New England BioLabs

E7490S

New England BioLabs

E7530S

Ambion
DWK Life Sciences
(Wheaton)
Ambion

AM9932

Thermo Fisher Scientific

29997

Millipore Sigma

P4504

RNaseZap RNase Decontamination Solution

Invitrogen

AM9780

RNasin Ribonuclease Inhibitors

Promega

N2515

RNA 6000 Pico Kit & Reagents

Agilent

5067-1513

Sodium azide, NaN3

Millipore Sigma

S2002

Sodium bicarbonate, NaHCO3

Millipore Sigma

S6297

10 ml Tissue Grinder, Potter-Elv, Coated
Absolutely RNA Miniprep Kit
Anti-GFP antibodies
Bovine Serum Albumin, IgG-Free, ProteaseFree
cOmplete, Mini, EDTA-free Protease Inhibitor
Cocktail
Cycloheximide

Dynabeads MyOne Streptavidin T1
Fisherbrand Petri Dishes with Clear Lid
HBSS (10X), calcium, magnesium, no phenol
red
HEPES, 1M Solution, pH 7.3, Molecular Biology
Grade, Ultrapure, Thermo Scientific
IGEPAL CA-630 (Octylphenoxy
poly(ethyleneoxy)ethanol, branched)
Magnesium chloride, MgCl2
Methanol
NanoDrop 2000/2000c Spectrophotometer
NEBNext Poly(A) mRNA Magnetic Isolation
Module
NEBNext Ultra RNA Library Prep Kit for Illumina
Nuclease-Free Water, not DEPC-Treated
Overhead Stirrer
PBS Buffer (10X), pH 7.4
Pierce Recombinant Protein L, Biotinylated
Potassium chloride, KCl

SUPERase·In RNase Inhibitor

Invitrogen
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358007
400800
GFP Ab #19C8
and GFP Ab
#19F7
001-000-162

903475
AM9625

AM2694

FIGURES
Figure 3.1. Implementation of translating ribosome affinity purification (TRAP) with Fah-/- to profile
gene expression change of repopulating hepatocytes.

(A) Schematic of expressing the green fluorescent protein (GFP)-tagged ribosome protein (RP)
subunit L10A (GFP:RPL10A) with FAH in the Sleeping Beauty transposon system followed by
injection into the Fah-/- mouse. Green hexagons indicate repopulating hepatocytes with stable
expression of FAH and GFP:RPL10A, whereas black hexagons represent injured, dying
hepatocytes. (B) Representative immunofluorescence staining demonstrates coexpression of FAH
(red) and GFP-tagged ribosomal protein L10A (green) in the repopulating hepatocytes. Scale bar,
50 μm.
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Figure 3.2. TRAP enables cell type-specific isolation of high-quality RNA.

(A) The yield of RNA is positively correlated with the number of hepatocytes expressing
GFP:RPL10A. The low yield of RNA from a wild type mouse demonstrates the specificity of TRAP
from sources without the expression of GFP:RPL10A. (B) Bioanalyzer traces of total RNA isolated
from repopulating livers expressing GFP:RPL10A and from wild type livers demonstrate the
specificity of TRAP. Total RNA isolated from wild type liver tissue devoid of the GFP:RPL10A
transgene shows that minimal RNA has been collected, whereas transgene-expressing tissues
provide ample high-quality RNA. Note that ribosomal RNA peaks are present following successful
TRAP [10]. FU, Fluorescence unit. RIN, RNA integrity number.
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Figure 3.3. TRAP-isolated RNA can be used for downstream gene expression analysis.

(A) Representative reverse transcription and quantitative PCR (RT-qPCR) results of Gsta1 in
quiescent and repopulating hepatocytes. No Ct value was detected with RNA isolated from wild
type animals. (B) Alignment analysis of isolated RNA after high-throughput sequencing,
demonstrating the importance of determining RNA integrity after isolation. High-quality RNA results
in a higher percentage of mRNA reads (green), while low-quality RNA leads to a much higher
percentage of ribosome reads (red), as most mRNA is degraded. RIN, RNA integrity number. (C)
and (D) IGV tracks of RNA-sequencing reads of mRNA affinity-purified from quiescent and
repopulating hepatocytes at the (C) Alb and (D) Afp loci. Note the 3’ read bias is typical of a
polyadenylated (poly(A)) selection pipeline.
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DISCUSSION
TRAP-seq is a technique for cell type-specific isolation of translating mRNA via epitopetagged ribosomes and presents an alternative to FACS approaches, as it circumvents limitations
such as time requirements of FACS [9]. Instead, TRAP allows rapid and efficient isolation of RNA
directly from bulk tissues, helping to avoid any alterations in gene expression. TRAP-seq is
especially well-suited for use in the repopulating Fah-/- mouse liver, as hepatocyte expansion
following removal of nitisinone is cell-autonomous and enables gene expression profiling of the
subset of hepatocytes with integrated transgenes. The TRAP vector can also be coexpressed with
gene-activating or -silencing molecules [14], including cDNA, short-hairpin RNA, and guide RNA,
to study the effects on global gene expression of activation or inhibition of a specific gene.
Alternatively, the RosaLSL-GFP-L10A transgenic mouse provides the ability to profile gene expression
in any cell with Cre recombinase activity. Since GFP:RPL10A can be specifically expressed in any
cells that express Cre, the role of other cell types in the liver during liver injury and repopulation
could be studied. For instance, crossing the CK19-Cre mouse with the TRAP transgenic mouse
could be used to express GFP:RPL10A in cholangiocytes followed by TRAP-seq to study the
change of gene expression in the biliary epithelium during the repopulation process.
To ensure accurate profiling of gene expression, it is critical to prepare all buffers and the
affinity matrix prior to tissue dissection. All steps should be performed on ice with cold buffers unless
otherwise specified to ensure polysome stabilization [10] and prevent RNA degradation. All buffers
should be prepared with RNase-free reagents and the TRAP-seq protocol should be carried out in
an RNase-free environment to prevent RNA degradation and low yield of immunoprecipitated RNA.
The affinity matrix can be prepared up to 2 weeks prior to use with gentle resuspension on a tube
rotator overnight. Special care should be taken to not vigorously shake the matrix to prevent
disruption of the antibody-conjugated, protein L-coated magnetic beads. The methods to prepare
the affinity matrix includes conjugation of magnetic beads to biotinylated protein L followed by
incubation with anti-GFP antibodies. However, commercially available protein A/G magnetic beads
can be substituted; if used, skip the initial conjugation step and proceed directly to antibody binding.
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Furthermore, alternative epitope tags are presumably feasible with the above protocol with
appropriate modification.
There are various points in which the RNA isolation and purification step can be paused
(see protocol above). However, once liver samples have been harvested, continuing to the
immunoprecipitation is recommended, as the yield of isolated RNA could drop by ~50% with
freezing at this step [10]. Tissues should be quickly rinsed with dissection buffer that contains
cycloheximide to inhibit mRNA translation. Insufficient tissue lysis could also contribute to low RNA
yield. It is critical to homogenize tissues on ice until no tissue chunks are visible with the motor
homogenizer while ensuring minimal aeration [10]. Additionally, sufficient washing with high-salt
buffer is crucial to ensure removal of nonspecific binding of ribosomal proteins to the affinity matrix.
Including a wild type mouse as a negative control helps to assess the specificity of the
immunoprecipitation and the efficiency of the wash steps. Additionally, using a commercial RNA
purification kit that includes RNase-free DNase treatment will increase RNA purity.
Moreover, it is recommended to verify the expression and abundance of the GFP:RPL10A
fusion protein and assess the amount of tissue required to obtain ample RNA for downstream
analysis. Tissue sections or lysates could be used for immuno-based detection methods to validate
the expression of GFP:RPL10A. The amount of RNA isolated can vary by: (1) the number of cells
expressing GFP:RPL10A, (2) the expression level of the transgene, and (3) the size and ploidy of
the cells expressing the transgene. A pilot experiment using half and double the amount of the
recommended amount of tissue could be useful in determining the optimal input lysate for TRAPseq. In our hands, we could obtain ~150 ng of RNA with as little as 1-2% of hepatocytes expressing
GFP:RPL10A from 200 mg of the repopulating Fah-/- liver, representing ~2x105 polyploid
hepatocytes with transgene expression [9].
The TRAP-seq methodology isolates ribosome-bound mRNA to profile a cell’s translating
mRNA pool. The resulting sequencing reads, therefore, correspond to the ‘translatome’ rather than
the transcriptome. Note that translating ribosome footprints will not be collected, as TRAP is
performed on native rather than cross-linked complexes. If footprinting analyses are desired, the
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above protocol should be modified with relevant cross-linking followed by immunoprecipitation
(CLIP) methodologies [15]. Another limitation of TRAP is the requirement of a sufficient amount of
cells expressing the GFP:RPL10A fusion protein. For experiments in which the cell type of interest
is small, combining multiple biological samples may be required to isolate sufficient RNA to enable
RNA-seq [16]. Furthermore, TRAP-seq requires the presence of GFP:RPL10A in the cell type of
interest. This could pose a challenge if there is no specific delivery system to the cells or if a celltype specific promoter to drive Cre expression is not available.
The recent development of single-cell RNA-seq (scRNA-seq) technology has allowed
direct sequencing followed by in silico identification of various cell types, enabling sequencing
without sorting for specific cell types of interests [17–19]. However, scRNA-seq still requires
dissociation of cells from the organ. In the case of the Fah-/- repopulation model, liver perfusion and
hepatocyte isolation are extremely difficult and inefficient due to the fragility of both the injured and
replicating hepatocytes. In fact, we have not yet been able to isolate sufficient hepatocytes from
Fah-/- mice undergoing repopulation after hydrodynamic injection of FAH plasmids. Additionally, in
the time it takes to process tissues, gene expression levels could change. Protocols for liver
perfusion take up to 30 minutes of warm ischemia time. Future methodologies to optimize liver
perfusion to decrease the processing time and increase isolation efficiency could allow scRNA-seq
integration to the Fah-/- mouse model system and possibly to other injury and repopulation models.
This would also support the study of all liver cell types.
In conclusion, the integration of TRAP-seq with the Fah-/- mouse enables specific isolation
and gene expression profiling of regenerating hepatocytes to identify therapeutic targets that could
promote liver repopulation. This method can be implemented to study other cell types in the liver
and other organ systems for disease-specific identification of gene expression changes to identify
potential drug targets or biomarkers. An analogous technique can be used to collect nuclei from
repopulating hepatocytes using affinity purification, followed by epigenetic analysis of these specific
cells [13].
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CHAPTER 4
THE DYNAMIC CHROMATIN ARCHITECTURE OF THE REGENERATING LIVER

Parts of this chapter were adapted with permission from The dynamic chromatin architecture of the
regenerating liver. Wang AW, Yue YJ, Zahm AM, Morgan AR, Wangensteen KJ, Kaestner KH.
Cellular and Molecular Gastroenterology and Hepatology. 2019. In press.
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ABSTRACT
The adult liver is the main detoxification organ and is routinely exposed to environmental
insults but retains the ability to restore its mass and function upon tissue damage. However,
extensive injury can lead to liver failure, and chronic injury causes fibrosis, cirrhosis, and
hepatocellular carcinoma (HCC). Currently, the transcriptional regulation of organ repair in the adult
liver is incompletely understood. We isolated nuclei from quiescent as well as repopulating
hepatocytes in a mouse model of hereditary tyrosinemia, which recapitulates the injury and
repopulation seen in toxic liver injury in humans. We then performed the ‘assay for transposase
accessible chromatin with high-throughput sequencing’ (ATAC-seq) specifically in repopulating
hepatocytes to identify differentially accessible chromatin regions and nucleosome positioning.
Additionally, we employed motif analysis to predict differential transcription factor occupancy and
validated the in silico results with chromatin immunoprecipitation followed by sequencing (ChIPseq) for hepatocyte nuclear factor 4α (HNF4α) and CCCTC-binding factor (CTCF). Chromatin
accessibility in repopulating hepatocytes was increased in the regulatory regions of genes
promoting proliferation and decreased in the regulatory regions of genes involved in metabolism.
The epigenetic changes at promoters and liver enhancers correspond with the regulation of gene
expression, with enhancers of many liver function genes displaying a less accessible state during
the regenerative process. Our analysis of hepatocyte-specific epigenomic changes during liver
repopulation identified CTCF and HNF4α as key regulators of hepatocyte proliferation and
regulation of metabolic programs. Moreover, increased CTCF occupancy at promoters and
decreased HNF4α binding at enhancers implicate these factors as key drivers of the transcriptomic
changes in replicating hepatocytes that enable liver repopulation. Thus, liver repopulation in the
setting of toxic injury makes use of both general transcription factors (CTCF) for promoter
activation, and reduced binding by a hepatocyte-enriched factor (HNF4α) to temporarily limit
enhancer activity.
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INTRODUCTION
As the central metabolic organ in vertebrates, the liver regulates carbohydrate, protein, and
lipid homeostasis, metabolizes nutrients, wastes, and xenobiotics, and synthesizes bile, amino
acids, coagulation factors, and serum proteins [1]. To prevent acute liver failure upon exposure of
harmful toxins, the liver has maintained an extraordinary ability to effectively restore its mass and
function, in which the normally quiescent mature hepatocytes rapidly re-enter the cell cycle and
divide [2]. Nonetheless, failure of regeneration can occur after exposure to harmful metabolites and
environmental toxins, as often seen with the overconsumption of acetaminophen and alcohol [3].
Hence, understanding the genetic networks regulating the regenerative process can have an
immense impact on the development of novel therapeutic strategies to treat acute liver failure.
The Fah null mouse model of human hereditary tyrosinemia type I provides a unique
system to study the hepatocyte replication process after acute liver injury. Lack of the
fumarylacetoacetate hydrolase (FAH) enzyme, essential for normal tyrosine catabolism, results in
the accumulation of toxic intermediates followed by hepatocyte cell death [4,5]. Fah-/- mice can be
maintained in a healthy state by supplementation with the drug 2-(2-nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione (NTBC) which inhibits an upstream enzymatic step that prevents toxin
production [4]. Alternatively, gene therapy that utilizes hydrodynamic tail-vein injection and the
Sleeping Beauty transposon system to restore Fah expression in hepatocytes can rescue these
mice [6,7]. When a small fraction (0.1-1%) of hepatocytes express FAH following removal of NTBC,
these hepatocytes competitively repopulate the liver in the context of injury through clonal
expansion. Furthermore, this method allows lineage-tracing of repopulating hepatocytes since only
those with stable FAH expression can expand and repopulate the injured parenchyma [7,8].
Eukaryotic DNA is highly organized and structured into compact chromatin to allow tight
transcriptional control. Transcriptional regulation can be broadly categorized into two integrated
layers: (1) transcription factors and the transcriptional machinery, and (2) chromatin structure and
its regulatory proteins [9]. Expression of genes targeted by transcription factors depends on their
binding affinity to specific target DNA recognition sequences, combinatorial assembly with other
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cofactors, the concentration of the transcription factor, and post-translational modifications that
affect protein localization [10]. The chromatin landscape is governed by DNA methylation,
nucleosome properties, histone modifications, and intra- and interchromosomal interactions [10].
Establishing the relationship of chromatin structure, transcriptional regulators, and the effects on
gene expression is therefore vital in elucidating the transcriptional control governing the
regenerative process. To date, most studies have relied on transcriptomic studies to document
gene expression changes in the regenerating liver [11–15] while two others focused on histone
modifications [16,17]. However, these processes are downstream of chromatin reorganization and
therefore do not capture the dynamic crosstalk of chromatin accessibility and transcriptional
regulation. To identify transcriptomic changes specific to repopulating hepatocytes, we previously
employed the translating ribosome affinity purification (TRAP) [18] to isolate translating mRNAs
only from repopulating hepatocytes [15]. To discern the dynamic chromatin patterns that underlie
liver repopulation, we now implement the ‘isolation of nuclei tagged in specific cell types’ (INTACT)
[19] approach to isolate nuclei only from repopulating hepatocytes. This is achieved by expressing
the GFP-tagged nuclear envelope protein SUN1-GFP together with FAH in Fah-/- mice, followed by
the sorting of GFP-positive nuclei from repopulating hepatocytes and ATAC-seq [20]. We identify
promoter accessibility changes corresponding to upregulation of cell cycle genes and
downregulation of metabolic pathways, consistent with previous gene expression studies [12,15].
Integrative expression level and chromatin accessibility analysis suggests that gene activation is
primarily associated with increased promoter accessibility, while inactivation is correlated with the
closure of select promoters and enhancers. We propose a model in which a more accessible
promoter allows increased transcription factor binding and gene activation, whereas decreased
enhancer accessibility prevents binding of hepatocyte-enriched DNA binding proteins followed by
inhibition of liver function genes so that the repopulating liver assumes a less differentiated state to
promote cell growth and proliferation.
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RESULTS
Adaptation of INTACT in the Fah-/- model allows for isolation of repopulating hepatocyte
nuclei
Liver cells in humans and mice rarely undergo division in homeostatic conditions [2].
However, with injury and repopulation, hepatocytes become facultative stem cells and divide to
replenish liver mass and restore liver function [2]. We hypothesized that this change from
quiescence to replication is accompanied by substantial and specific changes to chromatin
accessibility. To analyze the chromatin specific to repopulating hepatocytes, we adapted the
INTACT [19] method to the Fah-/- model to label hepatocytes with the GFP-tagged nuclear envelope
protein, SUN1-GFP, and performed fluorescence-activated cell sorting (FACS) to isolate nuclei
from whole liver at selected time points (Figure 1). The SUN1-GFP fragment was subcloned into a
FAH expression plasmid [7] so that all repopulating hepatocytes express GFP on the nuclear
envelope. Following hydrodynamic injection of the FAH-SUN1-GFP plasmid into Fah-/- mice, NTBC
was removed and liver repopulation was allowed to proceed for one or four weeks (Figure 1A). As
a control for healthy, quiescent hepatocytes, RosaLSL-SUN1-GFP transgenic mice [19] were injected
with AAV8-TBG-Cre [21] to label all hepatocytes. Nuclei were isolated from repopulating
hepatocytes exclusively at the selected time points by FACS-sorting with an anti-GFP antibody
(Figure 1B). ATAC-seq [20] was then performed on the sorted nuclei to profile the changes in the
chromatin regulatory landscape that occur during liver repopulation.
Immunofluorescence labeling demonstrated expression of GFP-tagged nuclear envelopes
in FAH-positive cells (Figure 1C), illustrating the specificity of using SUN1-GFP+ nuclei as a marker
to identify repopulating hepatocytes. Interestingly, FAH and GFP signals were not homogeneous
across all replicating cells, possibly due to the different copy numbers of plasmids taken in after
hydrodynamic tail-vein injection of the SUN1-GFP construct [22]. In addition, since the Sleeping
Beauty transposon system displays little insertion site preference [23], the loci in which the DNA
fragments are integrated can affect expression levels of FAH and SUN1-GFP [24].
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ATAC-seq detects differentially accessible chromatin regions
All ATAC-seq libraries were sequenced to ~100 million reads to ensure ample coverage
across the genome followed by quality assessment to verify the robustness of the data (Table 4.1).
We observed consistent ATAC-seq signals across various loci such as the Alb gene, which showed
a progressive decrease in accessibility at the enhancer region during repopulation (Figure 4.1A).
To identify differentially accessible chromatin regions, fragments below 150 bp, termed
‘nucleosome-free reads’, were used for peak calling. We identified 16,043 differentially accessible
regions between quiescent and repopulating hepatocytes (Figure 4.1B, Supplementary Digital
Table 4.1), of which 5,359 displayed increased accessibility in 1-week and 5,102 in 4-week
repopulating hepatocytes, while 3,580 regions showed decreased accessibility in week 1 and 5,304
in week 4. Hierarchical clustering of the differentially accessible sites showed a clear separation of
repopulating and quiescent hepatocytes (Figure 4.2C), corroborating previous transcriptome
studies that 1-week and 4-week repopulating hepatocytes have a similar expression profile distinct
from quiescent hepatocytes [15]. Replicates also clustered within the same condition, illustrating
the reproducibility between biological replicates. Comparing accessibility regulated in the same
direction in both time points (‘congruent’), 1,241 peaks were congruently increased and 2,033
congruently decreased (Figure 4.2B). Of note, only 28 regions exhibit accessibility changes in
opposite directions in week 1 and week 4 (‘incongruent’), reflecting the similarity in the chromatin
profile between the two repopulation time points.
Next, we focused on differentially accessible promoter elements. Differential ATAC-seq
regions within 1 kb up- and downstream of the transcription start sites (TSS) were determined and
KEGG pathway [25] analysis was performed (Figure 4.2D). As expected, pathways involved in cell
growth and proliferation were enriched among the genes with increased accessibility in the
promoter regions during repopulation, including MAPK signaling [26] and cancer pathways.
Interestingly, purine and pyrimidine metabolism were only enriched in genes with increased
promoter accessibility at week 1 but not at week 4, suggesting early activation of DNA synthesis
immediately after liver injury in early stages of repopulation. This observation is consistent with
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previous comparison of the Fah-/- and partial hepatectomy (PHx) models showing that the
transcriptome of 1-week repopulating hepatocytes in the Fah-/- mouse is closest to that of 36 and
48 h post-PHx [15], at which the highest rate of DNA synthesis occurs in this model [27]. On the
other hand, genes involved in hepatocyte functions such as complement and coagulation and
metabolic pathways displayed significantly decreased promoter accessibility at both regeneration
time points. Our pathway enrichment analysis substantiates prior studies of gene expression
profiles and extends the findings to chromatin accessibility in that proliferation pathways are
activated while liver functions are inhibited during repopulation [12,15].

Integration of chromatin accessibility and gene activity infers regulatory mechanisms
To evaluate the association of chromatin landscape and gene expression, we utilized our
prior TRAP-seq study [15] as a dataset of transcriptomic changes in repopulating hepatocytes.
Genes with ATAC-seq signals and TRAP-seq reads that changed in the same direction at the same
time point were identified as ‘concordant genes’ (Figure 4.3A, Supplementary Digital Table 4.2).
We observed significant overlap of the concordant genes with ATAC-seq and TRAP-seq (p<1E-16
for all 1-week concordant genes and 4-week concordantly activated genes. p=0.03 for 4-week
concordantly inhibited genes), while there was no significant overlap of genes with increased
expression in 1 week and decreased chromatin accessibility at 4 weeks (p=0.39). KEGG pathway
[25] analysis suggested enrichment of cell growth and replication in the week 1 concordantly
activated genes, and overrepresentation of biosynthesis and metabolism in both week 1 and week
4 concordantly inhibited genes (Figures 3B, C). In addition, pathway enrichment supported previous
observations that activation of the glutathione metabolic network is essential for reactive oxygen
species removal after PHx or recovery following toxic liver injury [15,28,29]. We conclude that
changes to the chromatin structure underlie the upregulation of genes involved in cell proliferation
and downregulation of genes associated with metabolic processes.
Next, we sought to investigate co-regulatory networks in repopulating hepatocytes. All
ATAC-seq peaks identified were first separated into increased, decreased, or unchanged
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accessibility, with a cutoff of absolute fold change ≥1.5 and false discovery rate (FDR) ≤0.05,
followed by subdivision into regulatory regions of promoters, liver-specific enhancers, or
cerebellum-specific enhancers as a negative control [30]. Promoter peaks were annotated to the
nearest genes and the corresponding transcript levels at the same time point were extracted from
TRAP-seq data [15]. We then compared the gene expression levels in the differentially accessible
promoters to those in the unchanged promoters (Figures 4.3D, E). The normalized log2 fold change
was positive (p=7.47E-03 in week 1 and 3.81E-02 in week 4) with increased and negative
(p=1.06E-06 in week 1 and 1.38E-03 in week 4) with decreased promoter accessibility at both time
points, demonstrating a significant association of promoter openness and transcriptional activity.
Differentially accessible liver enhancer peaks were similarly categorized, putative enhancerregulated genes extrapolated [30], corresponding target gene expression extracted [15], and the
transcript level changes compared to those of genes with unchanged enhancer accessibility.
Interestingly, decreased liver enhancer accessibility was highly correlated with decreased gene
activity (p=1.89E-20 in week 1 and 1.19E-07 in week 4), while no significant expression changes
(p=0.22 in week 1 and 0.88 in week 4) were associated with increased enhancer openness. While
the exact mechanism explaining this lack of correlation requires further evaluation, we posit that
target genes regulated by enhancers in the quiescent liver are already highly expressed in mature,
differentiated hepatocytes [12,15]. An increase in liver enhancer accessibility hence does not
further elevate the expression of these genes significantly. Another likely explanation for the lack
of significant association between increased liver enhancer accessibility and activation of target
genes could be the recruitment of repressors instead of activators to the regulatory elements to
decrease expression [31–33]. Finally, refinement of the computationally predicted enhancerpromoter pairs with experimental approaches could result in a more accurate correlation of
enhancer accessibility and transcriptional activity. Importantly, cerebellum enhancers exhibited no
significant correlation with the changes in transcript levels and chromatin accessibility in the
repopulating liver, as expected (Figures 4.3D, E, right). Our integrated ATAC-seq and TRAP-seq
analysis reveal that gene activation is regulated by increased promoter accessibility, presumably
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allowing recruitment of transcriptional activators and RNA polymerase II to the TSS, whereas gene
inhibition may be governed by both decreased promoter and enhancer openness, preventing longrange enhancer-promoter interactions [34].

Differential chromatin accessibility predicts transcription factors involved in liver
repopulation
Dynamic coordination of chromatin structure and transcription factors is required to finetune gene expression. Chromatin organization influences access of the transcriptional apparatus
by regulating binding sequence accessibility [35] and transcription factor binding stability [36];
conversely, transcription factors affect access of remodelers to the chromatin [35] and histones
[37]. To identify DNA binding transcription factors that connect differential chromatin accessibility
and gene expression, we carried out de novo motif profiling at differentially accessible promoters
and liver enhancers [30].
We found enrichment of the ETS transcription factor ELK1 motif in promoters with
increased accessibility in both 1-week (FDR=1E-76) and 4-week (FDR=1E-41) repopulating
hepatocytes (Figure 4.4A, B, Supplemental Digital Table 4.3). ELK1 binds to the serum response
element upon MAPK phosphorylation [38] to activate immediate early genes such as Fos and
components of the basal transcriptional machinery [39]. Furthermore, ELK1 supports cell cycle
entry during liver regeneration as Elk1-/- mice show reduced hepatocyte proliferation after PHx [40].
We postulate that promoters became more accessible after acute liver injury to permit increased
ELK1 occupancy, enabling hepatocyte repopulation.
Among the regions with increased accessibility during liver repopulation, surprisingly, the
CTCF motif was highly enriched (FDR=1E-78 in week 1 and 1E-49 in week 4) (Figures 4.4C, D).
CTCF plays numerous roles in transcriptional regulation to function as a transcriptional activator
[41] or repressor [42], insulator to block enhancer-promoter interactions [43], chromatin structure
organizer to form topologically-associated domains [44] modulator of long-range chromatin looping
[45], and even mediator of local RNA polymerase II pausing to regulate alternative exon usage [46].
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CTCF is recruited to the Axin1 promoter as a transcriptional repressor by the ‘long noncoding RNA
associated with liver regeneration’ (lncRNA-LALR1) after PHx, leading to activation of Wnt/βcatenin signaling to promote hepatocyte proliferation [47]. However, the function of CTCF in liver
regeneration is not fully understood.
In addition, we found the HNF4α binding motif to be significantly associated with liver
enhancers with decreased accessibility during liver regeneration (FDR=1E-146 in week 1 and 1E186 in week 4) (Figures 4.4E, F). HNF4α is a master regulator atop the transcriptional cascade of
hepatocyte differentiation [48,49] and a crucial factor that maintains hepatocytes in the
differentiated state [50]. Importantly, HNF4α suppresses liver proliferation, as mice with conditional
deletion of Hnf4a demonstrate increased hepatocyte BrdU incorporation and Ki67 expression [51].
HNF4α also directly inhibits cell growth and replication pathways, as illustrated by the upregulation
of cell cycle and proliferation genes upon acute HNF4α loss [51,52]. Moreover, motifs of other liverenriched transcription factors were also overrepresented at enhancers that became less accessible
in repopulating hepatocytes, including hepatocyte nuclear factor 1β (HNF1β) and hepatocyte
nuclear factor 6 (HNF6) [53] (Figures 4.4E, F). We examined the locations for CTCF and HNF4α
motifs within regions of dynamic chromatin accessibility and found that they are present in the
center of these regions with CTCF at those with increased (p=2.70E-04 in week 1 and 1.97E-13 in
week 4), and HNF4α at those with decreased accessibility (p=0.59 in week 1 and 2.48E-03 in week
4) (Figure 4.4G, H).
In summary, de novo motif analysis of differentially accessible ATAC-seq regions suggests
increased occupancy of ELK1 and CTCF at chromatin regions that become more accessible, and
decreased binding of liver-enriched transcription factors at liver enhancers that become less
accessible during repopulation.

HNF4α occupancy is decreased in liver-specific enhancers during repopulation
We postulated that decreased HNF4α binding allows repopulating hepatocytes to assume
a less differentiated and pro-proliferative state and carried out ChIP-seq on quiescent and 4-week
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repopulating livers to examine genome-wide HNF4α occupancy during the repopulation process.
We observed 508 peaks with decreased and only 14 peaks with increased occupancy in
repopulating livers (Figure 4.5A, Supplemental Digital Table 4.4). Remarkably, 42% (214) of lost
HNF4α occupancy occurred within previously-defined liver enhancers [30], while 23% (119) fell into
distal intergenic regions, and 10% (52) were within 1 kb up- and downstream of the TSS (‘promoter’)
(Figure 4.5B). These data corroborate the differentially accessible chromatin analysis of
transcription factor motifs that had identified enrichment of the HNF4α consensus sequence at
enhancers with decreased accessibility in repopulating hepatocytes (Figure 4.4H).
Next, we integrated ATAC-seq, ChIP-seq, and TRAP-seq datasets [15], and identified
hepatocyte-enriched genes crucial for establishing liver functions including complement and
coagulation (Cfb, F2), biosynthesis (Itih1, Acsl1, Pgrmc1), and metabolism (Ugt1a5, Mthfs, Rdh10)
[54] as correlated with decreased HNF4α enhancer occupancy during regeneration (Figure 4.5C,
E). To explore the mechanism responsible for decreased HNF4α occupancy during liver
repopulation, we next turned to the TRAP-seq dataset [15] to inspect Hnf4a expression levels in
quiescent and replicating hepatocytes. Remarkably, we found a 50% reduction of Hnf4a transcripts
in 4-week repopulating hepatocytes (FDR=4.16E-3) compared to the quiescent liver (Figure 4.5D,
Table 4.2). Taken together, these results implicate decreased chromatin accessibility and reduced
Hnf4a expression as contributors to the suppression of hepatocyte-specific genes and
downregulation of liver biosynthetic functions during repopulation.

CTCF promoter occupancy is increased in the repopulating liver
In order to extend the computational finding of enriched CTCF motif at promoters with
increased accessibility, we performed ChIP-seq in quiescent and 4-week repopulating livers. CTCF
occupancy was increased at 1,382 sites in the repopulating liver, while only 2 peaks showed
decreased binding (Figure 4.6A, Supplemental Digital Table 4.5). To characterize the role of
increased CTCF occupancy during liver repopulation, we first evaluated its potential insulator
function by calculating an ‘insulator strength score’ [55] at all gained binding sites. Genomic regions
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with increased CTCF occupancy with divergent flanking promoters within 50 kb were identified and
the normalized expression levels corresponding to the genes were extracted from our TRAP-seq
data (Figure 4.6B) [15]. Surprisingly, gene pairs with increased CTCF binding were not significantly
more enriched for differential gene expression than random gene pairs (p=0.9) (Figure 4.6C),
suggesting that CTCF is unlikely to act as an insulator during liver repopulation.
Remarkably, the vast majority (1,026, 74%) of the gained CTCF peaks fell within 1 kb upand downstream of the TSS (‘promoter’) (Figure 4.6D). To examine the targets of increased CTCF
occupancy, all differentially bound peaks were annotated to the nearest genes and their
corresponding expression changes were obtained from our TRAP-seq dataset [15,25,56]. We
found 545 (39%) peaks associated with chromatin modification, transcription regulation, and cancer
(Figure 4.6E), while 656 (47%) sites with increased CTCF binding were associated with inhibition
of genes in cell death regulation, stress response, and morphogenesis. Together, our network
analysis suggests a diverse role for CTCF in transcriptional regulation in which increased CTCF
occupancy supports hepatocyte replication and prevents cell death during liver repopulation,
possibly by enabling binding of both activating and repressing cofactors.
CTCF is known to exhibit divergent roles in activating and repressing transcription by
recruiting various protein partners in a context-dependent manner [57]. To identify these cofactors,
we performed motif analysis for the regions differentially bound by CTCF (Figure 4.6F). As
expected, the CTCF motif was highly enriched (FDR=1E-26) at all differential binding sites,
confirming the specificity of the anti-CTCF antibody for immunoprecipitation. At sites where CTCF
binding corresponded to gene activation, we observed significant enrichment for the ‘zinc finger
and BTB domain-containing protein 3’ (ZBTB3) (FDR=1E-10) and nuclear transcription factor Y
(NF-Y) (FDR=1E-10) binding motifs (Figure 4.6F). ZBTB3 is considered a likely factor binding 5’ of
CTCF due to its frequent enrichment ~10 bp upstream of CTCF motifs in the human genome [58].
Furthermore, expression of ZBTB3 is induced by the accumulation of reactive oxygen species to
promote cancer cell growth and prevent apoptosis via the activation of antioxidant gene expression
in cell lines [59]. Whether CTCF directly interacts with or indirectly recruits ZBTB3 is yet unclear,
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but the proteins are likely to interact based on their close proximity at promoters. NF-Y binds to the
CCAAT box present at ~30% of the promoters [60] and is required for cell cycle progression, DNA
synthesis, and proliferation in mouse embryonic fibroblasts [61]. Additionally, reconstituted in vitro
transcription reactions demonstrated that binding of NF-Y disrupts nucleosome structure at
promoters containing the NF-Y recognition sequence [62]. Recruitment of NF-Y could hence induce
local nucleosome repositioning to allow increased accessibility of the transcriptional apparatus to
activate gene expression.
On the other hand, the Yin Yang 1 (YY1) binding motif was enriched (FDR=1E-13) at sites
where increased CTCF occupancy corresponded with decreased gene expression (Figure 4.6F).
YY1 regulates embryogenesis, cell differentiation, and tumorigenesis [63,64], as well as enhancerpromoter interactions analogous to long-range chromatin looping mediated by CTCF [65]. YY1
functions as a transcriptional repressor via recruitment of the polycomb repressor complex,
resulting in trimethylation of histone H3 lysine 27 [66,67]. It is also a cofactor of CTCF in regulating
X chromosome inactivation, although the exact mechanism remains unclear [68]. Given these
observations, it is likely that direct or indirect co-binding of CTCF and YY1 at promoters induces
transcriptional repression or disrupts enhancer to promoter interactions to downregulate target
genes.
When examining gene expression, we found the levels of ZBTB3 and YY1 not significantly
changed in repopulating hepatocytes (Table 4.2). Three NF-Y proteins exhibited varying changes
in transcript levels, with unchanged NF-YA, downregulated NF-YB in 1-week, and downregulated
NF-YC in 4-week repopulating hepatocytes, albeit all with modest changes of less than 2-fold.
These observations do not rule out the possibility of post-translational modifications that might alter
the abundance or localization of transcription factors.
To analyze if transcription factors colocalize to CTCF-occupied promoters with differential
gene expression during liver regeneration, we performed ZBTB3 and YY1 ChIP-qPCR on quiescent
and 4-week repopulating livers. We observed a significant increase of ZBTB3 occupancy at Ctnna2
(p=0.023) and Smad3 (p=0.025) promoters, two genes with increased promoter accessibility,
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elevated CTCF binding, and upregulated expression during liver regeneration (Figure 4.6G, H).
Regarding YY1 occupancy, there was a significant increase at the Bcl2l11 (p=0.029) promoter, a
gene with increased promoter accessibility, enhanced CTCF occupancy, and decreased transcript
levels (Figure 4.6I). With the limited loci tested, we conclude that ZBTB3 is recruited to open
chromatin regions occupied by CTCF to activate gene expression during liver regeneration. On the
other hand, increased YY1 binding to select promoters with elevated CTCF binding could regulate
transcriptional repression in repopulating hepatocytes. These results suggest that increased
chromatin accessibility correlates with enhanced CTCF occupancy that recruits coactivators or
corepressors to fine-tune target gene expression to induce replication and prevent apoptosis during
liver repopulation (Figure 4.6J). Future experiments that utilize co-immunoprecipitation and highthroughput sequencing technologies to analyze interactions between CTCF and cofactors as well
as genome-wide binding patterns of the coregulators will aid in the understanding of mechanisms
underlying CTCF modulation.

Liver regeneration is accompanied by nucleosome remodeling
Most eukaryotic DNA is packaged around histone protein octamers into nucleosomes to
regulate chromatin organization and transcriptional control. Nucleosome properties such as
positioning and turn-over rates can affect the binding of transcription factors and access of the
transcriptional machinery [69]. The nucleosome landscape adjacent to the TSS is of particular
interest, as nucleosomes adopt a specific phasing pattern immediately up- and downstream [70].
Hence, nucleosome organization could act as an additional layer of transcriptional regulation in
repopulating hepatocytes.
We inferred nucleosome positioning from nucleosome-containing sequences by extracting
ATAC-seq reads longer than 150 bp (Figure 4.7A). Nucleosomes surrounding the TSS were
defined as ‘-1 nucleosomes’ within 350 bp upstream and ‘+1 nucleosomes’ within 250 bp
downstream, and the distance between the +1 to -1 nucleosomes was defined as the ‘nucleosomefree region’. When compared to quiescent hepatocytes, there was a median downstream shift of 9
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bp in 1-week (p=2.60E-13) and an upstream shift of 19 bp in 4-week (p<1E-15) repopulating
hepatocytes for the -1 nucleosomes, while there was no significant shift in +1 nucleosome
positioning (Figure 4.7B, Supplemental Digital Table 4.6). As a result, there was a global increase
of promoter openness in 4-week repopulating hepatocytes as the distance between +1 to -1
nucleosomes increased, while the nucleosome-free region was shorter in 1-week regenerating liver
compared to the quiescent state. The difference in genome-wide promoter openness in
repopulating hepatocytes at various time points suggests that accessibility of divergent functional
regions could be differentially regulated during liver regeneration. Indeed, the nucleosome-free
region constitutes only 17.5% of regions with increased accessibility in week 1 but 45.6% in week
4 (Figure 4.7C), whereas 39.0% of week 1 and only 26.9% of week 4 regions that became more
open fall into distal intergenic regions (Figure 4.7D). On the other hand, chromatin regions with
decreased accessibility show a similar distribution between the nucleosome-free region and distal
intergenic regions. These observations indicate that the increase of chromatin accessibility occurs
mainly at distal genomic areas in 1-week and around the TSS in 4-week repopulating hepatocytes.
To evaluate the association of TSS accessibility and gene expression, we extracted the
top 500 up- and downregulated genes in repopulation [15] and calculated the change in the length
of the nucleosome-free region between quiescent and regenerating hepatocytes as a surrogate for
differential TSS accessibility. We only observed a significant increase (p=1.15E-2) of +1 to -1
nucleosome distance in genes activated in week 4 when compared to quiescent hepatocytes, while
no significant change in the nucleosome-free region was present in genes upregulated in week 1
or genes downregulated in week 1 and week 4 (Figure 4.7E, F). It is likely that eviction or
repositioning of the -1 nucleosomes could expose transcription factor binding sequences and allow
access of the transcriptional machinery to the TATA box for gene activation in regenerating
hepatocytes [71]. Altogether, analysis of the nucleosome structure implies nucleosome
reorganization could affect gene activation but not inhibition during liver repopulation.
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TABLES
Table 4.1. ATAC-seq library sequencing summary.
Sample ID
SUN1-GFP-1
SUN1-GFP-2
#3603
#3604
#2383
#2385

Condition

Index

Cumulate reads

Quiescent
Quiescent
1-week repopulation
1-week repopulation
4-week repopulation
4-week repopulation

CGAGGCTG
AAGAGGCA
AATTCGTT
GGCGTCGA
GTAGAGGA
TGCTGGGT

119,120,180
111,970,248
97,320,484
135,005,202
186,365,116
236,418,952
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Table 4.2. Gene expression of enriched transcription factor motifs.
Transcript

W1 log2 fold
change

W1 FDR

W4 log2 fold
change

W4 FDR

Elk1

NM_007922

0.23

0.83

0.05

0.96

Ctcf

NM_181322

-0.36

0.47

0.23

0.66

Hnf4a

NM_008261

-0.17

0.74

-1.12

0.00

Hnf1b

NM_009330

-0.15

0.85

-0.22

0.67

Hnf6

NM_008262

0.54

0.49

0.11

0.92

Zbtb3

NM_001098237

1.26

0.33

-0.64

0.73

Nfya

NM_001110832

0.23

0.85

0.03

1.00

Nfyb

NM_010914

-0.74

0.02

-0.20

0.64

Nfyc

NM_001048168

-0.67

0.10

-0.82

0.02

Yy1

NM_009537

-0.35

0.42

-0.12

0.79

Gene
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Table 4.3. Primer sequences used in this study.
Primer name
MfeI-Sun1-F
BsiW1-Sun1-R
ZBTB3-ChIPCtnna2-qPCR-F1
ZBTB3-ChIPCtnna2-qPCR-R1
ZBTB3-ChIPSmad3-qPCR-F2
ZBTB3-ChIPSmad3-qPCR-R2
YY1-ChIP-Bcl2l11qPCR-F1
YY1-ChIP-Bcl2l11qPCR-R1
40S-F2
40S-R2

Sequence

Use

GACTCAATTGGCGGCCGCACTACTGGCC
GCTACGTACGTTAACCGCTACTATTAAGATC
CTCCTCGGATATTAACTTCTGC

Plasmid construction

TTTGTTCGATCACAGTGCCG

ZBTB3 ChIP-qPCR

TGGGAGCAACAGTGGATGAA

ZBTB3 ChIP-qPCR

AGACCTCCGTGCCTTTTCTA

ZBTB3 ChIP-qPCR

GGCGGTTGAGTTTCACAGAG

ZBTB3 ChIP-qPCR

CTCTTGTAGCGATCACCCCT

YY1 ChIP-qPCR

CTGCCGTCCCAATCAATGTT

YY1 ChIP-qPCR

AGCGAGCTGTGCTGAAGTTT

ChIP-qPCR control

AGGCTGCTTGGATCTGGTTA

ChIP-qPCR control
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Plasmid construction

FIGURES
Figure 4.1. Implementation of the ‘isolation of nuclei tagged in specific cell types’ (INTACT) [19]
method with the Fah-/- mouse model allows isolation of repopulating hepatocyte nuclei.

(A) Schematic of coexpression of the GFP-tagged nuclear envelope protein SUN1 (SUN1-GFP)
with FAH to label repopulating hepatocytes for fluorescence-activated cell sorting (FACS) followed
by the ‘assay for transposase accessible chromatin with high-throughput sequencing’ (ATAC-seq).
(B) Representative images (n=2) of repopulating hepatocyte nuclei show specific isolation with antiGFP antibody labeling. Gray boxes denote the sorting strategy to collect GFP+ nuclei. (C)
Representative images (n=2) of immunofluorescent staining of GFP and FAH show coexpression
of SUN1-GFP and FAH in repopulating hepatocytes of the Fah-/- mouse after 1 week (left) and 4
weeks (middle), and global expression of SUN1-GFP and FAH in all hepatocytes of the RosaLSLSUN1-GFP

mouse 1 week after AAV8-TBG-Cre injection. FACS: fluorescence-activated cell sorting.
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Figure 4.2. Chromatin accessibility changes during liver repopulation are related to cell growth
activation and metabolic inhibition.

(A) ATAC-seq shows reproducible signals across biological replicates and a decrease of peak
intensity in the proximal regulatory region [105] of the Alb locus. (B) 16,043 significantly differential
accessible regions were identified in repopulating and quiescent hepatocytes (absolute fold change
≥1.5 and FDR ≤0.05). Comparison of differential accessible regions identified at different time
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points during repopulation shows 3,273 that changed in the same direction (‘congruent’ peaks), of
which 1,241 were congruently increased (red dots) and 2,033 congruently decreased (blue dots).
(C) Hierarchical clustering of all differentially accessible regions shows that biological replicates
have similar chromatin landscape. (D) KEGG pathway analysis of differentially accessible
promoters with increased (left) and decreased (right) accessibility in repopulating hepatocytes.
FDR: false discovery rate.
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Figure 4.3. Association of expression levels and chromatin accessibility implicates divergent
regulatory mechanisms for gene activation and inhibition.

(A) Differential gene expression data were obtained from a previous study that implemented
translating ribosome affinity purification followed by RNA-sequencing (TRAP-seq) [15]. ‘Upset’ plot
164

demonstrates overlap of ATAC-seq regions and TRAP-seq genes that are significantly changed in
the same direction at the same time points (‘concordant’ genes) in repopulating hepatocytes.
Fisher’s exact test was performed to calculate the significance of overlapping targets. The
horizontal black lines in the green bars of the top panel indicate the number of overlaps expected
by chance. (B and C) KEGG pathway analysis of concordantly activated and repressed genes in
(B) 1-week and (C) 4-week repopulating hepatocytes. Dashed lines denote FDR=0.05. (D and E)
Association of changes in chromatin accessibility and gene expression in (D) 1-week and (E) 4week repopulating hepatocytes indicates that promoter accessibility changes are related to both
gene activation and inhibition, while only decreased liver enhancer accessibility is significantly
correlated with decreased expression of putative target genes [30]. Cerebellum enhancers and
their putative targets do not display any significant relationship to chromatin accessibility and gene
expression changes in the liver. One-sample t-tests were carried out to identify the differences in
normalized log2 fold change in differentially accessible and unchanged chromatin regions. Vertical
lines denote the 95% confidence interval of normalized log2 fold change in peaks with increased
and decreased accessibility.
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Figure 4.4. Enrichment analysis identifies transcription factor motifs overrepresented at differential
accessible promoters and enhancers [30].

(A and B) The ELK1 motif is enriched in promoter regions that became more open in repopulating
hepatocytes. (C and D) The CTCF motif is overrepresented in liver enhancers with increased
accessibility in both (C) 1-week and (D) 4-week repopulating hepatocytes, respectively. (E and F)
Motifs of liver-enriched transcription factors HNF4α, HNF1β, and HNF6 are enriched in enhancers
with decreased accessibility during (E) 1-week and (F) 4-week liver repopulation. (G and H) Motif
frequency of the differential accessible peaks for (G) CTCF and (H) HNF4α display enrichment of
the transcription factor motifs at the enhancer peak center in repopulating hepatocytes. Numbers
presented in (A-F) denote FDR.
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Figure 4.5. HNF4α binding is decreased in the repopulating liver.

(A) 508 genomic regions display decreased and only 14 display increased HNF4α occupancy in
the regenerating liver (B) 40% of peaks with decreased HNF4α binding overlap with liver-enriched
enhancers (‘liver enhancer’) [30], and 25% fall in distal intergenic regions that contain ubiquitous
enhancers (‘distal intergenic’). (C) Integrative analysis of chromatin accessibility (ATAC-seq),
HNF4α binding (ChIP-seq), and gene expression (TRAP-seq) [15] changes suggests the
suppression of liver functions including complement, biosynthesis, and metabolic pathways during
liver regeneration is associated with reduced HNF4α occupancy. (D) HNF4α expression is
downregulated in repopulating hepatocytes (n=4 for quiescent and n=6 for repopulating
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hepatocytes) [15]. (E) Representative tracks (n=2 for ATAC-seq and ChIP-seq, n=4 for TRAP-seq)
of chromatin accessibility, HNF4α occupancy, and transcript levels at Itih1, the locus with the
strongest decrease of HNF4α occupancy. RPKM: reads per kilobase of transcript, per million
mapped.
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Figure 4.6. CTCF binding is increased at promoters in the repopulating liver.

(A) 1,306 peaks show increased, while only 2 peaks show decreased CTCF occupancy during
repopulation. (B) Schematic to test the insulator function of increased CTCF binding to differentially
regulate expression of the flanking genes [55]. (C) Promoters flanking sites of increased CTCF
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occupancy are not more enriched for differentially expressed genes compared to random gene
pairs in the genome. A Fisher’s exact test was used to examine the differentially expressed gene
ratios from the two groups of gene pairs. (D) 75% of the genomic regions with increased CTCF
binding are within 1 kb up- and downstream of the TSS (‘promoter’), and only 13 peaks overlap
with liver enhancers [30]. (E) Enriched pathways of increased chromatin accessibility, CTCF
occupancy, and increased (red) or decreased (blue) gene expression during liver repopulation. (F)
Motif enrichment analysis identifies an overrepresentation of CTCF motif in differentially-bound
regions, the ‘zinc finger and BTB domain-containing protein 3’ (ZBTB3) and nuclear transcription
factor Y (NF-Y) motifs at sites with increased CTCF occupancy associated with gene activation,
and the Yin Yang 1 (YY1) motif at sites with increased CTCF occupancy associated with gene
inhibition. Numbers denote FDR. (G and H) ZBTB3 occupancy is increased in the repopulating liver
at the (G) Smad3 and (H) Ctnna2 promoters, two genes with increased CTCF occupancy and
expression during regeneration. (H) YY1 occupancy is increased in the repopulating liver at the
Bcl2l11 promoter, a gene with elevated CTCF binding and decreased expression during
regeneration. (I) Representative tracks (n=2 for ATAC-seq and ChIP-seq, n=4 for TRAP-seq) of
chromatin accessibility, CTCF occupancy, and transcript levels at Hells, the locus with the strongest
increase in CTCF binding.
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Figure 4.7. Decreased nucleosome density is associated with increased gene expression [15] in
repopulating hepatocytes.

(A) Schematic for identifying nucleosome positioning information with NucleoATAC [104]. (B)
Globally, -1 nucleosomes have an upstream shift away from the TSS in 4-week repopulating
hepatocytes, while +1 nucleosomes positioning is constant during liver repopulation. (C and D)
Distribution of regions with differential accessibility in (C) the nucleosome-free region that is within
350 bp upstream and 250 bp downstream of the TSS and (D) distal intergenic regions in 1- and 4week repopulating hepatocytes. (E) The top 500 upregulated genes exhibit an increased +1 to -1
nucleosome distance in 4-week but not 1-week repopulating hepatocytes when compared to
quiescent hepatocytes. (F) The top 500 downregulated genes are not significantly associated with
changes in +1 to -1 nucleosome distance in repopulating compared to quiescent hepatocytes.
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Permutation tests with 10,000 iterations were used to compare the nucleosome distance in
repopulating and quiescent hepatocytes. NFR: nucleosome-free reads. NR: nucleosomal reads.
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Figure 4.8. Model of transcriptional regulation in repopulating hepatocytes.

(A) Access to enhancers allows liver-enriched transcription factors to maintain quiescent
hepatocytes in the differentiated state (top). In contrast, chromatin-dense enhancers and promoters
prevent transcription factor binding to inhibit gene expression of cell cycle genes (bottom). (B)
During liver repopulation, decreased accessibility of liver enhancers [30] in conjunction with more
closed promoters prevents binding of transcription factor and assembly of the transcriptional
machinery at hepatocyte-specific liver function genes, resulting in a less differentiated
transcriptomic and epigenomic profile in the repopulating cells (top). Conversely, the promoter
regions of cell cycle genes become more open, with increased +1 to -1 distance and increased
CTCF occupancy at the promoter, allowing elevated expression of genes involved in the cell cycle
and DNA synthesis pathways (bottom).

173

DISCUSSION
Gene regulation is tightly controlled by a complex network integrating transcription factor
binding and transcriptional apparatus assembly, chromatin structure, epigenetic modifications, and
even intra- and interchromosomal interactions [9,10]. In this study, we investigated the association
of chromatin accessibility, nucleosome properties, transcription factor occupancy, and gene
expression [15] to delineate the multidimensional framework of transcriptional regulation in the
repopulating liver. By implementing the INTACT method [19] to express SUN1-GFP in the Fah-/model, we successfully performed cell type-specific isolation of only repopulating hepatocyte nuclei
followed by ATAC-seq to identify changes of the chromatin landscape (Figures 4.1, 4.2). Integration
of TRAP-seq [15] with ATAC-seq determined that gene activation corresponds with increased
promoter openness, while gene inhibition is linked to a decreased promoter and enhancer
accessibility (Figure 4.3C). We also corroborated previous findings that cell cycle, DNA synthesis,
proliferation, and glutathione metabolism are activated whereas complement and coagulation,
biosynthesis, and metabolic pathways are inhibited during liver repopulation (Figures 4.2D and
4.3B, C) [12,15]. In addition, de novo motif analysis identified enrichment of CTCF and HNF4α
binding sequences in regions with increased and decreased accessibility in repopulating
hepatocytes, respectively (Figure 4.4). We further validated the differential occupancy of both
factors in the repopulating liver with ChIP-seq and observed decreased HNF4α binding at liver
enhancers [30] (Figure 4.5) and increased CTCF binding at promoters (Figure 4.6). Integrated
ATAC-seq, ChIP-seq, and TRAP-seq analysis suggests that CTCF recruits cofactors to activate
genes involved in chromatin organization and replication and inhibit genes in the regulation of cell
death (Figure 4.6E-J). On the other hand, loss of HNF4α occupancy at liver enhancers decreases
the expression of hepatocyte-enriched genes crucial in establishing liver homeostasis and function
(Figure 4.5C-E).
In general, 40% of CTCF binding sites occur in intergenic regions distant to the TSS, while
35% of CTCF sites are found in promoters [30,44]. Interestingly, the vast majority (75%) of sites
with increased CTCF occupancy are located within promoters in the repopulating liver (Figure
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4.6D). In fact, CTCF can function as a direct transcriptional repressor at the Myc promoter [72] and
as an activator of the amyloid precursor protein promoter [73], strengthening the notion that CTCF
plays a more localized role as a transcriptional regulator in the repopulating liver via recruitment of
cofactors. Upregulation of CTCF in liver cancer is associated with poor survival, likely through the
activation of forkhead box M1 (FOXM1) to stimulate cell growth and tumor metastasis [74]. The
CTCF-FOXM1 axis could be triggered during liver regeneration to promote hepatocyte proliferation
[75]. Increased CTCF activity at the Myc promoter [76] or decreased CTCF repression at the Myc
enhancer [77] have both been observed in cancer cells that lead to increased MYC expression.
The high tumor mutational burden of CTCF results in abnormal occupancy [78,79], and thus the
cofactors and targets of CTCF could be different in the regenerating liver and liver cancer. The
multitude of CTCF functions warrants further investigation to understand its contribution to
mediating chromatin structure and organization in the context of liver repopulation. Specifically,
CTCF also acts as an insulator to block enhancer-promoter interactions [43], a factor that promotes
long-range chromatin looping [45], and a TAD boundary protein that defines expression domains
for tight transcriptional control [44]. Future experiments to detect changes in chromatin interactions
via chromosome conformation capture [80] would be valuable in determining whether differential
CTCF occupancy affects three-dimensional chromatin organization during liver repopulation.
The mechanisms of increased CTCF and decreased HNF4α binding in the repopulating
liver are also not fully understood. In the current study, we infer that a more open chromatin state
at specific promoters correlates with the accessibility of CTCF to its binding sites; however, we
have not assessed causality. Previous work found that enrichment of thymidine (T) at the 18th
position in the CTCF motif reduces its affinity, where low-affinity sites are more sensitive to loss of
CTCF binding during mouse embryonic stem cell differentiation [55]. Additionally, it is likely that
changes in DNA methylation influence differential CTCF occupancy, as methylated CpGs in the
CTCF recognition site can prevent its binding [81,82]. Demethylation at specific promoter regions
could, therefore, increase CTCF occupancy during liver repopulation. In the case of reduced
HNF4α occupancy at liver-specific enhancers in the regenerating liver, part of this effect can be
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explained by reduced expression of HNF4α itself. Furthermore, HNF4α could be regulated posttranscriptionally via phosphorylation by kinases such as protein kinase A and C, as well as AMPactivated protein kinase to decrease its DNA binding activity or nuclear localization [83]. Activation
of the MAPK signaling pathway is also shown to inhibit Hnf4a expression via activation of the
transcription factor JUN [83,84]. The fact that enrichment of DNA synthesis pathways is only
observed in 1-week repopulating livers and that Hnf4a transcript level is unchanged in week 1 but
reduced in week 4 hepatocytes strengthens the notion that activation of cell growth and proliferation
occur early after the initiation of liver repopulation, followed by a later reduction of Hnf4a
transcription. Future studies using, for instance, targeted degradation of CTCF [85] or HNF4α could
be implemented to identify potential promoters and inhibitors of liver repopulation. Technologies
such as cDNA [8] or clustered regularly interspaced short palindromic repeats (CRISPR) [86,87]
screens could also be utilized to evaluate the effectors downstream of CTCF activation and HNF4α
inhibition.
In summary, we propose the following model to explain the transcriptional adaptations that
accompany liver repopulation (Figure 4.8): during hepatocyte replication, the promoters of selected
genes become more open due to an increased distance between histones at +1 to -1, increasing
accessibility for CTCF, transcription factor recruitment, and transcriptional machinery assembly to
activate genes that regulate cell cycle, DNA synthesis, and proliferation pathways. On the other
hand, decreased enhancer accessibility in conjunction with suppression of Hnf4a expression evicts
or prevents HNF4α binding, and possibly that of other hepatocyte nuclear factors, to liver
enhancers, resulting in repression of hepatocyte metabolic and biosynthetic function genes.
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MATERIALS AND METHODS
All primer sequences are listed in Table 4.3.
Plasmid construction
The generation of the pKT2/Fah-Sun1-Gfp//SB plasmid was described previously [15]. The
nuclear envelope SUN1-tagged GFP (SUN1-GFP) plasmid was a generous gift from Dr. Jeremy
Nathans (Johns Hopkins University, Baltimore, MD, USA). We amplified the SUN1-GFP insert by
PCR amplification with the primers MfeI-Sun1-F and BsiW1-Sun1-R and subcloned it into the vector
pKT2/Fah-mCa//SB [7] to construct pKT2/Fah-Sun1-Gfp//SB. This construct utilizes the Sleeping
Beauty (SB) transposase for stable transgene integration into the genome. The plasmid was
prepared with the GenElute HP Plasmid Maxiprep Kit (NA0310-1KT, MilliporeSigma) for endotoxinfree maxi-scale DNA extraction and purification.

Mouse studies
Fah-/- mice were maintained on 7.5 mg/l 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3cyclohexanedione (NTBC) (Swedish Orphan Biovitrum) in the drinking water. Hydrodynamic tailvein injection [86] of 10 μg of pKT2/Fah-Sun1-Gfp//SB was performed followed by NTBC withdrawal
for 1 week (n=2) or 4 weeks (n=2) to induce liver repopulation [15]. The RosaLSL-Sun1-GFP mice [19,88]
were kindly provided by Dr. Jeremy Nathans (Johns Hopkins University, Baltimore, MD, USA) and
were tail-vein injected with AAV8.TBG.PI.Cre.rBG (Penn Vector Core [89]) at 1 x 1011 virus particles
per mouse to ablate the loxP-stop-loxP cassette only in hepatocytes. Livers from these mice were
harvested 1 week after viral injection and served as quiescent controls. All studies were performed
in 8 to 12-week-old mice.

Immunofluorescence staining
Liver lobes were isolated, fixed in 4% paraformaldehyde overnight at 4 °C, embedded in
paraffin, and sectioned. Tissue sections were deparaffinized with xylene and rehydrated with serial
incubation of 100%, 95%, 80%, and 75% ethanol followed by PBS. Antigen retrieval was carried
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out in Tris/EDTA buffer (10mM Trix, 1mM EDTA, pH 9.2) in a pressure cooker (2100 Antigen
Retriever, Aptum Biologics Ltd.) and cooled to room temperature. Slides were then blocked with
blocking buffer (PBS, 1% BSA) for 1 h followed by overnight incubation of antibodies in the blocking
buffer at 4 °C in a humidified chamber. Three washes of PBS were carried out the next day followed
by incubation with secondary antibodies at room temperature for 2 h. Goat anti-GFP antibody
(ab6673, 1:300, Abcam) and rabbit anti-FAH antibody (ab81087, 1:600, Abcam) were used to label
repopulating hepatocytes from Fah-/- mice after one and four weeks of repopulation and all
hepatocytes from RosaLSL-GFP-L10a mice injected with AAV8-TBG-Cre. DAPI (B1098, 1:10,000,
BioVision) was used to label nuclei.

Hepatocyte nuclei isolation
Liver was homogenized in 10 ml hypotonic buffer (10 mM Tris-HCL, pH 7.5, 2 mM MgCl2,
3 mM CaCl2) on ice. The homogenate was filtered with a 100 μm filter and sedimented at 400 g for
10 min at 4 °C. 10 ml of hypotonic buffer with 10% glycerol was used to resuspend the pellet
followed by dropwise addition of 10 ml cell lysis buffer (hypotonic buffer, 10% glycerol, 1% IGEPAL
CA-630). The homogenate was incubated for 5 min on ice and sedimented at 600 g for 5 min at 4
°C. Nuclei were washed with lysis buffer again and quantified in a hemocytometer. Isolated nuclei
were labeled with an Alexa Fluor 647 anti-GFP antibody (338006, clone FM264G, 1:25, BioLegend,
San Diego, CA) for 30 min and 2 μg/ml DAPI immediately prior to sorting. After gating for the DAPIpositive signal, nuclei double-positive for GFP and AF647 were sorted with a BD FACSAria II, and
only tetraploid hepatocyte nuclei were collected for further experiments.

ATAC-seq library generation
ATAC-seq libraries were generated as previously described [20]. Briefly, transposition was
performed on 25,000 sorted tetraploid nuclei at 37 °C for 30 min followed by DNA purification with
the MinElute Reaction Cleanup Kit (28206, QIAGEN). DNA fragments were PCR preamplified for
5 cycles initially, and 1/10 of the volume (5 μl) was removed for qPCR amplification for 20 cycles.
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A ‘R vs Cycle Number’ plot was generated and the number of cycles required to reach ⅓ of the
maximum R determined for each sample. The preamplified ATAC-seq libraries were then amplified
for the calculated additional cycles. Agencourt AMPure XP beads (A63881, Beckman Coulter) were
used for size selection to generate the final libraries [90]. Library quality was assessed with an
Agilent High Sensitivity DNA Bioanalyzer (5067-4626, Agilent Technologies), and quantity
measured with KAPA Library Quantification Kits (KK4835, KAPA Biosystems).

ATAC-seq peak calling
ATAC-seq libraries were paired-end sequenced on an Illumina HiSeq 4000 (Illumina, San
Diego, CA, USA) with 50, 75, or 100 reads. Reads were then trimmed to 50 bp with Cutadapt [91]
and peaks called with the ATAC-Seq/DNase-Seq pipeline [92]. Briefly, the trimmed fastq files were
aligned to the mouse genome (mm10) with Bowtie2 [93] followed by removal of PCR duplicates
and mitochondrial reads. Bam files of the same biological sample from various technical replicates
were then merged with Samtools [94] and duplicated reads removed. The filtered reads were
shifted 5 bp for + strands and 4 bp for - strands to adjust for the transposase binding sites [20].
Nucleosome-free reads were identified with the R package ATACseqQC using a random forest
classifier [95] followed by peak calling with MACS2 [96]. Artifact signals were then removed
according to the mm10 empirical blacklist regions [97]. The irreproducible discovery rate (IDR)
framework was used to compare all pairs of biological replicates to identify reproducible peaks that
passed a threshold of 10% for all pairwise analyses. The conservative peak set for each sample
was identified by selecting the longest peak list from all pairs that passed the 10% IDR cutoff.

ATAC-seq peak quality assessment
To ensure the ATAC-seq peaks generated from the sorted nuclei are of high quality, The
R package ATACseqQC [95] was employed for assessment. We first visualized the insert size
distribution to confirm the presence of distinct periodicity of ~175 bp associated with nucleosome
patterning in all samples, indicating the DNA fragments are protected by integer multiples of
179

nucleosomes [20]. The signal intensity of nucleosome-free reads and nucleosomal reads was also
averaged across all TSS to examine evidence that no over-fragmentation was introduced during
hepatocyte nuclei isolation, sorting, or ATAC-seq library preparation.

ATAC-seq differential peak analysis
The R package ATACseqQC [95] was used to split the aligned bam files into nucleosomefree reads and nucleosomal reads. The R package DiffBind [98] was used to identify differential
accessible peaks from the nucleosome-free reads. The overlapping regions from the ATAC-seq
peak sets for each sample were identified and merged into non-overlapping regions. Read counts
for each region were quantified with dba.count (score=DBA_SCORE_TMM_READS_FULL,
fragmentSize=0, bScaleControl=F, filter=0, bRemoveDuplicates=F, bUseSummarizeOverlaps=T).
Peaks identified in both biological replicates in the same conditions were used for differential
analysis with dba.analyze (method=DBA_EDGER, bSubControl=F, bTagwise=T) in conjunction
with edgeR [99]. Peaks with an absolute fold change ≥1.5 and FDR ≤0.05 were identified as
significant differentially accessible regions.

Integrative analysis of TRAP-seq and ATAC-seq data
To identify chromatin accessibility and gene expression that changed in the same direction
at the same time point (‘concordant genes’), the differentially accessible peaks were first annotated
to the nearest TSS with the R package ChIPseeker [100]. Genes with differential expression during
liver repopulation were obtained from a previous study that utilized translating-ribosome affinity
purification followed by RNA-sequencing (TRAP-seq) [15]. The concordant ATAC-seq peaks and
TRAP-seq genes were identified and the expected overlap and significance was calculated with a
hypergeometric test. To evaluate the association of chromatin accessibility and gene expression
changes, all chromatin regions were stratified into regions with increased, decreased, or
unchanged accessibility, with the cutoff of an absolute fold change ≥1.5 and FDR ≤0.05. For
promoter accessibility and gene activity association analysis, regions within 1 kb up- and
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downstream of the TSS were identified and annotated to the nearest genes with the R package
ChIPseeker [100]. The corresponding expression change at the same time point was extracted
from TRAP-seq [15] and normalized by subtracting the mean log2 fold change of the unchanged
from the increased and decreased chromatin accessibility groups. The normalized expression fold
change of the nearest genes in the differentially accessible promoters was compared to that in the
unchanged accessibility promoters with a one-sample t-test. For enhancer accessibility and gene
expression association studies, liver- and cerebellum-specific enhancers and their putative targets
were obtained from a previous study [30]. Briefly, regions with the presence of H3K4me1 but the
absence of H3K4me3 ChIP-seq peaks were identified as putative enhancers and refined with a
chromatin-signature based enhancer predictor. Enhancer-promoter units were identified by
calculating the correlation of H3K4me1 and RNA polymerase II ChIP-seq peak strength along each
chromosome. All possible promoter and enhancer pairs with a >0.23 Spearman correlation
coefficient were identified as linked enhancer-promoter units. Gene expression fold changes were
normalized as described above, and the normalized gene expression fold-change of the enhancer
target genes in the differentially accessible enhancers was compared to that in the unchanged
accessibility enhancers with a one-sample t-test.

Transcription factor motif enrichment analysis
ATAC-seq peaks are separated into promoter and liver enhancer [30] regions and Homer
[101] is used to identify enrichment of de novo motifs with the function findMotifsGenome.pl (mm10
-size given). Motifs with a p-value of lower than 1E-12 are considered significant to reduce the
number of false positives. FDR is also calculated with each significant motif. To ensure the
identified motifs are enriched in ATAC-seq peaks with different accessibility, motif frequency
surrounding 500 up- and downstream of the peak center from all identified IDR peaks in quiescent
hepatocytes and differentially accessible regions in repopulating cells is extracted. The difference
in motif frequency distribution of regenerating and quiescent samples was then calculated with a
Kolmogorov-Smirnov test.
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ChIP-seq library generation
100 mg of quiescent (n=2) and repopulating (n=2) liver tissue was finely chopped with a
razor blade and cross-linked in 1% formaldehyde for 10 min followed by addition of 2.5 M glycine
and incubation for 5 min at room temperature. Tissues were sedimented, washed with cold PBS,
and Dounce-homogenized in cold ChIP cell lysis buffer (10 mM Tris-HCl pH 8.0, 10 mM NaCl, 3
mM MgCl2, 0.5% IGEPAL CA-630, protease inhibitor) on ice. After incubation at 4 °C for 5 min,
nuclei were pelleted and resuspended in nuclear lysis buffer (50 mM Tris-HCl pH 8.1, 1% SDS, 5
mM EDTA, protease inhibitor). Nuclei were sonicated with a Bioruptor (Diagenode) for 2 rounds of
7.5 min each. 10 μg of sheared DNA was incubated with anti-CTCF (2 μg, 07-729, Millipore) or
anti-HNF4α (2 μg, ab181604, Abcam) antibodies in dilution buffer (16.7 mM Tris-HCl pH 8.1, 167
mM NaCl, 0.01% SDS, 1.1% Triton-X 100, protease inhibitor) at 4 °C overnight. Protein-A agarose
beads were also washed with cold dilution buffer three times and incubated with blocking buffer
(10 mg/ml BSA, ChIP dilution buffer, protease inhibitor) at 4 °C overnight. Sheared DNA incubated
with antibody and blocked protein-A agarose were incubated at 4 °C for 1 h the next day and
washed at room temperature with buffers TSEI (20 mM Tris-HCl pH 8.1, 150 mM NaCl, 2 mM
EDTA, 0.1% SDS, 1% Triton X-100), TSE II (20 mM Tris-HCl pH 8.1, 500 mM NaCl, 2 mM EDTA,
0.1% SDS, 1% Triton X-100), ChIP buffer III (10 mM Tris-HCl pH 8.1, 0.25M LiCl, 1 mM EDTA, 1%
NP-40, 1% deoxycholate), and TE (10 mM Tris-HCl pH 8.1, 1 mM EDTA). Chromatin was eluted
with elution buffer (1% SDS, 0.1 M NaHCO3) twice and incubated with 0.2 M NaCl at 65 °C
overnight to reverse the cross-links. Digestion was carried out with 10 mg/ml proteinase K in 40
mM Tris-HCl pH 7.5 and 10 mM EDTA to purify CTCF- or HNF4α-bound and input DNA. ChIP-seq
libraries were prepared with the NEBNext Ultra II DNA Library Prep Kit for Illumina (E7645S, New
England BioLabs) and Agencourt AMPure XP beads were used for size selection to generate the
final libraries. Library quality was assessed with an Agilent High Sensitivity DNA Bioanalyzer (50674626, Agilent Technologies), and quantity measured with KAPA Library Quantification Kits
(KK4835, KAPA Biosystems).
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ChIP-seq data analysis
ChIP-seq libraries were sequenced on an Illumina HiSeq 4000 (Illumina) with 100 singleend reads and aligned to the mm10 genome with STAR [102]. Bam files from various technical
replicates of the same biological sample were merged with Samtools [94]. Peak calling was
performed with Homer [101] and differential occupancy analysis was carried out with the R package
DiffBind

[98].

Read

counts

for

each

peak

were

quantified

with

dba.count

(score=DBA_SCORE_TMM_MINUS_FULL, bUseSummarizeOverlaps=TRUE) and differential
analysis were identified with dba.analyze (method=DBA_EDGER, bSubControl=T, bTagwise=F) in
conjunction with edgeR [99].

ChIP-qPCR
ChIP was performed with 5 μg of anti-ZBTB3 (ab106536, Abcam) and 2 μg of YY1
(ab109237, Abcam) antibodies with 10 μg of sheared DNA from quiescent and 4-week repopulating
livers as described above. Input and immunoprecipitated DNA were purified with phenol-chloroform
extraction followed by qPCR with primer sets ZBTB3-ChIP-Ctnna2-qPCR-F1 and -R1, ZBTB3ChIP-Smad3-qPCR-F1 and -R1, YY1-ChIP-Bcl2l11-qPCR-F1 and -R1, YY1-ChIP-Igf2r-qPCR-F1
and -R1, and 40S-F2 and -R2.

CTCF differential expression insulator analysis
Increased CTCF occupancy during liver repopulation could prevent distal regulatory
regions to activate only one of the flanking promoters surrounding a CTCF binding site, and
therefore leading to a larger difference in gene expression levels. We define this ‘differential
expression insulator’ function, in which a gene pair is either highly or lowly expressed without the
presence of CTCF, but only one flanking gene exhibits a decrease in gene expression after binding
of CTCF. An insulator strength score was calculated for all significantly gained (fold change ≥1.5,
FDR ≤0.05) CTCF peaks in the repopulating liver as previously described [55]. Briefly, CTCF sites
with divergent flanking promoters within 50 kb were identified and the corresponding gene
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expression levels from quiescent and 4-week repopulating hepatocytes were extracted from
published TRAP-seq [15].
Low-expressors, in which RPKM-normalized read counts are 0 across all samples, were
filtered followed by calculation of a rank percentile based on RPKM for each gene. Let 𝑥" and 𝑦" be
the expression percentile in the quiescent hepatocytes; 𝑥$ and 𝑦$ be the expression percentile in
the 4-week repopulating hepatocytes. The insulator strength score is calculated by taking the
maximum value of 𝑥" × 𝑦" × 𝑥$ × (1 − 𝑦$ ) and 𝑥" × 𝑦" × (1 − 𝑥$ ) × 𝑦$ . A differential expression
insulator function will have one of the following effects: (1) Increased 𝑥$ and decreased 𝑦$ : in this
case, 𝑥" × 𝑦" × 𝑥$ × (1 − 𝑦$ ) will be the largest. (2) Decreased 𝑥$ and increased 𝑦$ : in this case,
𝑥" × 𝑦" × (1 − 𝑥$ ) × 𝑦$ will be the largest. Gained CTCF sites with the top 25% insulator strength
scores were categorized as strong insulators. Random gene pairs not flanked by CTCF within 50
kb were used as controls and a differential expression insulator score for each gene pair was
calculated as described above. The number of significant (FDR≤0.05) and non-significant
(FDR>0.05) differential expression of the flanking genes were identified for all strong insulators
from increased CTCF binding and random genomic regions. Finally, we used Fisher’s exact test to
examine the likelihood of gained CTCF sites to contain more significantly changed genes when
compared to that of control regions.

Nucleosome location analysis with ATAC-seq
MAC2 (callpeak --keep-dup all, -B --SPMR, -q 0.05, --broad) [96] was used to identify broad
peaks from all aligned bam files including nucleosome-free reads and nucleosome-containing
reads from ATAC-seq. Broad peaks were then processed with BEDtools [103] to extend the peaks
(bedtools slop -b 200), sorted by genomic positions (sort -k1,1 -k2,2n), and overlapping reads were
merged (bedtools merge). Nucleosome position was identified with NucleoATAC [104] from the
aligned bam and broad peak files. The closest nucleosomes with respect to TSS were identified,
and those within 350 bp upstream and 250 bp downstream of the TSS were identified as the -1 and
+1 nucleosomes, respectively.
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Nucleosome positioning analysis
The distance of +1 to -1 nucleosomes was calculated for each transcript. We used the
Kolmogorov-Smirnov test to compare the +1 and -1 nucleosome distribution differences between
quiescent and repopulating hepatocytes, respectively. To analyze the association between gene
activity and nucleosome positioning, transcriptomic changes in repopulating hepatocytes [15] were
first stratified into three categories: top 500 upregulated (fold change ≥1.5, FDR ≤0.05), top 500
downregulated (fold change ≥1.5, FDR ≤0.05), and unchanged (absolute fold change <1.5 or FDR
>0.05) genes. The distances between the +1 to -1 nucleosomes were calculated for each gene and
differential positioning was carried out by comparing the distance in quiescent to regenerating
hepatocytes in the upregulated, downregulated, and unchanged gene expression groups,
respectively, with a permutation test (n=10,000).

Statistical analysis
EdgeR [99] was used for all high-throughput sequencing data analysis. For the integrative
TRAP-seq and ATAC-seq analysis, a hypergeometric test was used for identifying the significance
of overlapping gene sets, and a one-sample t-test was used to compare the difference between
normalized gene expression fold change in differentially accessible promoter and enhancer
regions, respectively. A Kolmogorov-Smirnov test was performed for global distribution change of
+1 and -1 nucleosome positioning and a permutation test (n=10,000) was carried out to test the
change in +1 to -1 nucleosome distance of genes with differential expression.

Study approval
The animal experiments carried out in this study were reviewed and approved by the
IACUC of the Penn Office of Animal Welfare at the University of Pennsylvania.
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CHAPTER 5
DISCUSSION
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SUMMARY
This thesis work is the first to implement novel cell type-specific labeling technologies to
mark repopulating hepatocytes in vivo to achieve unbiased profiling of transcriptomic and
epigenomic alterations that occur during the regenerative process. With the utilization of innovative
methodologies to exclusively track regenerating hepatocytes combined with extensive integrative
multiomic analyses, I identified several factors and pathways with important biological implications
followed by examining their functional significance in the regulation of liver regeneration.
Additionally, the gene expression and chromatin accessibility datasets provide comprehensive
information on the transcriptional regulation of repopulating hepatocytes.
By adopting translating ribosome affinity purification with high-throughput RNA-sequencing
(TRAP-seq) for the isolation of mRNA from repopulating hepatocytes, I identified Slc7a11, encoding
the cystine/glutamate antiporter, xCT, as a promoter of liver regeneration in the setting of acute
liver injury. Slc7a11 is upregulated for over 600- and 250-fold in repopulating hepatocytes after 1
week and 4 weeks of liver injury and regeneration. Nonetheless, activation of Slc7a11 via ectopic
expression at the time of injury still allowed hepatocytes with increased xCT expression to
repopulate the injured liver more efficiently.
The implementation of hepatocyte nuclear isolation followed by the ‘assay for transposaseaccessible chromatin using sequencing’ (ATAC-seq) allowed identification of the alterations in the
chromatin landscape and investigation of the epigenomic regulation that occurs during liver
repopulation. Multiomic data integration has enabled the detection of increased promoter
accessibility that corresponds to enhanced CCCTC-binding factor (CTCF) occupancy followed by
activation of proliferative genes. On the other hand, decreased liver-specific enhancer accessibility
correlates with decreased hepatocyte nuclear factor 4α (HNF4α) binding and inhibition of liver
function genes. These observations provide new insights into how mature hepatocytes assume a
less differentiated state to enable cell growth and replication during acute injury followed by
repopulation.
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LIMITATIONS
Considerations of the quiescent and regeneration mouse models
In the studies aimed at understanding the genome-wide changes that occur during liver
regeneration, I utilized two different transgenic mouse lines, i.e. RosaLSL-GFP-L10a and RosaLSL-SUN1GFP

, as sources for quiescent hepatocytes, whereas Fah-/- mice were used to induce liver injury and

isolate repopulating liver cells. While no phenotypic deficiencies have been observed between the
RosaLSL-GFP-L10a [1] and RosaLSL-SUN1-GFP [2] mice, studies have yet to demonstrate that hepatocytes
isolated from these transgenic lines after injection of AAV8-TBG-Cre exhibit similar transcriptomic
and epigenomic profiles compared to hepatocytes isolated from wild type mice. A small portion of
differentially expressed genes and divergent accessible regions identified in the current
investigations could result from the expression of GFP-tagged proteins.
In addition, the Fah-/- repopulation mouse could be perceived as an artificial model. In
patients with hereditary tyrosinemia type I (HTI), all hepatocytes are exposed to toxic metabolites
and subject to an injurious environment during tyrosine catabolism. However, cells that receive the
Fah transgene in the Fah-/- model are technically not injured. Moreover, mechanisms of injury
specific to tyrosine metabolism could limit the interpretation and findings to expand upon other
injury-induced liver repopulation conditions, further restricting the utility of potential therapeutic
targets identified in the current work. Analysis of injured hepatocytes could elucidate the
transcriptomic and epigenomic discrepancies between the liver cells in HTI patients and
repopulating hepatocytes in Fah-/- mice. This comparison may also answer whether similar
alterations in redox pathways are present in injured cells, similar to that observed in repopulating
cells. Finally, investigation of injured hepatocytes could add to the knowledge on signaling from
injured to repopulating hepatocytes to better understand the induction of liver regeneration.

TRAP-seq profiles the ‘translatome’
It is worth noting that TRAP isolates translating mRNA bound to the ribosomal protein L10a.
Therefore, the sequencing reads represent the ‘translatome’ rather than the ‘transcriptome’ of
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repopulating hepatocytes. Future methods to enable the isolation of nascent mRNAs particularly
from repopulating hepatocytes is likely to generate divergent datasets and will allow the comparison
of transcriptome and translatome, as well as the calculation of translation efficiency [3] during liver
regeneration.

Isolation of repopulating hepatocyte nuclei is time-consuming
While affinity-purification was successful in isolating mRNA from repopulating hepatocytes,
no enrichment was detected with immunoprecipitation of repopulating hepatocyte nuclei expressing
the SUN1-GFP fusion protein. This was attempted several times with various anti-GFP antibodies
according to methods described previously [2,4]. The exact mechanism of failure to
immunoprecipitate SUN1-GFP-labeled nuclei is unclear but we postulate that a combination of the
fragility of repopulating hepatocyte nuclei and the small amount of repopulating cells hinder the
affinity-purification of SUN1-GFP expressing hepatocytes. To address the technical difficulty of lack
of enrichment of target nuclei with the ‘isolation of nuclei-tagged in specific cell types’ (INTACT)
method [2], we turned to fluorescence-activated cell sorting (FACS) to isolate repopulating
hepatocyte nuclei. However, FACS is a time-consuming process and depending on the percentage
of regenerating cells, took up to over 4 hours. The lengthy process could introduce cellular stress
and cause chromatin fragmentation. In my hands, samples that required sorting for over 4 hours
exhibited low-quality ATAC-seq reads that significantly reduced the signal to noise ratio, hindering
peak calling in downstream analysis to identify open chromatin regions.

Limitations of the ATAC-seq technology and bioinformatics analysis pipelines
ATAC-seq makes use of the Tn5 transposase that accesses the relatively ‘open’ chromatin
to fragment and tag accessible chromatin regions, a process referred to as ‘tagmentation’ [5].
However, the Tn5 transposase displays sequence-specific binding preferences that induce bias
during tagmentation [6]. Computational methods to model and correct for the transposition bias
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have been proposed [7,8], but these have not been widely-adopted or experimentally validated to
date.
Furthermore, ATAC-seq is limited to only examining euchromatic areas and thus generates
mainly short fragments under 200 bp constituted of nucleosome-free or mono-nucleosomal reads.
This limits our ability to investigate the regulation of heterochromatic regions during liver
repopulation. Other methods that utilize sonication-resistant heterochromatin followed by a gradient
separation to discriminate subtypes of histone 3 lysine 9 trimethylation (H3K9me3) and histone 3
lysine 27 trimethylation (H3K27me3) [9] could be implemented to elucidate transcriptional silencing
and domain repression during liver regeneration.
The development of ATAC-seq to examine open chromatin regions is a relatively new
technology [5] and hence no pipelines have been proposed as the gold standard for data analysis.
The analysis utilized in this thesis includes a combination of the ATAC-seq pipeline for ENCODE
data developed by Anshul Kundaje and the ENCODE Data Analysis Center [10], as well as inhouse scripts developed specifically for the analysis of the present study. The use of alternative
bioinformatics programs could, therefore, generate distinct results. Nevertheless, I presume that
the highly significant regions with differential accessibility should remain the same or at least similar
across various analysis platforms.
Finally, chromatin regions with differential accessibility identified by ATAC-seq only refer
to the state of openness but do not infer the activity of the gene. A chromatin region could become
more accessible to allow the binding of transcriptional repressors, leading to suppression of its
target genes. Hence, ATAC-seq only provides a broad overview of the modifications in the
chromatin landscape rather than specific directional changes of gene activity. Integration of
additional genome-wide experiments such as ChIP-seq, promoter-enhancer interaction mapping
by chromatin capture methods, or other functional manipulation is necessary to guide the
understanding of the effects of altered chromatin accessibility. For instance, the integration of
TRAP-seq to inform transcriptomic modifications in this thesis provides additional information to
assess the consequences of chromatin accessibility changes.
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Whole repopulating livers are used for chromatin immunoprecipitation (ChIP)
In both studies to profile the transcriptomic and epigenomic changes that occur during liver
regeneration, ChIP experiments were carried out on whole quiescent and repopulating livers to
elucidate the mechanism of Slc7a11 activation as well as the occupancy of CTCF and HNF4α. Due
to the large cell number required for typical ChIP assays (1-10 million) [11], the lack of sufficient
repopulating hepatocytes isolated from the regenerating liver has prevented cell type-specific ChIPseq. Thus, it is possible that the signals of increased activating transcription factor 4 (ATF4) binding
at the Slc7a11 promoter are detected from hepatocytes undergoing injury and repopulation, as well
as other cell types in the liver. The lack of significantly increased occupancy of nuclear factor
erythroid 2-related factor 2 (NRF2) at the Slc7a11 locus could also be the result of chromatin
dilution by injured hepatocytes in the regenerating liver. Similarly, CTCF and HNF4α ChIP-seq
experiments were performed in whole-livers that underwent 4 weeks of repopulation in a non-cell
type-specific manner. The changes in CTCF and HNF4α occupancy detected are therefore likely a
mixture of signals from injured and regenerating hepatocytes. Changes in binding patterns specific
to repopulating cells could also be diluted by other cell types and the surrounding dying
hepatocytes.
Development of novel methods to utilize micrococcal nuclease-based native ChIP without
cross-linking — including ‘Occupied Regions of Genomes from Affinity-purified Naturally Isolated
Chromatin (ORGANIC)’ [12], ‘Ultra-Low-Input micrococcal nuclease-based Native ChIP (ULINChIP)’ [13], and ‘Cleavage Under Targets & Release Using Nuclease (CUNT&RUN)’ [14] —
allows ChIP-seq from as few as 1,000 cells, depending on the abundance of the transcription factor
of interest. Further optimization of these methods for hepatocyte nuclei will be useful in obtaining
cell type-specific cistromes in repopulating hepatocytes.
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FUTURE DIRECTIONS
The downstream effectors of Slc7a11 in regenerating hepatocytes
Slc7a11 overexpression promotes liver regeneration after acute injury, however, the
effects of xCT activation in chronic injury has not been studied. Upregulation of Slc7a11 is observed
in human gastrointestinal tumors [15], breast cancer cells [16], and hepatocellular carcinoma [17]
to increase glutathione (GSH) synthesis for the defense of reactive oxygen species (ROS) and
promote cell growth [15,16]. It is plausible that xCT activation in the setting of chronic liver injury
plays a similar role in reducing oxidative stress to confer an advantage for hepatocyte survival or
replication.
While Slc7a11 is not an oncogene, the safety of long-term xCT activation should be
rigorously examined, especially in the inflammatory microenvironment often observed in chronic
liver injury that could ultimately lead to tumorigenesis [18]. On the other hand, transient xCT
induction could be considered as a treatment for acute and chronic liver injury. In APAP-induced
liver failure, N-acetylcysteine is often used to restore intracellular GSH levels and prevent hepatic
necrosis [19]. The efficacy of short-term upregulation of xCT via viral delivery of Slc7a11 or drug
treatment can be assessed in the settings of liver injury to determine the extent of prevention of
ROS-mediated cell death and promotion of hepatocyte survival.
To identify the mechanisms of Slc7a11 activation to enhance liver regeneration following
acute injury, coexpression of Fah and Slc7a11 cDNA in conjunction with the GFP-L10a fusion
protein in the Fah-/- mouse would allow for specific isolation and expression profiling of repopulating
hepatocytes with Slc7a11 induction. TRAP-seq of these cells could determine the effects of
Slc7a11 overexpression on gene expression. Similarly, implementation of the clustered regularly
interspaced short palindromic repeats (CRISPR) system to mutate Slc7a11 with the expression of
FAH and GFP-L10a could establish downstream targets necessary to promote liver regeneration
that are dependent on Slc7a11 activation. In particular, I hypothesize that genes involved in GSH
metabolism, including Gsta and Gstm isoforms, as well as redox-sensitive transcription factors,
such as NRF2 and AP1, will be activated following the upregulation of Slc7a11 and inhibited after
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Slc7a11 mutation to support the induction of redox pathways [20]. Gain- and loss-of-function
experiments of the top effectors of Slc7a11 activation could be carried out to further assess their
functional significance during liver regeneration.

Regulation of oxidative response during liver regeneration
Expression profiling of regenerating hepatocytes identified massive induction of multiple
redox pathway genes. Genes involved in the oxidation/reduction network have been implicated in
liver injury and regeneration [21–23], and depletion of GSH availability or inhibition of GSH
synthesis delays regeneration and exacerbates toxic hepatic injury [24,25]. What remains to be
shown is the spatiotemporal regulation of redox balance in replicating hepatocytes during liver
regeneration.
Recently, a method was established to determine the redox status of zebrafish cells in situ
[26]. The effects of a biliary toxin were measured and determined to show that the toxin induces a
more oxidized state in extrahepatic biliary cells [26]. The assay utilizes the redox-sensitive GFP
biosensor, termed roGFP, that contains an engineered dithiol/disulfide switch sensitive to cytosolic
redox states [27]. Different redox levels alter the state of cysteine amino acid residues, resulting in
a shift in emission at two excitation wavelengths (405 and 488 nm). The coupling of roGFP to
glutaredoxin (GRX1), an endogenous enzyme that catalyzes the GSH/GSSG equilibrium, allows
for the specific determination of the cytoplasmic GSH redox potential by roGFP [27]. A high 405/488
signal indicates an oxidized sensor and conversely, a low signal reflects a reduced state.
The GRX1-roGFP biosensor could be adapted to the Fah-/- model to assess the
intracellular redox potential of repopulating hepatocytes. Mapping of the spatial and temporal redox
status in repopulating hepatocytes will enable the elucidation of the oxidative stress response
during the regenerative process. Furthermore, the expression of GRX1-roGFP could be coupled
with overexpression and inhibition of Slc7a11 to determine the effects of varying xCT levels on the
redox environment of repopulating hepatocytes.
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Regulation of HNF4α occupancy during liver regeneration
HNF4α is a crucial factor that maintains mature hepatocytes in a differentiated state [28]
by suppressing cell cycle gene expression and inhibiting hepatocyte proliferation [29,30]. Increased
hepatocyte BrdU incorporation and Ki67 staining were observed in mice with conditional Hnf4a
deletion, demonstrating the requirement of HNF4α to inhibit quiescent hepatocytes from reentering
the cell cycle.
In the current study, I observed a loss of HNF4α binding to liver enhancers during
repopulation, but have not investigated the mechanisms that led to its decrease in occupancy.
Several possibilities include a loss of liver enhancer accessibility that results in HNF4α eviction
[31], downregulation of Hnf4a expression [20,32] or protein abundance [33], and decreased HNF4α
nuclear localization [34] that prevents its binding to liver enhancers. In fact, TRAP-seq identified a
50% decrease of Hnf4a transcripts in 4-week repopulating hepatocytes [20]. Whether other
mechanisms contribute to the alteration of HNF4α occupancy is currently not known.
Elucidating the functional significance of altered HNF4α binding in the regenerating liver
could also inform the utility of inhibiting HNF4α as a strategy to promote repopulation. It is plausible
that HNF4α occupancy is required to maintain a euchromatic conformation at enhancers regulating
liver functions [35], and a loss of binding could cause nucleosomes to become less accessible
during liver regeneration. Targeted HNF4α deletion in repopulating hepatocytes in conjunction with
the expression of GFP-L10a and SUN1-GFP proteins would enable the understanding of the direct
effects of modified HNF4α occupancy on gene expression and chromatin accessibility.

The functional significance of CTCF in repopulating hepatocytes
CTCF plays numerous roles in genome regulation as an activator [36] or repressor [37] to
modulate transcriptional activities, as an insulator to prevent enhancer-promoter interactions [38],
as an organizer of chromatin structures to form topologically-associated domains [39], and as a
modulator of long-range chromatin interactions to mediate looping [40], to name a few.
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Understanding the functional importance of CTCF during liver repopulation will shed light
on its utility as a therapeutic target and enable identification of additional regulators of the
regenerative process. Incorporation of targeted degradation of CTCF mediated by the auxininducible degron system [41] with the Fah-/- mouse and cell type-specific isolation technologies
would provide a model to study the effects of CTCF deficiency in repopulating hepatocytes.
Genomic strategies to analyze changes in chromatin conformation [42,43] after the induction of
CTCF degredation including chromosome conformation capture (3C) [44], chromosome
conformation capture-on-chip (4C) [45], circular chromosome conformation capture (4C) [46],
chromosome conformation capture carbon copy (5C) [47], Hi-C [48], and chromatin interaction
analysis by paired-end tag sequencing (ChIA-PET) [49] could provide insight to the functional role
of CTCF in nuclear organization and genome topology during liver regeneration.
The ability of CTCF to interact with distinct proteins in a context-dependent manner enables
its diverse functions for transcriptional regulation [50,51]. Transcriptional cofactors are recruited by
CTCF to specific loci for transcriptional activation and repression include Y-box DNA/RNA-binding
factor (YB1) that enhances Myc repression [52], YY1 for X chromosome inactivation [53], class II
transactivator (CIITA) to induce expression of major histocompatibility complex class II (MHC-II)
genes [54], and general transcription factor II-I (TFII-I) to promote metabolic gene transcription [55].
Chromatin proteins also cooperate with CTCF to mediate insulation, looping, and
transcription. The cohesin complex coordinates transcriptional insulation [56,57], H2A and H2A.Z
induce localization to the nucleolus for insulation [58], and Suz12 recruits the polycomb repressive
complex 2 to suppress the maternal Igf2 promoter [59]. Other proteins demonstrated to interact
with CTCF include Poly(ADP-ribose) polymerase 1 (PARP1) for post-translational modification of
CTCF to modulate chromatin insulation properties [60], the nucleolar protein nucleophosmin to
localize β globulin insulator sites to the nuclear periphery for insulation [58], and RNA polymerase
II that induces pausing to regulate alternative exon usage [61].
In the current study, I identified increased CTCF occupancy at promoters with elevated
accessibility during liver regeneration. Stratification of changes in transcript levels revealed several
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likely protein partners that cooperate with CTCF to differentially-mediate gene activation or
repression. The transcriptional activator ZBTB3 is colocalized with CTCF at upregulated genes
involved in cell growth and proliferation, whereas the transcriptional repressor YY1 co-occupies
CTCF-bound downregulated promoters related to cell death regulation in repopulating hepatocytes.
Assays to coimmunoprecipitate CTCF and ZBTB3 or YY1 should be performed to evaluate the
direct or indirect interactions between CTCF and its cofactors. Experiments that implement
genome-wide methods to examine ZBTB3 and YY1 binding sites could also be utilized to identify
additional loci of colocalization. Finally, studies to manipulate levels of ZBTB3 and YY1 in
repopulating hepatocytes could inform the functional significance of these transcription factors in
liver regeneration.
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CONCLUSIONS
With the development of cell type-specific technologies to profile transcriptomic and
epigenomic changes that occur specifically in the repopulating hepatocytes, I identified Slc7a11 as
a potential therapeutic target to promote liver regeneration after acute injury. Future work to assess
the utility of Slc7a11 in the setting of chronic liver injury, the safety of viral-mediated or drug-induced
transient or long-term xCT activation, and the mechanism of Slc7a11 to support hepatocyte
replication will allow a more extensive understanding of the regulation of the oxidative/reduction
network during liver repopulation.
Furthermore, my work provides insights on the combinatorial modulation of increased
promoter accessibility and decreased liver-enriched enhancer accessibility underlying liver
repopulation. These chromatin changes enable the activation of cell growth pathways and
repression of liver metabolic functions. The mechanism of decreased HNF4α occupancy in liverenriched enhancers and its effects on the liver metabolic gene program will enable the evaluation
of whether HNF4α inhibition could be used as a strategy to induce hepatocyte replication during
liver repopulation. The effects of CTCF on chromatin modification, the regulation of differential
CTCF occupancy, and the mediation of transcriptional activity with additional CTCF cofactors are
intriguing questions that may reveal the importance of nuclear organization and genome topology
to fine-tune gene expression during the regenerative process.
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